var title_f29_26_30112="Mixed gonadal dysgenesis 2";
var content_f29_26_30112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mixed gonadal dysgenesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Laurence Baskin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_26_30112=[""].join("\n");
var outline_f29_26_30112=null;
var title_f29_26_30113="Shoulder and upper arm stretch video";
var content_f29_26_30113=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1070px;\">",
"  <div class=\"videoplayer\" h264=\"./images/PC/61978/Shoulder_upper_arm_movie.mp4?title=Shoulder+and+upper+arm+stretch+video\" style=\"width:480px;height:336px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flexibility exercise video: Shoulder and upper arm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This exercise to increase flexibility in your shoulders and upper arms will help make it easier to reach for your seatbelt. If you have shoulder problems, talk with your doctor before trying this stretch.",
"    <br>",
"     <ol>",
"      <li>",
"       Stand with feet shoulder-width apart.",
"      </li>",
"      <li>",
"       Hold one end of a towel in your right hand.",
"      </li>",
"      <li>",
"       Raise and bend your right arm to drape the towel down your back. Keep your right arm in this position and continue holding on to the towel.",
"      </li>",
"      <li>",
"       Reach behind your lower back and grasp the towel with your left hand.",
"      </li>",
"      <li>",
"       To stretch your right shoulder, pull the towel down with your left hand. Stop when you feel a stretch or slight discomfort in your right shoulder.",
"      </li>",
"      <li>",
"       Repeat at least three to five times.",
"      </li>",
"      <li>",
"       Reverse positions, and repeat at least three to five times.",
"      </li>",
"     </ol>",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_26_30113=[""].join("\n");
var outline_f29_26_30113=null;
var title_f29_26_30114="Case illustrating the evaluation of speech and language impairment in children";
var content_f29_26_30114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Case illustrating the evaluation of speech and language impairment in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/26/30114/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/26/30114/contributors\">",
"     James Carter, MA, CCC-SLP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/26/30114/contributors\">",
"     Karol Musher, MA, CCC-SLP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/26/30114/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/26/30114/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/26/30114/contributors\">",
"     Marilyn Augustyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/26/30114/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/26/30114/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/26/30114/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children learn language in early childhood; later they use language to learn. Children with language disorders are at increased risk for difficulty with reading and written language when they enter school [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30114/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. These problems often persist through adolescence or adulthood. Early intervention may prevent the more serious consequences of later learning disabilities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=see_link\">",
"     \"Specific learning disabilities in children: Clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Speech and language evaluation in children has three components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      To determine whether an impairment in communication skills exists",
"     </li>",
"     <li>",
"      To specify the nature of any impairments",
"     </li>",
"     <li>",
"      To initiate appropriate intervention strategies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A case to illustrate the evaluation of a child with a language impairment is presented here. The etiology, evaluation, and treatment of speech and language impairment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21399?source=see_link\">",
"     \"Etiology of speech and language disorders in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26343?source=see_link\">",
"     \"Evaluation and treatment of speech and language disorders in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Concern",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Sammy\" was four years and two months old when brought for a speech and language evaluation because of \"poor back-and-forth communication\". He attended a preschool program where the teachers were confused by his ability to excel in areas such as number and letter recognition and memory skills while experiencing great difficulty in general communication. The parents and teachers wondered if he would do best in an academically accelerated kindergarten that would foster his strengths.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history, obtained from the parents through a questionnaire and subsequently in an interview, revealed no difficulties during pregnancy or delivery, immediately following birth, or during early infancy. Sammy had had several middle-ear infections prior to the age of three and suffered from eczema; otherwise, his health had been good. He was described as a peaceful, affectionate, and well-behaved child who seemed eager to learn when interested in the subject matter. He loved looking at books and naming pictures, listening to music, and playing with trains and computers. He responded well to routine and was excessively upset by disruptions in his schedule. Family history for speech, language, or learning difficulties included an aunt who had \"some type of learning problem which was never officially diagnosed\".",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment was conducted with Sammy's parents present in the room because he became upset upon possible separation. He would not cooperate for formal, objective (norm-referenced) testing, so parental report measures and observational data were used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Parental report",
"    </span>",
"    &nbsp;&mdash;&nbsp;His parents reported he could follow directions, identify pictures, and point to body parts, but his ability to express himself was limited. He had a large vocabulary but did not always use words meaningfully. He might use a word appropriately on one or two occasions and then not use it again, did not ask questions, and, in general, initiated conversation only to express his needs. He had learned the alphabet, colors, shapes, and numbers by 30 months and easily memorized sentences or phrases in books and movies. Sammy would sometimes use these phrases for no apparent reason. He did not interact well with other children; he tolerated their approaching him but did not initiate or actively maintain interaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sammy played with cars and bubbles for a short period of time, interacting superficially with the examiner. Eye contact was inconsistent. He repeated words and on occasion spontaneously used words to make specified requests. He focused intently on tasks and generally was indifferent to the examiner's presence. His expressive language was characterized by the use of single words to label, protest, and request and by two- and three-word utterances to request. He had difficulty using personal pronouns, relating experiences or past events, and describing pictures. He often was echolalic, imitating words or phrases with the same intonation pattern as the examiner, and used rote, memorized chunks of language. It was determined that his receptive language skills were between the 30- and 33-month levels and that his expressive language fell between the 27- and 30-month levels, with a notable difficulty in the appropriate use of language (pragmatics).",
"   </p>",
"   <p>",
"    In addition to the problems with language use and general interactive skills, Sammy exhibited an abnormal preference for routine, inconsistent eye contact, an unusual strength in rote learning, and echolalia, all of which are consistent with the presence of an autism spectrum disorder. Subsequently, he was referred to his pediatrician for a",
"    <span class=\"nowrap\">",
"     developmental/medical",
"    </span>",
"    evaluation that confirmed this diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INTERPRETATION AND APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;This case highlights some important features of the speech and language evaluation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concern by the parents or teachers regarding a child's speech or language should prompt referral for a speech and language evaluation.",
"     </li>",
"     <li>",
"      The information provided by the parents on the questionnaire permitted further probing of areas of possible concern: ear infections, distress and disruption of routine, and family history of a learning problem.",
"     </li>",
"     <li>",
"      Observation and qualitative analysis of the child's performance supplement, and sometimes must substitute for, objective test results; they are essential for making a diagnosis and devising a treatment plan.",
"     </li>",
"     <li>",
"      Sammy was reported and observed to have impaired communication skills (inappropriate use of language and inconsistent eye contact), as well as abnormal preference for routine and unusual strength in rote learning. These features suggested his impairment may be caused by an autism spectrum disorder. Appropriate intervention strategies could be initiated once the diagnosis was confirmed.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30114/abstract/1\">",
"      Lewis BA, Freebairn L. Residual effects of preschool phonology disorders in grade school, adolescence, and adulthood. J Speech Hear Res 1992; 35:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30114/abstract/2\">",
"      Lewis BA, O'Donnell B, Freebairn LA, Taylor HG. Spoken language and written expression&mdash;interplay of delays. Am J Speech Lang Pathol 1998; 7:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30114/abstract/3\">",
"      Stothard SE, Snowling MJ, Bishop DV, et al. Language-impaired preschoolers: a follow-up into adolescence. J Speech Lang Hear Res 1998; 41:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30114/abstract/4\">",
"      Johnson CJ, Beitchman JH, Young A, et al. Fourteen-year follow-up of children with and without speech/language impairments: speech/language stability and outcomes. J Speech Lang Hear Res 1999; 42:744.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 618 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-D52EA7ED9E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_26_30114=[""].join("\n");
var outline_f29_26_30114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Concern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Parental report",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Observation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INTERPRETATION AND APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21399?source=related_link\">",
"      Etiology of speech and language disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26343?source=related_link\">",
"      Evaluation and treatment of speech and language disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=related_link\">",
"      Specific learning disabilities in children: Clinical features",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_26_30115="Intravenous copper: Pediatric drug information";
var content_f29_26_30115=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Intravenous copper: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21715?source=see_link\">",
"    see \"Intravenous copper: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F13225075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Trace Element, Parenteral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F13225095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     200 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Incorporated into parenteral nutrition solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Parenteral nutrition supplementation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     ASPEN Guidelines (Mirtallo, 2004): Preterm and term: 20 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Manufacturer recommendation: 20 mcg/kg/day;",
"     <b>",
"      Note:",
"     </b>",
"     Premature neonates weighing &lt;1.5 kg may have higher daily requirements due to low body reserves and accelerated growth rate.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F13225082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21715?source=see_link\">",
"      see \"Intravenous copper: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-6 months: 200 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-12 months: 220 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Recommended daily allowances (RDA):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     1-3 years: 340 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     4-8 years: 440 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     9-13 years: 700 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     14-18 years: 890 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;19 years: 900 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Incorporated into parenteral nutrition solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Parenteral nutrition supplementation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ASPEN Guidelines (Mirtallo, 2004):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants &lt;10 kg: 20 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants &ge;10 kg and Children &le;40 kg or &lt;12 years: 5-20 mcg/kg/day (maximum dose: 500 mcg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children &ge;12 years or &gt;40 kg and Adolescents: 200-500 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer recommendation: 20 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Parenteral nutrition supplementation:",
"     </b>",
"     ASPEN Guidelines (Mirtallo, 2004): 0.3-0.5",
"     <b>",
"      mg",
"     </b>",
"     /day; manufacturer recommendation: 0.5-1.5",
"     <b>",
"      mg",
"     </b>",
"     /day; high output intestinal fistula: Some clinicians may use twice the recommended daily allowance (ASPEN, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Use caution; contains aluminum",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Use caution; dosage reduction may be required",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10414685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 0.4 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10414477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13225083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not for direct I.V. or I.M. injection; must be diluted in a volume &ge;100 mL; direct administration of 0.4 mg/mL solution causes tissue irritation; pH: 1.5-2.5",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13225079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13225076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Supplement to total parenteral nutrition (TPN) to maintain copper serum concentrations and to prevent depletion of endogenous stores and subsequent deficiency [FDA approved in pediatric patients (age not specified) and adults]",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13934215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cupric sulfate may be confused with calcium gluconate",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F13897407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Generally well tolerated; excessive copper levels may result in the following adverse effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: Hepatic dysfunction (including hepatic necrosis)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13225077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to copper or any component; direct intravenous or intramuscular injection of 0.4 mg/mL copper solution (cupric chloride, USP)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13225091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with high output intestinal fistulae may require a larger dose than the recommended daily allowance (ASPEN, 2002). Copper ion may degrade ascorbic acid in TPN solutions; to avoid loss, add multivitamin additives to TPN solutions immediately prior to infusion or add to separate TPN solution container.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4-5 mcg/kg/day is associated with CNS and bone toxicity and tissue loading may occur at lower doses.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13225078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Copper may accumulate in patients with liver and/or biliary tract dysfunction; consider dosage reduction or avoidance of copper in patients with biliary obstruction; avoid copper use in patients with Wilson's disease. Direct I.V. or I.M. injection of 0.4 mg/mL solution may cause tissue necrosis due to acidic nature (pH: 1.5-2.5).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10486767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: Copper may decrease the serum concentration of Ascorbic Acid.  Management: To minimize the risk for ascorbic acid degradation, add multivitamin product to TPN solution immediately prior to infusion or administer multivitamin and copper in separate containers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10414481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10414482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. It is not known whether administration to a pregnant woman can cause fetal harm or can affect reproductive capacity.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13225080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Copper is an essential nutrient which serves as a cofactor for serum ceruloplasmin, an oxidase necessary for proper formation of the iron carrier protein transferrin. It also helps maintain normal rates of red and white blood cell formation and helps prevent development of deficiency symptoms (leukopenia, neutropenia, anemia, depressed ceruloplasmin levels, impaired transferring formation, secondary iron deficiency, and osteoporosis).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13225081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elimination: Bile (primarily, 80%); intestinal wall (16%); urine (4%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ASPEN Board of Directors and the Clinical Guidelines Task Force, \"Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients,\"",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2002, 26(1 Suppl):1-138.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/26/30115/abstract-text/11841046/pubmed\" id=\"11841046\" target=\"_blank\">",
"        11841046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Department of Health and Human Services, Food and Drug Administration, \"Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,\"",
"      <i>",
"       Fed Regist",
"      </i>",
"      , 2000, 65(17):4103-11.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute of Medicine of the National Academies, \"Dietary Reference Intakes (DRIs): Recommended Dietary Allowances and Adequate Intakes, Vitamins.\" Available at",
"      <a href=\"file://iom.edu/Activities/Nutrition/SummaryDRIs/~/media/Files/Activity%20Files/Nutrition/DRIs/RDA%20and%20AIs_Vitamin%20and%20Elements.pdf\" target=\"_blank\">",
"       file://iom.edu/Activities/Nutrition/SummaryDRIs/~/media/Files/Activity%20Files/Nutrition/DRIs/RDA%20and%20AIs_Vitamin%20and%20Elements.pdf",
"      </a>",
"      . Accessed August 24, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirtallo J, Canada T, Johnson D, et al, \"Safe Practices for Parenteral Nutrition,\"",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2004, 28(6):S39-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/26/30115/abstract-text/15568296/pubmed\" id=\"15568296\" target=\"_blank\">",
"        15568296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16823 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-80A65F7FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_26_30115=[""].join("\n");
var outline_f29_26_30115=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13225075\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13225095\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13225082\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414685\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414477\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13225083\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13225079\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13225076\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13934215\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13897407\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13225077\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13225091\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13225078\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299092\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10486767\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414481\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10414482\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13225080\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13225081\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16823\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16823|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21715?source=related_link\">",
"      Intravenous copper: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_26_30116="Variegate porphyria";
var content_f29_26_30116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Chronic skin changes in variegate porphyria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erosions, scarring, and hyperpigmentation in a patient with variegate porphyria.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_26_30116=[""].join("\n");
var outline_f29_26_30116=null;
var title_f29_26_30117="Cocci lung stain C";
var content_f29_26_30117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coccidioides spp in lung tissue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 315px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE7AYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6Wo9KQD1pasQvrUUIkDybzlScrUvrRTAcDxmjJxSdRRQAiNklSDkU8cUirg5FL3oEOPSkNBIxjPNI3Knk0AOFJVO8vI7G0M8zYReDmq+n6xDc2Ut0wMcSZO5uAR60W0uVyO1zQlcRksxwgHWvO9c+JtraXM0VhCLgREqxY7cn2rnvEPxQn1Zbqy8Mwkrkr9qIzj6D+prz2w02+vVvLuXcWiY7/kzz3OK6KeHctZ6I76GFjHWqeoQ/Em7nt45pLXyZC2NifMG9j/jXWeHry08RxjUpWlR4mKGJmwFI5/rXi9nq+6BYzauXjA+ZRgbu5NU9c8W6tDpv2RbeeKA8b4jjj8Kt4e7tBWZtPDxkrQ0PXfF3xHt9OhmttIX7TdnKRuR8gPTJP1qj4b1XWNR8I3c00m66ZHMDDue9ee2l1ZXHhWz+wpNJfhuRL09fpS+H/HupNaSadN9mjGGjCKdjJz1qvq9otRWvmKOHTSUFr5nQ6r4hur2y062dZbbyyPOmj7/7NQjX7+6kW0tZvMith824cN9R3qzp2pmWwWC6tUkRed7g5J9awLSENqE7W52OxIbP3fSqUF22O6NKOzjaxri4kvZykz4L/LlF4GasmAWczyxXJ+zW/wAhkzjc3oKzbSeDT5ZBJKz3LgoGH3U+h9cUzVphdW0NnZZ8sYOPVu9Vy9Ea+zu7LRBfa7Pc3b/Z5H8kfLknkj3pLiM6daF5n2TyrvwV4Ue/uavafZWOlxLJdBZJsZUZ3fNUOoWUuq6nBNdyBYphkhedoHan7uy2G5wjpFWivxK+gPHcKYIZY4bny9xDjG+pLO/j0oObi+zG7MEXrk/Sna1ptpcXaG2ikj8pREZwNqug965/UdHV3+2xtmOFsKh7k96dlIjSXzOjtJ5daP2SFsHmSWXGPl7AVyOu+PNF8NXWzSbZb2+ixmV/uK3t61T1nxQdG8K3MNuWS+vTsMg4Kp3xXlttpd5qjsLSJpjncxAzgeprNwcnyo09irNvbseir8cteWdpDFanJOB5f3f1r0f4efFGx8VxHS9Z2217IMB04Vq+dPE+hTaFdQw3Ekbl4lkynbIziszTLqS0vIpo2KujAgg1i6STsYSp05qzjbzR9a3Vva6fcuZiksePLTYhBwc1gxbLazkmEWx87drdPY1q6dfx6potheyo22RFPydc0+5tNPeFonlkY7h8hOT19e1axf8AMRB8ukhNClP9lX8Ms/lsRkKRkE56fzrHvHCB4UBbJGwg+hro9S0+yFi9xazRoFIyv97865zTAbzUXaFBIoxgdOO9VGzuy6TjaVQeTdfZHiijxCfvMB19vpUtndWFpAk84AuguUHLKpzwa6bX4o49CjSOExYPLAEDnqPeue0a30eV3W8uRAMcFue/AoTTVyY1VUg3Z/IefEtxKI4tTtQ+75g5Tr9aiiktdS1aOGL/AEWTOR1+YYrfl0qwEcd3a6kj7P4ZuARWZFDpzyC8uY1WePLFWb7/AKEe1Jcv2TNVI7xjYqXmnM0jBY/NYHKuOOK09KutR03TrZ47U3EcjE7cfKnpmqk+tXd7dyxi0i+yqBt2rtAA9/6VbvNZluRGkDtaWmT5iAckYxgHtQ02rNDlzziotGb4nEOp3ZDJJ5LZLRhgdr98e1VobKLSbdYbaNA7HL7uwNTXF5DaODaREkHBc8gis1rua/u44N2wBt2ZFyd3+FWk7WWxpGlon0RqXsNtBexGKVfI2iQkck+xpNXl0C8bzlt1a8xlpSpyAB2HrU5+2qLjy40aaJfncRjp7UW5sLiEWd/L5cjIHEpQLk++OvNJXWpHKmve1sVdGtg7mM4eOUjazDkHtgV0+jvptrezrPC8WoLwe6k+1VrKzttNVbm6uluFT5lMfOD6DvWFrvjJrkzSXFutnBDj96BlzzjpWbTm9DKadaTtsWtasxc6pGbedpJoySAT1PpWnrssCabFbyEzX6AfJGDhTXEyTtB5Wo2d00kUrblc87jnpWvP4ieW3XaIopRxIwT5mFNxbs0bOjJqPLqkR3GozXMojZFhLcMB2PrTjo1zIqtBfrEuPunufWoLSK8vr1IbUQmWX5sMckfWth7d4W8u41FRIvBG0AUX5dhVLK0Voe1Uc0tJ6Vwo8AWgdKPWlHT3pgHvR2pOaXpQAoPFLTaXPNADZFyyMDgg/nTnBK4U4PrUVyu+IgMVz3HWmRyF1ZNx+Xg5HNA7Db+KB7YrcLuj9M15n8T9etrbw82kWM7NLdgJuTnYuemB61D8SLnXrSaK2t9QVLZyWBztY+30rA8Pm6W9R2tFvWfGXiQ7lFb06d7Sex6FHD2ipt3KGhfZNCRLWWznK7CQwG0McdTnrWFN4iS7CSkSIzgqsS5wecZ96s+JNWnuPEl3PdI8M8A+zRKcfKMnk/nmmeHhDLd7opQlrHhYZZUzuKnOT9TXXGN/fkdavvbUuQ6Ql1BKr/aLGR/mMqEsvtmtCy0TSkkaOXU5XCx4ZsgBvpkVQ1jUdVt5NzXMEtsWwYrf5cp70y8ktZre1u1V1O5lRQpAyPU9Kr3mtwipW10udVpmgwW0Li3u4wkgGGxkf/rrG1TRdN0TV0vIQ8t20mShTjAA5/Guf13VZ38mWzlCxouAEyATn9TXb+GtbsdT0+wv5hte33RSqPv7scdeoNT78VzMpXg+Z6lafVhfTA4XGNsaRjBJNZ73Elr56vDGu/q2PmxXQazp9vqTSXdhGsUgwVVRg57jj86yptOeORVuZWMu4Ehhw1TFxOmE6aX6DLK2a5h3R2rSqwLF+gHtn1qVLNXR/LlWIopDHPI9QPety4vru2jjMQTypVwEjXOK5szEw+WXIlJLGMd/qaFJvYmM5Su9i1peiPcwicXAjVMbN+PmJ6VZvoLqytfNeQKAwQuRkKPb1rK1XVLxYoTZ2kW1QA65zn6DNR3viy3l0u20y8CRSJIJSsYJPXoR680PmbC1SpJW1N7xBun0iRbFlkm8vcAeAw7ke9c7qNxaWel2lvdeY07EEjOCB/nNayaxZahA5t5kWYcKpXYR+dZ9/Yf249sY2AuIWyGOPpg0Q00ZHLKCs9DkPiRpsOq6Da3mmRgm2ysirnp615lomuXeiXjPaTvAWUo5XuD1BFfTeiabDplulndSwzxMxGeCQT2NcN4++Dc9zO11oGwh8s0ZOMH2qZON7X9C6eIUVySfpc8W129S+uI3iZ3CqAS579/pVK2tzNPGkYJdjgAV39v8IfEqkPcQRxQ5+ZjKvA9etd14B+HFvpt4bm7xdyxMOEIwB3oSV7yexUq0H77sdR4aQWXgm2hkI3KgQjuPeq7XstvEjF/keceWpGSQCcn+QrTnvFa4+zRW+8I2MthdoPrVVp4l1oyXGzy7b5RtGR9aceraMoq7d1vqJqdtcB4Jw37uRTIsYXOBnFRS6kdC8MT3unhDdOcF+OtXbm7j1We4vCrC3jQqEjNYX9l3d3AZbWLdCuSVPaqjZr3ilT54csnb+tiS18Uahqmhx296wkuJWycjge4/lW1Pol7f6ckcMFtbKoXarffkPrms/wAMeQmqxicAzL0BGeat+IzfpqU0/mK8TnAK8bemBQ9JWirEuHJJU4adS0fDy6faNcX93bsoGREjk7T6VgWks6TSOvzq3yhXOeKmtlW7nHmjj+E544Faml3VvDHLGzrFM3KMR1/Gi7W+pbbpp82rGEahcRxQyskEKjcAi8fjVu4t98IVFARVIAA++fSnhpIAZ76R2BG3rwfTFNkuo2KTzfISeF6npxUXMk29loLo8WkC1Z7+3eS46eSCeffGazo7RZZru7WQaXLGcDfyCB2waW9e5aMIlqiGY/uzI4BJ9R6VDo2mXVzeXEN7D/pBXGGbqPX3qtru4ctrz5jV0nVLiPQ3u76FXQH5Zk4z25qlcw2+pF5bWYPOBlUcYPvWouj3Q823jjEFlH8w3uCAxHOKx9RthoQjeKdHmmGAE7A9zSVr+6ZwcXL3HqynLdNBdlLvdCgAwI+R7n8qo+MvDtxb6Vcw6Yqym5VSkznIK9TgetXbieK8thCoKbRlpSOpx0zTrPUbuLSYI0iLxwnaxPIFaJuLTR0VKbktNDmvCEd7PYrHfwssVvhY4du0H3rrXtdlvtFrGm5tpVjyaWfxYZ7oRR2vlgLtdtucDjB4ptodzLOkzTLuDYY5NRJtu9rEJTStLQ6ARaT4e0x763UNdyrtwGzzXETs1xJ5rHl+eua7zT/LvoS99EodiTsxkCsS5sD9ol+zbPL3HAPas4Pe+5jQmoSae57b2oPaj1pPrXEeIKOh4pegpDxTZD8uM4J6UAO3Ag0dhUNtFHEreWCNxyc9zU2OKYw6UuOaSlFADCuzc/JJpVIVAX4PequoTyQ2zyIpZlPCjvTHkjuLF2UMQyk8ZBNBViLUNFstTmjnuY1cp93cM4rJudEWxuY20+JkTq7IcfhWno85MDxF/njbAU5yFPSmX900ky28bETIPMZQedtUnJaFxck7XPLbjwhPcWuqKscc+pykyozDoCegPrXJS/25pukWthq3h+WO1RHCzW4BkyD1Ir6DjlKYZYcOSFyV5APvXM+JtbT+1BaXGl3axojFLgLwT9fSumFZvRq51069SUtEeRaNfwagk1vBZ3U16F+8y9B7/pU7yX00Rsrm2jMS/wCrUR9Ce/8AKuivYTpksx0meFUlwXCja3TuTWVqOqXsYV5UR2XhiBjcK3Uk3dI9G0p+8LNol0nhyKwurSM/ZxhWGCwH/wBf0ptv4UvI3ik06RWjLAGNhtOcdvUVRt7vVGmeW3aW4gc5wpJ2s2Rg+orTttZ1u1l2iJi8L4wEzzin76FCM9otXLNxfzaY81lKrRSMMnBIwa0rXWori2X+1EjcxjaHbkiqtlbz6rKZtSDPO3y7MAY/rVG406ySSSMtMkqnBDDjOe9Z2T33NuWnJcslqF5fo7M4O1T2GfzFS6FaWt/lPPcTHJ35yK6DRtK0qGVfNvYSPLy6NyOawNSeG31Oa201fLizkY70KSd1EUZRqN04XXmQeJdMW2tHWxkeSbYWJQ8DHpXn2nWcbXSy3FwI2VskY+Y+lelaUUgmLYadWOG3HGBXSJ4Y8N67G0t5aiGUDkxsVP40nLlWpvTxiwl4zTafVbnmeu3tjLY5gx9oGApA+Yn8K6DQxPZaTa3t0mZpsCOJm2nPYn2raOh+H9NuHTSdPee7A+WSQlxn6ZqtJIYr3zdWiEsjwkR4YAQtngbf60JpqyM62IjVSUU7ee7/AOAVrWBrnWP9IQBY23uVY8Hr3rpbDXYrOcpsa5THysXIGO/5Vy2nXBS4u98vmBzgkjduq1qUlpOPMMojKJtZB8uSaJK+jMasFJ8stiTxBqkdxqrm0dnthyyK2fqKtaFaLdyPO0rRRtGQIiSrfUViWl1FayxbrZpGTlgTgH8aunVlC3NxHbpG3AQGTJ57AUONlZDnBpKMPvJdTmtvscQEbG4ibbvccsM02CCEabeSTogmlIRGZgNv0FV7aNnlaS9ddygMiMf4qlnsxd2salm84yYwe+eePyqttLhypaXF07TZdMhaQgSIZF+42ePUiobnUxJqIjtlZIOFK7sA+uaallcIJzazyrGFKujcsfYVnwziC3klntXDk4WToKLXdylFSbvqzd02C2tM3UEQW6GQpZvlHHByayIxcTzH7VKW8wkkg8GnicXdnGsSlVRgZWJ4+laEcdtGqstxHKSRkL2HvRtqwS9ndvcsQW32uKGOG3yid1GOfrVqfQkt7eOTVZIVTPAbhz7Ckj14WwaOG2DSfwKvJx6ms24W+upo7i+ZQ8jfIsh+6D6VHvHNyzcvedkRTT293qrobqSCFVAQMcjcO+O1QDU1gv4mKi7VW46j8ahuY2tZZrONA9wPm8wYOAexrasbiJ7diYd94VEZBUc/Wr0SN21BbXRWuJbfW9QtoY5Win271VFOIxnue5NVJJtS0/VQtrf2zylchuuB2z71DJpF5YGSXfKmW48kg4z2qGGZdPXdJbCRGyX+bD+wzQl8wjFWtF3XY17mTU7XTIrqbVFuElO14gmRisDUrlLq8t7aGVJUkO3zFHGScVbg83UIBFFuWF33FV4KepqG6tIbC5spbaApErCQMw4kx2FVFWZdOKhKz3NhpI5Z004QxW1rGd8jAfMQPWmeDbEyrezzO3kM5VFOORVa5e5kvJtRni+UoqxoOm71NdLpxtG06KKWJlmRdzHdkcVEnZW7nPUcowsupTutAFzEPs5SCBj80gGCwHXFYsELWytDACyhiAR2Geta+peIEj0xRa4cRpjIP55rJ0+Vnjt5ZAxil5G0cFs9KE5W1CnzqLcja0+6uRpYuI0Uxo3l+Y5IDe9DPaKx3yCVjyWQ8VmX9+bZILV8GEEB1Xoea53xRousXGrNJoFw0diUXC+h70oU1OVm7GM04LmaevY+l88UxX4OcceleU6t8VSNcbTNM0+R2HAkfpn1xV+88bSW+jMuM3kinBRCFU+ua4/ZTte25xfU6ul0WvG3xHtdBaaC1h+03MfDLk4B/D0rzu41fxL4gmGrRXBSKHDeVE2B17DrXPy/2jdXoChRLLIZTK653Z+vWtn7LdaJKs14m9c/8s/kU+lddOjGCu9z0lhqdNcsdz1vwh4ia4sMamzpd8Eq4xXXRuHjVh0PNeCw+LLc6ij3Fu0flgFADlmPqa2NS+Lr21vssrAzT9O+1aynRk37q3OSpl9Ru8Uey5AFQYkkLAkoueCOteVeHvixJdXkNvqumG1V+A6sXyfyr0W71JpbeIaeDJJOcKcY2DuTmspU5w0kjjnQnTdpIJ2tk1aLzbhzMylVQH+YrTlVVjXJIVeT9K5LVLN472zkN1E11C/mNJMBwOmAewq54g8Qix0m+lKFfKjysh5VsjtSa0Vh+ycmkupPrOrpa2U5wPMK5QryT71zegeKVV0N637wggnHpXjl54p1a4vXuJLl0VyFiQDAGetajTyGNGjdgG6+vvXTHD2Wp6tLAR5XGR7fqHia3sNMS9uHjELYJHoD0rMv9Vt9U8MXWqWkxkgjjdh/COleZXM8mv3NjZPIywLhWGe3c/lXUeNDb6TosOiaYCqSKGdc5O3t+dT7FRsur/Iy+pqE4w+03+Bw8Sz3bRzgyOivulY8rn/9VX7pxfDE33MggJ161UvJZbDw8tvA5E0su5gv8IqKWCa00yFl3rtBDSHufUGuq3U9STudFbPf2ekW/wBitkjtl5aRRy/oT9OanHieCN0OpW8kMh+/JGvLDt+NYOg6lNNGUjnbfBGB06DqAf1rc3WOo6fBLrTqsiNhmLbSRWcoq/vI4eWN/eX3blTUbxows2lXMkjSP8uR0BrS0y40670+7h1aZZLr76nZtYkeprIutKRz9o02aIQltqrkn8ap6jbXVncrcTpEY8cgHqKOVNWudahCpFRT1/EsTRwRXm+1l2iXrjPy+tbGp2On3+iRXd5KLZ4mIMsQ5kXtx3NZV1rsZt0jsLOG3jQZZtoZie/NWNEVtRvoH1BSLfJJWTjI7YFOz32CUZJKctLfeN0tLWZmWxhupcECMvxn6mtvUraGznCSXIiDgNITJx9MVNqPiSy0pktdPtohFAWywwAx9j9a5SfVFvZHvJLNHZv9ZIzbgPQAVKvLXoZKM6j5mrI0bOae6iklWIpZ7iF2kgn096jGmXTgSSArGflBIy2c1kadr108ieVmSONhtXG0E11F14kuLKFTHp7RXE5yyyNx9RxVOMovRBJzh8FjPvLDXILfy7iLyLKMgL5ChmI9c1SjsbCyKvEZd5fLLNhic9varsPiSa7eRJHMJIxsDEj6im2ejfvFvbmcymI7gDyg+vrQrr4tAScV+80/ULmCO7jkZpEgCDnC9/Sq1gkNvdfKjXFugySOOT7/AFrQj1KCSzktvKWQyZxjgLnqfeq9rZ3HkwpbvG0YYj5TjjPemnbRlptJqWhsahcR6qqKVjjRDuPtxgc1lbzbxJmQqi4bzB2aovENx+8miCiOSMhSF4zxVzQIUuLV47x18qRdoJ9QPSla0fIXKoU79BLGG6sLtplmWWUrvkj54+p6VbW4t9cvbQXkASOIbmjB4yPWokima3ulWcSsseAxPQA1Qguf3KS2cEagfLveXbubvx3FTa+vUyfvtvr3H63d2rXRijjFnCG/eyouSB0AxVJJrWC68mO4knVckuRjd6CiGzL3kpmuwfLBEvGVZm5xTYWt1vJUSONzs2KF+UA+tWrLQ3jaKstbGhaSGNvNNmZFIZVbdgNnsfWo2WaVnkmYJJEBsVun05qTUJLuW4tbS1tiTAFkRI23Db68dSTU2peS37282o8hHCj7pz0+tSZX1v3M/Tg1qG+1h1mlbllG7BPr+Fa/hvUrFpLzzgiSK20DJ+cCsa7t7iG3kuheruckH5fmIzW9odnGPDbShoVnLFnkJAYKPX8KJ2tdir8rhzPqVNTvIb7VIYLO6W3wwYuT0PpzVrVbS1uLqO0ubyOWV3BZwoUKB1PHrXP2r6fNrsRaNvswYFmPQ81p63BYwXM0qIZFl4jTdyF9ePei1mkTKnyyjFXWhvTrbtp7WsMQUoCA6rtUe2fU1gXUaTaJcxylUaFAUBOcc8YrPuI9WuNNk3OwiiH7qOSTAJ7ZxVoSPf2scUixNciFVWOJThMdTQo8oow5OpX1O6X7JDDEzh3wSoHerCyG3tZNivNI4CrH9TyaqC0nCWr3ARGx8oz8wye4rQnnitYrkrIHMq7VZecD14pu2xpK20dSlqNxZW1n9ndlkuGG1wo+Vc9qrrbxWViJ3nZYc/uoeuX9j2pmn2Fu8cssknmlRkD07cj8afeQ+bLYQpGY4FlyVP8AePtQ+1x2S91P1Ok0LRLe4uUuJyZLtcSfKflUd6l1LUQLx/3duFJ+Xjt71pWbQ6Lot2427ACZJpeBn0ryi/1VJrjzLqRo3I4WM4XFZ005ts5KUXVk5N6I9AisIJIMwQRxQRyZM0i/MygDp+NVtd8QrYPEsUMQicbVXy9wx61uXMlzbab517Fudjk+Z2HoBXJ3WoQo/DCRxyFHC/Tmpj7z1Kpp1He1xip9pvvtpTPA272x9doHAplzanVXYhm2xnBUnaB35rZ0bVtKmaRNUuorctyD6Grt/beHrHT5L5boXkpB2pu+8T61o5WNXNwfLyu/oc/a2ljaMx1BEmfZtjRGyVJrMkhXY8zeTBFvxtkPzH3wO1b2maJNrkRvZUS3th93ackVzF5YwSqbYzObkOVJHIPPFUnrvqaQ5W9HqFte2NlqVtK0wngz8yquD+FdbqHxLmttkGm26IX+USOuT9cA1y9j4cj+0xwuvnXB6FJPu/WtTWrbS9Play2q86gEsg6E9cmicYyavqE4U5yV1cdqviy6vLmM3R2tGBvOMB/bFY2ra5f3unSF5ZGgjOShH3jnpVa6sUDCY73wcDnGK1ra2hfRLhbuZF3khAR3Hemowik7G0Y06UbxWpWi0mHU7OS4VnF0kQeKF8AAcZ/HiixglSxaUlV8vIwepye1O8M6Xdwm4vLi7EscSHZGeeg4x6YqCW5iu7u3W2hKoGxIWbnJ6mq62uTSe9+h12iaVJDbvcSRrCYxudnHRSKw9avGaWSeSTczD93zyFHSug+Iupiyhs9LhGEKK7OrZ3L7/jXENEl3JCAs5dpBkgE4Hbioppy95hh03F1qnU1NKvoXiDS2qzz7vlXJGTjqa2ddMOo+HGKTIl1C4IUD5SuOQKpC8ey8yKSGIwom7p+8U5xkmp9SMT+GHlsGMaxkCVlHBP8AnFJ7pmMnzyTOe0fQJobS41GwuoZUk/10RONoHTrTWuftiGD7O24ENuByFx1+tXvBkRutQuYY598Hl7mdCApBB6g1pX2hW2lxR/Yr1prk/vNuP4T/AIVpKSTsx88Yy5Xqzo/CENi2mAXBiEqdCOeCOMjtzXDeLtQmsdf+x/Y/tEGRwoPz59PQCtfwxDdWN5c388ohso03TS9Rj0966D+3tE18TJpMkbz7MebICAv0zWV+Wd7XRg+aFRtar8jC0XS7KSL7TcKsbjmO33b2U+46VPPPazoJtVtywXC4UlWx+FZul+I4tB1aQCGK7ZjtDg4wT3FYOveI4dLme5klWS6kkLJAvO3nvVNO/wCR2qlOUtfk/wCtjcWzivrqIi0e109HJaQ5Zse4NdLDY6ZZ23lWU1mscnz5nJ+Ye1eXx+LfE2rwSw26i1gPB2pnI+tUbfUrrT9QT+2FM9tkBmXqopuMpaGssJUqLV7dNz1KPXbC3Jt47KCHy+UkRd6FvceldNDrWnX2mWlxexQNMh2n0Hr9BXGzWMFzZpcWB860ZNyuvOKzPD93BFqDW19GZrdyR3+Ws+RSV0cUsNTnHmjuvvOy8WaRptxZR6tZIkMoAJVDlXHoPcGsuykMFi0s0YMB+XYTyc1d1BYF8NrZKgtrreWjj3cMM9654Pdwq8dzDukxuxnoPaiN2rMKCcqfK3s/wNb7VDqN59mMSWyEHYV54HrTYIT9neESlYwCUKY3Dnk/SoLRFlil+1ypGypsi2d8jJzVsr9it4bWJSHkXeZTwSB2HtT20Q2rPlRjXlt50M1zIzFmmx09B1qbSrdVgjWVmVpXKjJ4x7VoXEvkQIygkSDbhuh96W3sxe37DZl4k+T5sg/hVc2li51Hy67FQpNbSSQFl8mVMMM8dazmsJYxGpdFgjOXJ55z0HrUl9FdRaiY7osJV7HnI7VoNcRrcNF9jaWB1UyZOCp9qL22G7xSa1uRXsE/2c3ukxRyQDEcqZyznHDEVW8NaZuu5rrUUZVIDKRyAfQ1Ul1qTTvt1/pf2fyIWIETA7yOgPXr+FU5U8T3irqE0qqMAiENyR6HHFCvaxpGlPlcW0k+vX0O0066P26VJYkWWNCI3TjA/wAKzLy3nudXtprlcWhcoinqxHU1X1fWmk0+1aK0EZMQZbgYGWzgrj2pl9cS3FpaKZCJI13AgHgnGamKd7nPCm0+bboXtVsWluCiSAwIOvQMB0Ht1q5fwWkGk7ZdsiMAQ8RBwfQ1i6YuozzJHbN5jH5XjPJA9T2rVuNHv5JorSAQqZGDOoOCmPWh6WTZM/dai5bGHLtkTbDbt5rAgHOBxVjwiZHv5IJbTzpGH+sbkL/9atnWIreHT2WJt8kKFXnTghvwqlpOq22l6fN8zTzygooIIwOvNPm5o6Ipzc6bUUJdTvbXTmFkYqdpJPH0ApJrC8Msu6IWouFLoyH5WH1qJdTs7mwiitonN6rHaoThs+9RNd3MNtJBNDtu+cDecYGeAPWizJUJLpqXJLSSx04Nf2hPmLjzWbPHY1ztxcKlm/8Ay0eQ/Lt5C+1dJb+KGn0eHTngIlRTy68ewxWE0McN3DADuVm34HPPfFVG+vMXS5k3zrUo2NldtHIIwN0mBjdzzW/qsg061tbQsst5GQ8hAzj0BP41RuILm01Ka/lX7PCFMqBuregAqLT7e5nPmSbvOuWD4xyq+p96JO7uXKSm1KT0J9Ql1PU7GG3MsMdsH3bGGcH6ComsraPCv9nYgdXHJrq9d0m5jiSe1YJDHhCOmPesO6t1uZd0UczhRtLLgAkfWojLTQ5/aRmrLYoan4o1a/kkkuoyM/cUdGH0pVhvbwFppYoi4G6MLgAe9WNUthpkh+0uJbggbSo+VPp9Kn0GNNUS6iLolwVBjd5CAx75prlSvFHReNOHNFaFdbfT7cukm2RgPmCYwe/FZ/mW2sh7HS4UtgDuDyOTu+naptQ8O7dTf/TDJKQF2xjKZ9jW/caCNL0xZHRI7tSohTd97nkn9ad0ldu5Dq7a7nOWlre2Vo+7VbqGOR9n2cSFVdqyNS1W308GG3gnmv8Ap7Ka0dX0+6tr+1l1FXaRSWRA/wAoBPpVbxHMk9q0kdt5cCcu3/6uTVrzNIq2vRjtD1jUI4t0Swx3Mi4Zm+dsfTtW3okaPKVv8ylm3mUnnd/hXl2kSTm8gdxL9idx+8PHFeiaUJZ5SltGRCDgzseg9fSqqQ5dSrqdN20L/iW4jt7JLeKMSrLyv97P4dBXO3KXuoXNpDvUxxk7li6qOvPuewrrimmw2/lxQyyTBsSyvyxHoM9PwrP0yezt767vZoVh8sf6NCzcEjuR1JrKEkiYNKFoo2XaXQPDs91qTIrSII7e0/if3IrjLawnaOK/lDDc/mBBwMA9Ksfb7nXtYee/Jkf+EYwFHoKu3N8Ld9skZE2B5aJyWyehXtTSlH1Zag4R5er3/wAiS6Nvq0k2p6hOI2yqCLrjHT8MVHrGujS7uK28P7ZprkAtIw/1Qq3a6IbKwbVPES+VbgEx2vSSQ9hjtWTpc1sHN7NBskBysfYDtQreqQmozVlql9xda3aLS2EzbpZHEk0rr8zn0HtVa58+50+PT9zW1tIxJOMZA5Oaq6pqU7XCk4+Y/Kuc49zTgmonw5qWp3LEshEMY7KpPP4800na42lTjqXvDsFlawx7VCm4B+bcQNo45rdtGgunPmRmUx4VrmFSoII6Y74rIs9KnhFpDNHcI0luHRNmQpI4z6fSuk1BrfwzpNvBuX+0ZyHbC4ABqZvU4naUko6tmLJp8dxpl3breMw3YYljsYZ7irVjpmi6Jo7SGJTcuDiSIcdOldB4QXT725KXIiXzc7lwcuff0pnjtrXS1it7e1h2SAxLnJI96z523yDU3KoqVmcMl1pkFm4gs3bUnbI3chR64ryXV7iS61ueeZwpRvu+1e4eEYEsbu8mltnmlaFgoRd+eleX/ETQr46jJfW9jInm4ZgEwAa2jK0z06dSEZSht53PpL4Z22lXng3Tp7a2gLSQL5mUGd2OQad4v8C6XrEDOIUgmCn5o1Azx3FfLfgb4keIfBd1IsZM1seGt5hlR9PQ12Nx8dPEN/cW/kW1skRyHgVMl8+5rnlQq87cDyFhMRGtz038xvgHVZLDVNQ0+GRmt1O5RngHp0ruALVWjlu4ooCrh5CBkyAdh6Zrn/Cvg+803S7jUr0RxSzDzdvVlHXGK07ZZNSUxuQlxCd5zwAD0/lW0rN6M9CtKNSblF6dWQa3rcN5fmVYG2qcRY/hxxW+J/7QsI5JGjilgj3BWXDSD61kLo8hCz+bu2yeWcDhT61LeXPkQvChR5JF2jAJwPU0mlookSUJWjT6FrSFgvLiMTqFiQFueOfSm3N20920kgBPMaOTwo9qg1PfY6VajcA8oMaALg/55q3pdlOlkzXUQKgFQrDHT0FJ9yXZe+Q3M4uPsyfPLtYKNy4z9KtzWD2MwurHU1DOMywyjlD7VAzLbRQGJmS6BDLAx3bQe9VL7Wp5lfz4llJyNwG059/WhJvYFGU3aOwX19HqDwyNtNxH8hO7GR1BqldvP5cc0UxZpML7r9at3WmxR6XFeSRwlZRltrc59qq2ltcXeXtoJGRE2gkZGfxqlboawcUrrZE+n6dpl/Z3Vhdx5udhKXAHKnqPyNZWry69pskca5u0Un5k2lCPqOR+NbVvBFYMZpZd7hVifH8K98Vf1SKS6vYII4Ft4nH7vH931b3qXuKNVwn3XmYXh/Qbm9FqZ5AN5Mm3G4KN2TxW9eSv9onsppYVhRiFymN3PC8fzqIwy2Op2sNk+ONsrt6HNQtPi+ks2QzXikOWK5XHJzSd2zGcnOXM9ixYalDpRuLGa3AYkHcp6YPc96q22qGTTr+7ExSZ5BGCfvYpphikjMs8qPdTvl/MOMDttFJoemxXV1vRAgAEiox6sKLK12HLTScnuRQanb6XeiBoi+9A7u5zzjnirlpKniLVHuLmFUhwVjXcE/E1QGh6hfarP5yskaAskhA5zkgCoZftcFwXFusU8W3LHg4+nSqaT23G1Fr3X7xs2WnGCC4ms5IVMLkPgA49xVS3a4ubnzVdTbwzYLsPvN6U+91OWD7HuCNFdqR8owxf3H1xUWlTT2z3EAjMoIOwIRkHuxHrRq9WRaVnJlnUrxhfxXE2nhmkHlxpD29yccmrV/bw6fbPd3EaJNboDGgAGXb0qC91K5j06CIr5eG+QDl3J9ao7klu/Ovt7ZGAgOcnpgUlciEW/T8zI8TS+IdUW11CxaGMyMEQORwOn412Vvd2XhaxhTxBqFuNYuAAoIB2N2OPSoba2022aC7vocBXxHGzZ2HrjGetcdr/AIdGveO5dV/ezvuXy4i25VwBjH+FP3anuvRL+rGdSLqO0dInV6peXVtp8Npc6mLmWWUysw6bD0FU2ikDE2tuZI25ywzzWrHZWOj6NPc6sA1/LxFER86jp0rQ0LXNNt9Mhj8sZxk5x/WsXKyulcXPyL3FcrC5/tF7oX1gF0zy8o2Pun1FVtH0vT2+Xj7M6l3eTqfp6YrOv9c8y9gsLAFIchcFuGPuatSpJcxhor6OCG1GZDtwCfT3qkrLsjZQaVnpctzX2l+HLRhp0beZK2POmb171g6pqD3lwqN5s0a4Rix5z1+WsPVr+fXNVeacsLeNwseEwCB2/Sumilhit7WaVEeYAuY05YH1IrRQ5bOW5pCPJZ2u2EdtviWC7tZlVcgbWBDKPf1p8/gldTEhtdQhtYyeUI3DpyKWxuW1OOeNZ2W6jPmxuF6DuD7VHZxSafbFbm9uJ0Zmw6D5gTzzj0p3a2eonzJ+67MdqMGneGdAGlaeYp53O+aZwBtX2z0rmZdeXyZF0mEyIq4JHQnuato0V3cxvPamUE7cMM5/CqNzHp2mwzjT1kaf5maIc7QPaqUf5tWyow9mrWuSaLZ61JD9quOGuTiMY/lVd9I1GOWeQloVdtpmnYNkjqFA6VvaVDqF5YwXN/C9pDgLDGSfMkz3A7Cq2pPFvaS7ilktoxtSNHJDN7kU72bRVK8ne5jLrUWkxyQ6ZC89ynR34BPQn361b8P+IZNMDTRQo2oklncncSfT2FRReHJdVcTS7rSHBYqo6Ct3TfA8kUitbSxrH1LTNg4ok4JamlSpShpIydS1eS/cNfSs8jnr1wPYVIIZZoDKBgdEyOuOv4CtXUzZ6ZMkenKs8sZ+eXbuyfQZp8eqXVrb+ZLbx7pB5SMyAg5POB/nNStlZEKrKXwoyJ4tMtr+GBJWlvYyDMzjC89x7CukuL37dHDbWaOLaF/MwqnDH1I9elcXAz32ryRJvlnkYKSRkk5+7XoEME+i6VMzS7pjLtwR0Y44/pRUVku5nW3UXqy14a1uGHUUs5FeRyR8xbIGP8KZ428PyNqkM8bbzK/yg8gZGcGqGmWsEN7FI0bG6Ul329mPb2Fbep3kl/EjSrOAHy+zgLj3rB6SvExa9nUUofMXSNLgMcrZ8i8aM/ut2QTWF4inuNV+zWl3FsvLZc4PRwO36da0L+9aOWK6tVmdsgGRhgfXNVta1eS5v4PLjAkSPaZCuNxx3PpmiKfNcdKM+dT/AKRQ0zVZbbalvCqyMSkmQflFS3OrSw6jBdJG/kuu10ZflPpirG9bPS4/NjIu2BJLLxyetZcrTXlxb+S2ZVPJPyhfbHetEk3sdCjGbba0Okl0DwteyxPqenW0d1MvPoc/xe1Rf8I34c0W8aey0+Ey4+Qjt7isN72GzF20xN3dsdqnGQtNj1Oe8ba20SOAOD0HpU8ku7sZLDS35nY0dW1e61SAWsIW3g27mcuN8uPT2qlBP8jSuFJMe0cY+X0/Wq0lqEwgZXKNtV+gHPGf1q9Bp0jQStMpiiBG91IYOM87RVpKKN7U4RsPmjW10uBbUkLNkuCc7hnHFRXmmvZqzzEI7suwhuCO+ao6zfRrBLw4gtQQpYbWIznpWTpGu6l4iiJmtpZEEnlQ7BhYxjOSe9OMJNXROsWtdztbcDVr+3lui21RthZeqEf/AF6w9RbVJNQuY4f3k4zvIbhUHXnpmtS3mttLWDUJJfnjXakHdn/vfSsmewW/W8WwvSt4fnZM4WQdWXOetSt/ImGj5nsNsL1hJNJLI0jKTsBTg8f/AFq2bjTrb+xDfTN++X5iq+n0Fc3p1neWc8U13G32XcG3ZyABkgYrchuVlnnmuP3cO3b1wD9BRJWehpVWqcHp/WhlTGAzvJOGWMLgKOP0rstBtA3h1LZSIlbG+Rl6n0Fc6dJszbs/23MjH733lx6Vo3pjsPDluBqc4YkkAdzjrjrilN3SSMa8udKMe5V1BlgdbfO+0RtsjovLNnnB+lU9Tv7q41FBbJJFaov7jeeWA70JqEosIoV8oEc7mOC5PcVJHdRxSRO8qyqoKBCNxGfftQtC4px1auZ9vcnVL2VZSWeTG1Rxk1qXUn2OyAgYNqcr+S/cqBxgfhVLRbdUkme7t23IcqV4IPp7Cn21lJCk1/cn5n37GzkdappbFzUXLy7FnUV+0ra2ktoUkUjdc5B49jT/ABHp66cLGW1uHkZhuCg4OB64rJX+0rlhbWhQALwzHJxnrjtWlcSNA8MOqQBZCmxHU5R+Ohz901OqsRySi1Z/IqxXd1eXIYlxHGuQEbnPcCtW9ltLmS3khieW5CgEMTx9axLOKSWZms7VoRHyTu3FmH0q5pmpwW0DW8UM89xMfmduGJ9qbXYU6fWPT+tTP1GyeW52SMCxf7kZ5iXPJFat9qv2W4s9P0KyRBs3G7m5f0z7UkWpmC+ks7o/ZWSPe77eWHpk06xtrvUre5ntomS0dgpO3946j09BTf8AeJc1Je9svuKmpauZA0cTedc7dr3D/wAIHZfSqN66Lb2zWxE0vcL/AA/X3rQ1CJzeQ6TBHFbyMuXwMADrlj9Kv3+k2v8AaFlYafJEVKb5JvQDrmjRWKjKEbL5lPw/Yvqd8k1zuMEJyFI4rfudQWznMGkQoZE+84Hyxk+vqazrrUhFpTWGjW8ytu2mbbgEeorTtLaPStJgCyxi5kRnkmODz1x9azlrqzlrTvq/kv1OT8QXnlXATz2uZnba0+OfwrobDwzvtlaS4Ck8gbOcY71l3NtI32a9vMOzyAO23lAe2PpXZyWk92I5ba6iSDYAmTgkeppSlayTsKrUtFJOx53dXAt2eGCOLe5JaQLzj2J6UXNyZrfyZs+WgHlhOBkfzqpZ6TcXaB1mXbnDITnb71fhtorKNlWV5pGUhw4woPsa1skd8nHTl3Ld1JBd2aRMBvXC4x8uccH1BqzpFgyyrM0RRkB3Fj7dqxBqMMCpsRvtEbcA4IP41TuYNS1i7VrBmAjIYlW798VSi3psQ4tK2yNnzpraO8ZYjKSu3cCM49/es2Eajcx+cHMVtGcCFQS5J6k1enjuGM6gbWCfvMjAB6Z+tPtbG4tdINwb7agJA2Hk/jT0WoJWRQnuWjtYzFMIZJQSGOCVB7j04qtpl7Bpt55OjWzSyvzLcz/NJKfX0C1dggs7aylnvS0t2xzHb9cnsWPpVjTpNPjimtrYj+0HXLOx7j9AKbaV0aSULXav+Qk8Oqa1Okl1dqkKnbtBwzn0A9KuQ2TTadLJK+IITgE8E4PP8xWtpcdvpWmT3mYp7t0K73/pWL9tn/smeFT+7kJ6dSSRwKx5r6IwjJydo9y7Ya3BaWcZt4JJroNycDGPes7xBq14gxdkR7wWAGMqOtaNvHZRaf8AZ7mOUSIN0eOMe57HkVzP2Cadp5nZSrt8vmHlvT3NVFRu2a04wTbsVtF1C6vLwpbqnloGdt3Gfck1Y1l4r+7g+zTpEAQqRl8MT7e1WHsobXEbx7pSobylXkmrWi+C73UtVN9cRCCIDCM44X0wK0vFPm2JqSUFzNmx4T0V9D1m1kS3+0h1IMmc/OTz+XFd34gsoJopEMDFmcO525BIqvYWeraUYot1u9nEPlcLlye5qbxBqN6WAs9vzrhAeCD61xzm5yTPKlOU6ikmcBr1kTay6rZ3f2a4VyJYGJBJz2qKz1u4eC3VXVTIcOzfrmpfFbNPpn2zU0MVwriML/z0965dLlZViMcYXkAKO9bxjeOp7NGn7Smubp/XzOiv4g8hmt7kyI/Bif1/2ag0OP7XPGrRMBG+1xu4PoWzTElkiijVXKsOQGBABHrSAXU86x2xw82CTnG4+tNLoUk+Ro0detTp+orNNMsyHDBCchazrrV5ZnZYIWBbrJjp7D0q8+h3DyLPMxu5UIUwZxgetX7K2W2kligvFNufmngkjyUHr70k0lrqZ+0iorW7RlaVNm3k07YkPm/MXOCw9q1NSt7PRtCtJIoglzLLtZi2WI9f5VR0yO0kvvPE7RTvKI4125+Xpk/Wn6k0dt4ghguTLNFDguX5Az0GKb1YSSlOy9X5k04OmJ595pzzLKowQ+QpNNljAjS8smJdF+WMnkEc496k1JZptOkeZ0jtlYMAVOWGeKyre7UQeZAqkQYkOeAR3pJXQoJyVy1ZaHe6ikt9Ikcqykh4ncLkdPyqvZXGnWplWzuzaxo5iaJv4l/2cd6lt5pdW0y5tkdLeAPlHZsNz2/nXKWtv5V4d4MkAkCsW6D8fwqkr3TNYU+fm53t0O6fQk1Gwe5idy23Ea7eD6AmsCw0O++2SQTEJIrfcD7M9+tdPY6qr2cscjF4IsKQhA2jPy4NY2s6pbXREcC7LiKQFHDckepqFKV7GNOVW7h/SLqW17e3/mTW6Gfy8Irk7EAHLt6moJdDmAae7uhdbTkRrlRinW+oBpWs7o3H+lJgvGMHHYZzxW1LcrmFntc3CxN5HYHHA3jrzSbkjNynTdlsUPDjG7hubXUbeGOGM5yBgqfr6U3xDodrC63d1eSCIplY4gDkdsZ71rLc7LYI0UYVhumOcBmz6VjrFerfqWhjltnP3i/K/hUpu91oSpNyc72MuPQ5NQ1KD7JO5txHuLyL9znocVHbXQ0nUriO+hDsDhWUdfSus1HX0tSLOKS1tY9mGKD5sjrXJarfW+pTGZhiWPgdt3vVxk5brQ2pznU0mvdOlbVLCWNYVZVW4Hls46Bh2+tVrK3mijlsp7qExwybIlJ/U+tZlpBE+lMBaiSXzBIoHVBwM045ldsxGO83bsN8o+ppWS0RnyJXSIvCl/Z2Xi7U7TUxJudiVlA+XHAAzUnj27s222NtcK0bOjI2eVGecn8Ki1GSCRgHiVbhhncjZK+1NstOtLW3efU4UaNhuDk5dfSml73MdCcVJVHe/Ye13NFATa5t7TG2Mk/NIMYz/wDXrY8LS6akcwe4T+0dgZVOPlXOT+POTXLyztqNxubz4rcYSMqm7AHSmWuhLcamiWSuWlYKZnBXYD1603HSz0JqU4uLjJ2OyNhD4s8RNeY/0S0Xy+OPMPc8dqdf3GmaRf8A2oXMguo4miitYm+UZxyw6dv1qjqmpDQ7KLw9oIMtyxPmyDkk9xWF4ZhNzFdXVxZMsUZO55jgufpSUW1fojjUIqzk7Lour/4csQzzSNNcH5pJhtaTHOPQVrW6QWVmIiRJe3OFmcciJP7tZTXUvlT3MYXy0YIi7TyPb37V1sCv4ftEuZY4RHIpaXcuSOOAPxNObsaV5W0RnN5sTz2uFaOVcQdjtxzzWTpuuafc3LWvkLHdBdkULN8v1z6irUHiaIXH2nUYDcS7doCr0B9KxZLawuNcOo2VhLECPuucKCfSklvczVKd7NfM6qxaaJCGltnb1JwE9Tg9frUseony1Ake5KjDPHwufQVzuotBKRPOBHGowIwOXxWTBcrtbMssfzHCR/dUenWp5L7lLDqWrIdR8S3t3PFY6dZjT7Nn+dQuC/PUnrWpcH7RYyxKfMdV3euOOn4VSuQsuqMqTOq7irFgMn6VZ0yTUvtc+y0K2VvghygG76+vStbK2iOjlVO1io9vAloqxsi7iMFyAT/hWf8A29LpyeRpsnmzDvH91ST3PerjCyuppP7UkKq5JCxDHOf0FSWOiW9vHezWajyI1zu+9n3rRW+0XOXQbpuo3iyB7hPNypMjE5Bar7T3F+IVtYmCoMqqjjg84q34VjhNtHNdwxTRFzGNzYf8BTY5bmx1OVli87ydwSNfQn1pSau9Nieb3mkti5q0E11BGHVIWkABdlwf/rVycVk8U5ttOhe6uGcgsoOT9faun8MXUOpajMbiWSWWV8JG54Q46LVybw9qdnczyaU8Aw2VUN8zc1nflfKzJVfZ+63YyLHR9XZi+sLcxoPuqiZX8aux24vtYitYJMWsQ/eyxx5Cnr+fSrEUOrSyGPU2mjBQrhGzj3J7Vz+q3P8AYNlILCZ3mZh8qcgn+tJXb8you+t9fwF8R31vDK8Ebzs7OQsQ6t7nvmqclxdQ2YubhFQFsDPGOKZoa2+nxS6h4gSa71S6GYrZRnvnOe1drpcMGpW6XGuJ9nhRd/zLtQ46KPU4q5NQWv8AXoKVXlW10ctpuvtHJLe+THNMi7VVY8549fWup8MXl9rO+5l1GZbdPme36eX6CqNlZW2t679m01FsLNcnG3O+ur/4Ru4g05YYvJQJIXbyv4j6t61nUlFdLMxrVILR6Nl10mliS4V54LMLsIByevU1n6frEMM0cEbPP5ZJkcj7/t+FZt5qV3p1x9mnmP2WRP3YAyGfuT7dawLfVYo9dlktPmRVLLj9azULk08O5pnX+IbnTtXuHhmtFmSFfMUIOQe9c7PBpKW63NvatA8ZzkrkH2J6VBpksj3bTO7GeUkgg42D1PtUOr6xLsNpDG0yIxLOehJrSMWvdR006Tg1CL09R0bDULlZ7thFb7iTJg4+lSWbibVJZgsbQRk+WFbBf0AqlBDqeoRRRxwS7CPkAXC5zV/TVfT9Qt7a7tg04kG5gMfKe9U1Y2lypNJ/IsJLb3V0RDDdWtzNhQ6k4BHvR4h1AQjyLWGRJlVIpLiQfvJT2BNbMmqwQWctwkKKFcooZfmB/wAKyNU2XMcWozkm0WQfIf4mHNRHdX2OenaU02tP1LZt7K3itp7iaNblFDRKO2PWo0RbsxyXU5KT8uQuduM5OfwrL1GaHUnubuZo7SKJS47s47ACsrSrmS6jW1tvMkZ25QkgAetUotq5vGi3Hmvqt/Ik8R6rd7DFGzSxQLuLRrnIHrjr9ag8KXb3Vs41G1CRuhJ2nbkc4zVuAzRXcgi/0eWIbJQPmBBJzx61mPp+qm8mC2Vy0D5KseAV9/StLJqxslG3LdJFpXht42kjC7AAixkZLn1xUUs7m3SGAmTzRlkVCNoHapEtb2WOSQxxpGhCt5Zzhj0rsobezgWK4RkWFVwEDbST3JqZSUSalVU/M5CGydkcpBJCeCcMTu92qe80e402Bb9jA8TYUNuGM+5NM8ZpK+lpfNI9vbpukMkJzv8AQGvMhp/iLxNp7vZJdXMELhRFECdpY9cUatXTKp801zt2j1PV4tc0yxt45Eu7O51MnBAlG1R/Wr1lezXkDZ2iR+Nyj5gD0xjtXhHi7wn4k8J2ltPrASNZOAocMy/Wn+BvGl/o2qwuZS0WQHRujD0rPlv5iVKjUX7t3fmfSNr5dyIrZlWefBIRh2B71c1qzigihuJY1FtApL+WehPrVe6tDdW2l6xpzBQrBpHHdSMn61T17W9OvLee0sJ95lHzt6DNZLV6HkpSlJOO3XyM230XTn0b7fcEStIdwdnJCLn09ayzbWXmzNb3MbeVEHChRg+oz69Kf5c1jZtAWVrUncu4dOfX0qC506ESr+8y7gEqD1/Kt16ndBNN3lc6DRLeG/0yaW6mWMIoLAAAEgj+gp15cvfTRwaeplcEKbjpx2qvpulFtPnF9KDbD55GUYIUc4H1pkN3q15fRWej6dHZ2cKhzI4/gPcnuai12zCSTm2nt9yNSz0bTH1QaSQZpwvmSzdMfj+NYHiUR3utLZ6bDvtYPlCRc7m960muLi3nmjjngSdwUe46tj0HvWXoljJY3nmK/kKN37wsDv47+nNC01bKppxfO300/wAzfht49LaK0mlja5kIGEXtz8v61V1iY2EsUdu6ecE4UdEPqfU1Wik06x1hb/Vp5JJ0bcpQZ3Njr7AVkJJN4h1IxWCSLBuxn+Jvf6U4xvqKFO755bLdmx4NsYbCOTWL66hN2QfKEjjqTz9TSePPEQvbd4bBUWBV3ysg5J96t67YadoFlZwlfNvd4O1OvNRnRjqbPdPF5UfC+Rx8wH9TQmnLnZnzwlP289exg295Ha2mhQXcgSC4mLLz8zsO59q2vE+py6tqBsbJ98cb4BJyHPqfYVzvik2+pXFkogRY7IkQYJBAz/KtjSLNI7hHvmEEb/ORnDkY4AH9atpaS6l25f3tT5DrDwvNcTrF9rQxp80rR/wsDyAc0S6jZ6N+6GnSTTjODLLnBzwTWjdanCbSS10UNGrHLMoHA9z61j3Gi/aoP+WnmZ3PI7HJ96la/EEW5u9V6djM1Fr3VWLLG0sgXG2JcADPQCoP7F1eMAR2hKkA8+9em+HPCi28XnSSFi3I57Umqz6VaXZiuJmEijkKalVVe0TNY2z5IK9jjIrKyivIZ7glRsDcKWYn2x3pPFeuM1pFB5TQWirkhWw3PTdmtq+u10SwWSdILe4dN4bIJHoMHvXJ2F0dVvGn1JFmijbzGDAfMB/D71Ufed3sjoh7753sjD02zS+lkeG7h3gcI2c16Bd34S0Om2BWGBYcTyqMZPfHrWBr1lZxPLqFmkdrI4DbI1wuzHTHSs3RYhqKNJPcSLCG2grzkjoPpWrtNX7GjtNKctPIngSeNz5E0wgR94ViArfWr8/iP7XcJEUEEedrMMjaMVmxXscmpF5ZGMMPADJgE/Q1S8UT/Z5ofLhEMbnexC9T61TV3ZlSs3saP9q2NlHmC3kimLMBKh4I6cd6mXV1iKmFJ4ggXJduGJHp1rgraPU7m4820ilk2HP3CQBnrXaWsuofYy1/HETjAQpyB6tmnOFtzNJOVjSjuJ5Z/NurwkFckKePpxWDq91PJE1osZCFuZQMZ57VZsLK4uLkCCMJGBudmO3C55Ip+qajYTrJa6fE6sr48+R+OPb1qUrMp8qdtxmm6hBoUSzRSx3WoNwsJjaRgPr61fv2+0wO96sgmYBgkzbvL/AcCix0S202E6jqM8sTsBsSMgmTviodTu4L4rEkEkCOcvK/6dOgpO0np94U4Xd+h1nwc0mE3NzfCQyeUPLA2ngnqcmvQY7c2V86wAssjZIY5x9K53wbc22k6dCsGZLV2CmQH5dx74rq7mS3s3NzI2ItrF36jArjrSbm2eTipudVvozH8RWNvcNGsqRAIrPkcbPcn0ry7UbK1j+0XVv8sJwMrxub0A9Kl8T+K5NYv54o4zb2IPykDlwO5+taWhra3s/2y9McdvCn7qAtjJA/zxWsIypxuz0KFOeHhzS+4pWMV5fMkcaxRxsAHLcEqPWrEF9Hp91MuzzxEpIKDKq1VdS1K48m5a22QQOc7V9D71jedJOxjlkVYiegOO1aqLludEYOXxbHS2ni+4Z2b7OGc4VfL4H51V1TUPtksTXG9Jozn5DwPYnuazPtu1VAQLCvA2L1q8kP22QzTjyo1Xd8xxu/xp8qi72NPZQpvmSsWbc3upWLj5pCCdrHggCox5s6ia4IaC32xrGTx9arm5v0vI8/Ja42rg459MVWmuLoRywxQGRmOdx7Cly66CUb7WGa0txq1+tnaoVQP0QZOM8mtPR7RZZktbVJFdnMSy9mOetaWj282laJNLtP2ydSGPHyqeMk+nNWLC8t9Pmth9ph2KnLKQWHuPSplKysjOdZtcsNkZ1zqWn+ELu+sobhLvWyoZRIpCD15q1FqV7rmnyJJc2zXW3zBDHja5xzXjvxN1mG68RS/ZyzBAI1kJyz89TWJZX1/ozLcQXjrICG25I/CjkUkn1Omnl0pR55P3t9j3Xw4buKK4t3MduzODsZeSQe3tTvGFpdQQi4igVY4lwzBs7h6+tReGtefxDoMNx9n238SjEgHDnupPr3q5p8Wo6pBeT3jj7LkhkJ5Jx6UtU+ZnC3KFVylZWepxvxGvJI/AlvDztnIbAHIAHP61zfhfxrpUXhoaLfie3hebzpZoZNrso6J0z+VenHSU1zQn0vVEzJG37l+4U8AivBfFfgy70nUJleN2hViFkAzx74pxs24+Z10nGrTdJbp3/4KPoyLRNH+Ir6fqGqWLpDCm22SRsmWLHVvxrx74y+DdL8Ja7ZtYBhFcAny8fc/GtDwF8Tn0Cwkg1G2+0TWyeXaShfmCf3fp3rC1KbXPGupyX+oqxiLAgjO1R2A+lOMZxnq/dMsLhqtKteTtFHp2n6le/8KrsIR8oICH1Zcmn+HtCnntlxDJsI+Zugx6Va06yjm0qy08szmNArKB0Irpte1NdE8PLEqK1252Roh6e5NZ35fdju2c86zTcKa1k2Yc9naaT+6lkacEZCk9DVOC4gif7VcxmNVBMcQGSx9zUJuJ7iFTLEJHySz9ifTPoKt2lhPqV4kbXMcWzBKYziqtb4mUrRV5st3Ekq6b9p1nUDFbyKD9khQAnPYmnXuuajdeHzHaxpboU2RkH5to4BNW9O0WHUb6STULyOWzgP7tWOAfr9Km1jR4IU+0WsoukddiIH+VT6j2FZ3jezOWU4OSi9/wADmLa80zQtMgF1KJ792BYhckNnp+Ap0/kuqPIu6eZmcRgHOe38qqam1ja7IHK3d0MF2252nPr+Vdr4S0x7iCW/vmJdozHGn/PMH0PrVyaiuZms2qUfaM5fwhp+m67LPDcwMWtBulLE5z3A9BVO18V2lhc3VxpPl+W4MaqsfzDbxznpWb8M76/0X4janp91CxguS4kJOcbScNn8a17Xwlb6jc6pdaeBDB5uYkxkuSeST6VUoqMmpbaW+ZKlab9q/dKSW94tv/bepMHLHKxknPPT8apWV5q1xNNIDP5t422GFScqo4ziuu8XaeIIdH0iJkku3cs/fjHJ/Suh8O6J/Z80V2Ss7Ff9aWz8uMjH/wBal7RKN31CWISjzy+SOT0jQLjT7kTa7GREFDKueCc9Pr3rl/GN9b2fiI3NsZZ2KBgrN8sXYBh7eld340m1C50S/KxHzC6G2Leuea82sNLuP3h1CZXlLEu2c5rSlreUmTC+IfNLf8DV8Ga4ptLo3iBRn5Aq8sTWtK2p3CGeG2UW4HCu2Nw/OoNJstPyqS3y23A5ChuPWtiXw8L6wlNncXMloODMZMbh32gCok481zaU6cHqyu/ie5awSyW6khDDaPJX5vzrPbTrq2wse5lYb900nzHPc1a06w0+0LSXBltUhH7uRlGPrk1iajrNg925NxPcf7cY4+lKK1tEUYxcrUl+BD4r1e8uLiF2tJTPtKkuwGR6AUaDf39jMz3NlCsR2lVdQc985rqzp1le6ZPqOpvsCjMadz6Z96p28sd8YrezaQyldqgpkqo/SqjJJcqRrzRkrW0W5R1+5e5sGlm08rbuQxcNj5D6D0rBv9bae5Ww0a1+zWUYX5mQAse7Gu78R2NtLY2sF3crujhKSEjGe4xiqmh+H7A6OY7m+QxbidvfP1/KqjOKV2Zc+ikzitcuMyKunq8rRIFd8ZBHqK7nSdRtL/Sba5urHYtugV/NTHP/ANesC28SWWn3N1Y2NuZVMhXG0YAHfd61pRa099J9ljhhtlfgs5LkDv8AjTlqrWKmpSW2iNvUteiknsrCxSOxDjdK6qBu9AKzPJvkv5Zr8RQKCGDz/MsmOg461i31hi6JuG3vDja+75VGf51r+ItUjmW1hjG90JLdxjHaoUUrco1S5bRgZWveIdRuopLa2jhViflZF4A9BWNY6dqF8HdYN8q/NI2MfnW9MPtUkYsk2sR0j7fn/Wugt9JSOFUmu4bB3wGMjfOSetVzKCskVdUrOxS03Sb1NGuJ5jESVLESfOYgO4HTmuZ1O4tYEi/tL7snRIwWJ7Cuy1HWbaG0GjWMwuAq+W7qp+Y9sn0FUdBsNKjDteTC71RFLm1j5C+nOKiMt5MIVWouUtyzpGr3Vvp6m7tGSzGAqFNvI6YrR8U+IzDpP2KRnJuU3L7Z7GuW1PxFeXtzBHKRFEhPy468/wD1qde4v5ZLp8CT7qg+o60uS7Tkivq6clKat6EUwN3psB8rbNsxuYYG3tTDZPbzxypHIFYDnOQTTr2/unFqiqQwBB9614NRRdN2yo6zKoMYHINaapG75oLTqSWXhu51ZGe5kWGLOQm7n649Kx7tbQ3kttbrmJDtaXuQOpqpJJqFxc/upZS8p2hI85A96t28mkQFkgeVptm2SXr83tRqtWSotSve/kuh19l4atruyj8q9j343KfT0Brn55ZNO1tLS8RLoQk7wvpis6HXC8qx29wm7+JgnfPNOsbqKOeW5ldHnk4xjJxUqMle5EITXNzu6HDUIlDKUxtYsWJzj6VLqD/a7PzYTIXXkMB/D3BqWXSJLq9tpbYROXy5jPG7npirVpIs8txBfBreKElRGq5JPpTbW6G5xTTj0J7ZZPsNvcSShIZtqsjNyQfQVoafZac+9VtHnmxhieB+NYNsiMszbtsSfwnngHA4q8niEy20yLaOZI4cjyejDHfvUST6GU4yfw/5Hj/jDw5fWWrfaxbNJGsh29SpGexrn7r7drV9EPIVEAxgenvXumqavHNo+nxLEJXlXMkTjpg1VitFtvEEIjtoYllQFgy4CZ9fpWifc9KGMlyWmtfzsbPgp7bTPAsOnrIBOZjvZFySeuKWC6vdCa5F7HutJ8ncf4SeKp6ZqltbTobYKGJddwXgE9GqTUtf/tCwuLK7khZAMMzD5gc9RWTTu9Nzy5Qk5vTRu7L8F+LPw+13dkCZZRHEFHUA9P61XvLldQlfyQka43Ss6blGfX3rlNMd7qby5A8yxNmNCeAM9TXU3c7qsYjihhgYZZm+6xHT605RSY501Sl5nN3+j6K1xbx28CNK5ALE4y30Hauhn0v7G1nb20coByd4TjA61i3ryahqAnikjgjR/wDXKmASB1roLrxqNLnjimlSaN4xGWK/dYDluPWh8zslqFWdRJa39WVLuWa00ue/tLiK2IcHewz8gOCMYqPR7u38QaxdyXFwskUCZwSFx6HHpS+OZ7G9s7GL5SZos4TknJ4qlo3hy3SJ7q7k8qDaN6ghdwHTJ+tNW5LvciKbi5vS5sz3dvcTzypsNtAnkwg8byO9SWVzYqJCzNFI0QV2BJ+b0FcVrVzNNMbXSVAz8obPQeta/hy0ttNQf2pqiFpuBCDuY++Bzihwsr3CpGMFZnSHU9Pe1W2iik3KNo2LwB/tVlz6hNbEqsEjW8X3CCAvvnFa9yfD0Fi0cbz3EoGQgBCr9ayLx2vQsdvZRxqx/i5+nFTGwqSi9bO3mXXg0xIIpbtc3kjBvl6AY6E1v2OsabFDAhuQghbHlpk7q5O70u4gtFbUJitsQT124+ma5SfWIUf7PYwCUk7VKglmz/Oj2ftNmEqEKi96R0mpaxbPrN6+n2ywrM/zzEZdx6Z7Vow6/e3UYi0DTpDKo2mUD5QPWsfTriGz0prWa2zqVwdpVfmaJO5PYH2rYuPGN3BMsGg26C0ij2DzVwM+uBTlHokOUY2ShC/rt6jbOFtOllur68WXVZQUR5eEB7gnsK19V8UWVhpdjCbj7VfRFXIt+VBHUemO1ef3lve6tcNPevNI7nJIUhfyq/pOlW1rcKLuHzEOMEtQ4reQp0qcrObu/IueIfFVxrMYhVUt4t33VYFj7e1Vo/DmoX4CrEy24XcETqxPqaq+I2NtYSz6dp4ZYvvv/GB7dqo6B4z1/TrIwx2pmjuQSryZXy/fPpVxi+W9NBP+Hy0VY2PDOnabeancWF3eotwpwtuuchh/Dnv9K9Cu7yx0DRTDNMuUXGPQV4holze2GqXOp5E95I5xLtOFY9fqa67wzpt3ruotd6pvmmDBtjHr7kelTVhrdvQxlhXGPNVehdj0p9edr7Wi8Fi3MNvnbuHqRVaZ9Mt5DDY2eYY/lyF716O0OmmY2l4B556Mx6/Q1Bc2unwSbYSioRnAUH/PSsVVuYRxmuq06I8ss9UlubiSIkrIwBUOP0rsPC+kT6ZJPPPKm+VCoiiAJ6da4q6ngnlt2spCs5jAk+QYZzUmm3Ou6VJvLGUSZMIZjjIrolG6stD0qkJctlpc09ds7maRngs7rzmOwlz07Z+lWZZobHRIdPXbNdsPm24faT/e9+9ef6zrfiS+nWO4udvm5+QDG2tjwdCixi3MTSTyPzKT8xJxVKm+XUGm0ubobSeHF2J5ko3H533KFYZ6/U0us272Om/ZLSQpcO+XeFcuq44BNXLovo11dNLbreSliFkMnK+wH1qo16INNubqfe0l5wqgfMTnn6Cpu3qJSb1eqOe0yG7lMjXPmSjrlycZHc10+iWEEdn9tluA0MRyyxLu3Z4xn3qhp+o2xnez8uaGPyz5iZH169e1a+jRKIglkFW0Zw5gTJz3B9TTm36BKo5baIs2l7ZrOYUtltFfhmDAs/cAelYOoR7LhpJAzbQW+Y5OPxplmtvHc3U1ysjN5u5D0781e1G3kksIrly6R3fCrnLEZ4z6fSptZ6GqSpv1M3wlHDFFqN1HGXvWIEQkyVIPqKdZagmhXNzNHAv2pxteTvj0FPWyWzh+0RFwY5VSWLdng9D/AErak1zR3tVS60lJnYjc2cfQcdaqTu773FbrGPMmZX2u1njW4uoX3HITaMjPuaUW0t9GbiGJ0UZIbp9aXxRcS3c0b2VvHbWyDEa5Aznqf0qnBJq3kRSMqgKMqC3GPaktro0i7xutGaVnHbaak87ym4vVxsjVdwH/ANeqaSyynfcyCJn67jjHtzWhpgZpPJg2yTSjdJIFwAfqazPGUxCxadEIjMuCZAPmoWrsS52lZ7s1tMSSJohbzqI05MhYYJ6kZq7rWmaPNqEavcR2hmi3RusQ2k993rXHaAsloEiZN7tlmDnHXp/jXVXEdteG2gguUju0GHE8eRn0B7UpK0tzOUXGSk2TWnhtNLW1uIHtL3BwzFQBg1ja9DFb63I9qiG2VgWaMcLnt9K6V9JsRYG2uLr/AEvBPDYXPpWTYx3UNvKLeKK+sycSxj/WAd6UZXd7k0pvWV7/AIE8Fx5L283m/MAeMcFabO96J0mbYqu3zI3PH/16rXu2JVMJNnAgyBNjczZ6e1VtReS3jjuZrkOZBuRQTnHSi1yowu15kuqvE8rvZsURlCFWUZJP86autLpdsRYQBmA+Z36dOgFcpqupX91dwQaauzdyW9B6mu6itrdPDVs822S8T5Ao/jJ6nFVKPKlzFzcY2hJXOe0+N/tcVy+6XPzYA4xViLF9qkp1CZoyAQyoctt9Kraj4gvo2S30+zAkYbEIjzz9K3PAfhWXSftGsa7Kst7Mp2xZyEHU7j605O0eaWnYiriHBtNajdIe23yW9ldCENJiPcgyFHUn2qW7bTrvXBarbO6RxktPFEPnakubexlZpIlDSN0SIEADPc1JbXz2th5LwqFYFchOevaofdEyTl70NzC8e6Xe3Gkg+GJfJlY/v4s7XCj3p9pBcwaHaQ306vcomWUfNz7+lXLd3u7lYyjRwMcMSelbFodO0kNJPKJlY+X5aAHGe5P5d6bk1FR/4cmzpyu3dnLXPn3Vi9sI4vLTqcEDHrVE6JPfSiM2ytggny+BXd+IJIreKP7O0ce+Lbt25zmsKZ4LYlLeZ1VR+8fJxmiM3ujSNRTj8Jei0aOF4nvSiLEBxuBJ9AfT6Uy7uI728WKC3zsACRghkxzyaim8u/hiCSpGSu4uzZJ/Cqsl4mlI5iniLkYPy5qVd+ooxcvUp6vpk1nCbiAjzpOE2dhnk06506Syt7OHSnE2oyjmNoQ0in1z1rV8P293qF4b24sJplQAov3VJ9a1LbVjoetG5udLuJw/+smjTJDeg+lVzNabmVesoaPVoztI03xBZwf6ZY/O56bcu3+FbEpv9OjMotbWyVVB8yYk8n0z3ra1PxjabTJZxO7qMBmGAGPauUt70XTSXXiG4M9sHLrET8qk+v07Csrylq1YxjKpPWSSOb1XSdb16YzvNcX0asDjJwfYD0rUF7FY25s9MsUt7oAJNdnDOh7qvp+dW9Q8TTzRC20ONreDbtaZhtYj2qlY6f5aKdxCDnLdSf8A69aOTatI6IxSV5q3l/mFjpe7PzMMjLkHlvqa6DwtZwTXHzhI4I+pcdfaoNJE1zObeIL5ca7pMHH5mmXeox2mmNaoMzsxCnIxyeprOV5aGVRyqPlNy/16xs0Szs7VWBJBlYggDufesG+tNM8xbhNTSbPzFMblWscOFgcyu7D7o29x6ClutRgmkiIszFbRLwvUsf6Vap22LhhuX4b+Zu2Uc9wT9iQyW7D77gKPfGadJYaVaxOdTke6uMDCqflX2A71zV94svYEEMLJCQMLEEyQKyLfVp5blZ7lnaUd+gqvZS3COHk7u9vzOsnSLC3CRwwxRnKxIo/X/GktvFVtpFxFPqVuY4zkM8ZOT70WVq99AqpE5eRdwORg/nXM+LbCQW8a6m3lWsfIK/MaSUZO0hckZ+7JnYQ+NbTXL/y9PsLmOQofLnnXAYDuD+fWpr2QQmKOKV2CxjLKMgnJzXKeFjLNYRxaM/nwYy0kh2kDuPpVa78Qx20zQi8tfk+XCAsB7ZxS5NfdRzywkE+W5D4ZMYNuJdu0fM2Tg5robmZru/Mm0QWyKSAeTj2rP0fR8sEZj5ucnBzn2FaQslOpfaZnEdspCsp/XPpWkmrnqzacm2TxQWJEbxWnnNK4WTzBkYNb7xWUEkENuPscobjyVB5PvWPqeuWdzazR6cyhd6sroBwVHrUxttTu4kuJJfL2x7i5HA/2c+tZu+70OOUW1eWhi62sl1qVvDHfKVeXJDkBnPrn+laKaPdz20Eqn90ku0xqBlh7GuT1Cxu7/wAT2EgSGO1t5NwkTODk966zXZ5LLRLazW6aNWmO/bncf/rVb0UUjRp3UUZErxSaozw20NvJGW3PnkgDr6VR8IaqE1PU7g3LqvnCUNjBZR/D9PpVuDTrXVonENxDp6wKQ8k0hBbPqen4VlpZ+FLWTE/iJGfGGMYbaD7HvT5oq6ZrKnGWiT+46jU9V07UbO7uIoZEuCpYRg4XNc/Y+LL6ytEiudPNzA0mY/NB4I7CrlxfaWlwG0K/t7tGQI5YYA9Me9btlLBpOlJLPBNdTSsS5UAqv+FSuVLa5m9FypX8mYVlZ3jySXC2nlo587ynfO484J9hWZqy3BnWORNsxOQqjoPau+t9V0uFU+2xeSs5IDZLMAR6VTu5NHlhWK1M91PghJDEFP4nvQpu+qKhVknZxObi8N3lxbG78xkts5VHbkGlmnmt5o4/nO35Rt5Cr3rRs75pbwW8s0szDnbjOcD2rQS1vdRaI/ZltwBhCwPygdyMcUOT+0HO6btMpaDO4a4ubWLzHT5V3dMcZ4FVprS2uZJLm6cfbeWjUjbu/CtQWcmhymS0uopowQ06K4yfw/GoL5Hl1OEjymiVCSz5VgT0XFTza3QudOXMjh5keS9HnBgqNjrmujmsrh/K+xNEflU4Jw341aitnbzIZkYq5AVwmF6n/wCtTNJS+stU2NbRb4s8yDAI+tXc6Z1uZXWljZsbe2hhl/tUF5QBLvhb5lHQADvVK8tooLmO4tZ50MhBIBwfm9quxQpfXLSTtLbhVCq0Z+VvXJpviDU7OCYi7t45p4SuxonB3EdM4qFe5yRb5rLUxdSlj1fUI4NNgMku3BPU5Hapmt20fym1eEu8gOG3ZwPapJdVnEsn2C1EDzKD+7jwR+NRJcNFIJtZladiMJGTnB9hVq6Vv+HN/eta2nbqbVgnhy7hkFrJtlfDv5o24I9KytUvoLi78+0G+GL7xPRuPT0qG1u4IIJVeCSZnBGzaCvPf61NotpbThRdEpCeZFXjAz3/AApW5dWZKKg3OVymdcWTzBHKkSJ8y7Acgj3pkMWo30InufPktwMqWf5cemKsXCaHFf7ND0qaeABg8sr4DewzV+XxTA9lHYizaFVXbtU7uMfr9ae3woX1mG8I6eYWt4l1bfZI0WNyM/l2AqJ9VUyKIk2wx/LnGcnuaraWLW7ut1sJ9saFskY3HsK1Liw0zTojHLcL5u0HCnczN3AFS7J2Zd6d9m7lDxMI20uNrTY8zHJEYIGPf/Co9DtJECXE6rM4XG08L1zz9DVyJPPIjtLW4+f5dzjANP1i3ijht9NhuNsiDzJzGfmPtTvZcpm1y76llYXvbsPKyskK7mA6AVem0+ymLSebEWCjKsRsHHAxVGXX4IbVItM0uSKTbgS4BJ9/eo7SwfUra5vbuUxQgbVHQse9Z62u9CGm1eXuoyfELbp7W3ttskpO1SpA2r/QUmnWyaVN9rvoUuY1b5QHH5+9chq0F1Fq7LFJ8m4Abj1Fb6eEtY165W8nu47HTYQAglfGR7Ct+VJK7si6lVQhyrY6648aSyTMLS1aKIRAIxQ53989sUhuGuwsV3c3PnzEEiM8be/yiprWN4tOnWyu7SYQx4AQZ3YHJNZq6FfG6t79L6NVLAyc8qtYJRWi0MYeya00/r0Ibm1tJ7qFZ1WfTbWbKRxAgZ7s5PVu1RzBNX8RSGEJFbAjbH2Hb8TVvXddSWW8s7a3H2eZw5fGC5HHH5Zp3g+0R9TWSRMLGC20Dv2zVcztdlpezg5vRlq50uNJY44ECEcs5OcD6VZML3EwtUIMY53beg/xrT1NJbiTeihexx0NZtrM4a6hVvLATh++e/8AhWSbaOZTclcoXt3Do8dzaWSl7yY4LZztFedajqktpfSWupLJEQ3yuFzn0rr7K7tLjUbxWTc8ZBaZ24Dc9agu9Autcu1lilWQbRtRMMM9OtdFO0fiOmL5NdvMt6ba3b6TH5tzsDNiBQPmJ+vpWdqE39jW7z3Y+0Sh8CNjjn1NddY6RYaQY0u9Uhe9iAJXrt+grM1rTYtS1qCSRRDEW3s0mMSYqYzV9diYV2277GFDfJr0XnXdgLWRVwu37uB3OaznXUU1ezh0q1iWEkMZJRwPXJPT6VpzlYdUnisTJPaO4Z++wfyxXRTpZWUSw3ESuz/8tGH3R649avm5eg6itFLuZ82uWejWt1cXRNxMSVjQPxn0GO1co8d/4osbkSosCvgpngAZ6CrfiK1tdR123FpAE0+3ALFVwXx1z7mrcmrPcfuXthHABkLGoG0D37mhe6lbcUabbckjSFnFo/hY6dFeW8aTR7GYHEjHv9K5iPwXDZxqkroxYbwTL2NWE3SzE2jMturZMjLkirN3Pou9Ptk99JPtG5gmQfpQuaOie5FnD3pL8Dq4bSWLT/PSFUl243Z4xjrWJeXKzWk1i6sGAJLK+VyT1z3rHt9Yi1q6ljZGgt3bG1XJLAfyqe/ikNuyKCN4A3RjIUeg/wAaSi0/eOyMHtLct6VpcmnkXEwSW3UblQMPmb39BW1qXiFJd0EK7bXb8qKclmPc1VvrWPT/AA1Zt5rXG8Y8xzjGO2KwtZ1K005InhZwxXOQBnJ+tDtN3Y6VP2tm1dmrFNdJ5UTW/lrGeSBksAemK0ZZtPuNLutUu4ZHNv1Ltxj2x3rzS78Rtcll3TexxnFbPiGeXT/hVKzqQ+o3Q57bVBPFKomo3OmeFcXG+jb/AOH/AAOfll1rx9qZsdChNvp0WNwXO1efvMepNW/iH8MNV8KeH1uhdRXqswVvLUgrnvz2r2X4Badb2Xw/tbiJFEty7PI/c4OBXQfEfVI9H8L3l68MU7QpvWOToxFZ1Kvs58kVovxPNlmFX2/sqWivax8hx22qaaIpHRFCgZ2HJ9cH3r2nwtq3n+HI7x5nklVtgSVBsOa8nh8b3C22rRfZLRRqTFpP3f3eeAvpXoPw2lH/AAjyR3MEckYkaRd4z2rd6x1R6NZOdNSluvxRo3dzFM7SSRsoxwEHANWRFNqGn7bRwzKQPLCgMM1sTn7bb+VbQW+1lDL82NmPWm6LeLpVvcvLGGfJ8zauCuP5+tZ82mhzuq+W8VqZlja3ml6jbRWsaPqMh/dJnn3Le1XvEFzpWkn/AIqjUrq9v2+9DAxAT2wCAKboGqRW9pr3iAh/MhAtrZZOSCf/AK5rx/WtS83UJZ7tjK8jE4J7k8k1LvKWvT+rHRQoSrTbelt31b/RHrkHhLQ/Edp9v8J6lLBdryYmckg+hBNVrK5uwkxk2f2lbyFZkcDqO+a8w0fxA9nfx3VgTa3CDAZG4PsR3FdhpOtSajrMl5fbVFyR5hXofcCqUZd7oqrhqsU+Z8y6X39PM6q38WXDSomo2uFDDaQucH2qa98rUr5Vi2xQtz1wSP8Aa9KcbXQWtv8AQrud7mR9qRSH7pHcn0qHUtPg05VBlW6lc5LE8n2zS92+mh56dO/uqzG3F5BFMscEjzKo2YAwv/16geXRlf8AeB3ud2SgTqewohjiwsayATsf9XGmT+J6VpvoMEMaSSSSQzuCSOpJA/Sq0RbnCOmph3UkkLMIp0WSc7fKjP3Rn7ufWrWn6bLcRvdSNuIPMf8AEaks9AtIbX7RqcuDKu6OFSQ+e2f8KdFaaXp0apfzXnnDnZHyUHq3+FO62RbqRatH8iS7s3juXt7hZLK2cZ81fnzkdPamGGzs0MVvNI6MuJJmXA/AVEpe7vEm0+eSa1iOT53ABPYZ6mtGCa1kuPLvBJISM7dpKp78VOqM3Ky11IpdPudWFumiTWsNnCOQ6EMxPfpzUsvhy30i1F7rcxlVSdqxHDSt6E+n0pl1aXKTSypCHgCjDRSYz6ECsK+1HU9bdIrgSFYh5UaYxyf5npQuZ7PT8SFhlVas7RW5YFze65dG209Y7S0iHAXhVHuepNSRQpZX8cVrC99eAY56E/T0qTTdFv8ATmkGrSLZWaR7ywwST/d+tLaanLDIbrToUWMHjeMt+Yp3Wy2NuZSvGl8K+S+8ddavqcVrdR3ipbMAQFPykf41xd3erHiQs0krcEFjlj/hXZ69c3WvK8d44hLjEap2Xuc1X0DTdLR0txEmSSGuDy2e9OLUVdoScoxdlbvY5jwhv1vXBbnUPIuy37qIkgZPXHv1r1G78OaXoBtV1KC9v0lbDSCQ7UPrtz0rmJPC+g6ZraaxY3sz3EDZSOMDJfHQ+3NaMniPU5G824uTE7nAITO1aVSTm04PT7jk/ezfu6R+5sn1H4fxar4ljvLdhBpICnyzncMf3frWx4gtdA1aAWa36hbNgXjVyFPoDXMXmoXV5CFkv2MQbG4SdT9Kz7XRrNmd5r6NSxzg53NUe9Zc0ttiVhW9Zyf5nYeHNNsLWz863CpywJ35AGe2e1N1myMsJFlKRar8+e7f/WrlY7GwSQIt0wIPckYq/Nd2luPnnnuHHG3OBUtO97lKi4yvC7+RnSW6x3YuHPzKOFJJGasWusSWMUiqqqzHn1OaqyXrSXDXH2YyFR8iYwq+59a0fBWhjULm6vr1WZoyrIDwM9en4VbSSvI6alow5qpe0xLqbfcSPIZ3XEaDIxz6VWvvDMkqk308yux3FYjggGto69MyzDTbOS5ulBHI2qPqawbQeIIYri61JztwWZQOgqVzb7HJzTv0RSsvD62r3rQNJ9iX7+77zHvk966WyW10nQ4rlZ/s8bITx1z/AI1AdQS90Fzsa1QL96QjGD3xXJatrFhaW1s9+7T2VvlIolXCux6mqSlUdi3zTXv6JD1km1ieOc2zxxAbSYh8zn1yelW4NCvlWSS/nfyAo8lSxydxxijS/EEkunJHCiW9m4+WNh8wP1qWfV7pGSG3ia+uBgncpKp6YqnzbI2vNr3VZHUW+kWHh+zlbf5rbNzkn72f4a5K7uSbNLi4WS4Z/uKD8qjsKgU6gl2s+sWMwidsgtkKD9K2L+7tmQWtkV8sqFLIMcjnipSa1epEYOL11v1OejlE8pmu1eGJegQd/eujh8NwfYVvI5lmZxu6cbfQVTltnt4DLeSrbsV+UsfvCsC5luNRkjt1vo/KiyVVJMFv8+lU05bOyHOTl8ErGn4l1m30WWCz06KKIkb5EljHzKfc1WTV/DF8POaWS0c8NERkA98e1UfFPhu6XRrTUYjJOWwTuG7ZXFTpOr8pEcjP3cYrWFOM4ppnOkottSbPRYtItHlVoY/sqbd0jDnirs13aWUca2V6J4QMbD2+orfs7Vb23ugybWMf3v8AGsG08PWLR3XkSMGYY3HkKB3rFST0l0Or2qbs+hl+IL68gsDb+UHidiRjnANcB4pNx9njdjwRnnqcHFesDRWgWPdKLiFcYdT0FZeveGojp8aTQ5hJOXUn5c+/fpVcytZHdhq8ISVzxrTtxKhXk3k9c8V7zquiQeIfhfFaw7jeW0Ydcryxx0H4GuKsPC9tBfxqxWSNsbGB2j8a9A8Oq1oBHYkzFnwzddn4U61pRsgxla/JKD1jqea+CfiTf+E9KOiXlo0sME/mK4k2sq91x3rs7z4p+GNf0jUhqaNGXiaOKOVA7jjAYDpnnOKseNPBWl6mfPe+tobxss3lrnefwrz5vhgbeQz6hewRwtyvJJYewrJuNTWS1MFSw1a04uzv5nB2tk+q6oEtom8ot8uFxkZ6176ukwaLoOnmKQEtHlgcAehrE0bT7DRNOAtEP2mXhXIzx9O3atHVxJq9olzb4PkJiS3DZIx6CtX0Na0+aSS2/MvSyWUcYkgkklZwIyRyoI7ZqG2uLlrYFPuKxPmEAZ9vei1tzDpMMt/a7Y2Vmt1UEHPHzH1rTsNTW3XZeRGaEDGQOD6VD+853otFc5nWYb2OQLApNlcOJZI8dHAxXlfiy3VNfxLuiiLfMMdBX0RdXenC0lACSSIowmNpFeY+KLFNbmaRIlUuxRWb+I9s0oavY68JXclyyVkcDfraqkLWn3nxhFHIGO9em+C9BuLrSoZTbPkNy7D7v/1q5208Jy2NwpmtgJF6lmODXf8Ah29uHjeK9kZLTdj938grVt8uhvjK/ue4yn4j8O30U9tNAEj2rt+UnJ9wPeur0LS7fTtMiuNbnLMDiOM8nJHpVRb2xt5Hjt7kyL2YksF9OfWq6zWxnN3evLcykfuw2cj6AcVk3KUbHjTU5qz/AOCaNrDp0Nx51u7LcM2QEGQKuTgxyC81W9iDKwIjHDAViPf6hcShrXTjHkAK+MkU630OS5mludRmPmoN5jyCxFJrq2Dp21m7fiy1qGt6EkMkjyl2AwrsMZP1NYOizf2lbzSTlyJ24Pc+59BSz6DDc3q/u2aFnPzSjA464rPn1C6GoXFtaWESWCNtR92CQD1z6VrCKatEXIlpqdRYaHMqOY7u32H5iN3C4GBmrNtNaszRxSxwJGv7yfbksfb0Fc3G3nSKluhjBH948/T1rpdL0r7NaXUkyNJIy5MfGMVnLzY6kVBe8ynfTwQ4ksb2VlflUUZBPrg1jLq9zZ3q3DQF3UllXJwTWm1tbySLJDCIMDBVicfhVK+geOXdHHCrlCoaTLADPvTVtjeny2tv6nKXXiGS9vZXvi5UtucEkZJruNF8R6UbEmKxk83gbHPy4qHS9D05JEl8QXVqqP1QHnjtU1xquj2V2YtBsvORf+WjDAJ/Gqm4y0iiJyVR8tm15aIivmluJGuI7Z7aMgheMAk+nrTbLR7yeENcOlmi/MSuBu9c/WmyyanfzfaJyWVOgAOF+lWNP0rU9UlJZJjGvGZPlU/hUN2G6vLGyaRLdWf2WyL2ZMikDAxkt75qjcC6WznlSJIEReTJ95j6CtnUJ5NLhj063jE92RvAcZ2j1NYFrJexah5ksgmmU7tjgsCc9ABwKI3auZxblG7fp3LWjXun6npjxXNgy3ysPm+6MjvWLdAi8ZYJlJ3copyB9DXQok+oXDJrt5Fp8IYh4kAVm7inw3NnpbPBa6VLJuywkc/+PZ7/AIU766CjiI0Ot2Y2n6PqGpShIipDHqeCK3tM8C3Cy5vBu28kJyf1qlc+I7fTr+IaXYywuW+cycKSecj2rubXxYp0xJri2dSRywGV/SpnKotia2JxDipQ2ZHp+iWWlQySXEIIK7j5vO32zXL6/wCKYYGMeiKhtZV/eMnBz6Yo8Q+KNYvXaKxsXmsSMMyDkj69qq2uszWb21vL4WhAkxmQtu4PelGD3lr8zCLcHzVdX2uYtlfTrqSXFnbzxID/ABSHac9c+tdtqNj5yxR3mqpHJcAMYYjj5Rye9c5r1yLXUGht/LSEN8iycKCRk1Q1i51lRHNNDEsa5xND8xGRjmra5mmtDsnCVVxcbI6K80WGZngtXkdyowsjYQjPHNUtV0FZNIgiuGs28txhMAlcViWV/feXG+ozs0MfJKcseOg9PxqfUnhuEdYnmidGDosoCkjqc80JST3H7GUWot3GzWFhEmEklSVCAD1yc/wjvW1p0uq28CtZ6fMqEgl2TDH3rNg13R7e4gRoh9oVsiWY5wx9D6VtnX3tJvPvp4nsJcg+W4JGB14olzPoTVlJ+61f1K2ra48kkn9pLMASB5RX7vFZ63trLGVihVTnKnvmrWuXFjCpu/tMkzAAiORcAA1mxavZXsifZ7OON1G4kNgf/qppK2iKpQXLdIt+M4JLfQFuNSD3kLJnzIzyhx29q5rw7oWmvY2eswTSb5CTsmcKUwcdPwruLO6nuYVs51jEAO4qwyNvsarXGixyShFH7pSSIoxgD1xQptR5b2OaKtL3mUbq7vYbPy7a5uEV/vKH+XFc4NOhYs0u8sTnsK6HUki0u1lvHikkjgOAjHAOe1XLfxDY3sEc9t9nijZR8jKMqfShNxV4myqxjpFXNOx1+Fbee28trSSRdhcc81nTRzWAh8mbchGC2ThgeoqraalHc3NzBFEHSIZDnBOfrWo8clxZW80ULPDJ8j7RuCGoa5dQTjF36GXBfXpd0hKbQeFccDB4xit+S8uLjTkOowlxyAD0z2OKyPDBjsmuWuEWSSKQskfQyA9hV/V9ak8tY4riITSrvFq45jx2/Kqau7JDqO8+VIpX9myW8LmEK8r8KexFLp2kXN5PLHZ3Qgw3Ifjj29ae9xLfRquP3gUbj/dLdcflVeKeRrnZGsghj/iBOB+VPWxbcuXTcuLo8cd20b6irSBeAB/P0qlrUCCSOK7BmnVsABsgKehBq9Hd24keZogu5fLEr8jP+0KhMAFrcSySnewJWQY28dqm7vdkwck7sr26hdPumjtgk8bEI/UkVz3gi0Gna1cXF5I5zz3G05z+NdJorzzQlbdX86HIxG2Ovrn1qNlgjjeO9hkF2SSAev0PrVqVrruaN3vFly88UG+1MxWzqsbDZulHyj6CoZ4JxAU8xZEMmdyLjgDvXLywpHuKRncvLZ+6v41Z0/XJlt3tjKgQnACgMT/9anyWXumroKKTpl+SVlv5fMtzOxUKAjZDfU064hWHTGgmg2b28wHGdvsK0tJlsdJi+230TtdMNggz8rD+9VibVn1El7TTIxHnlWGc/jUXfQw55X0WnczYbV55rYajOVsygZXkXgn0zimaq8dsiw2atLGSQnpz+Fas2sStC1tf6Zu242LGuF/OrFlfvM6K8EAibjywBx6UtUZt1Fq1oed6b/akOoyvLbN5UJzISpCrzXYJqgtbSFU8hD1YsMk/lVnVI9RurGeB5reKzMhO3Pztj09qn0SytljSKW0EcbdZ2w2T64NXKakrsvmXLzT1ZC+r3txEwjaHaeoWMjA9ar2yOLicSMrvMByrYxx2rpNQsIHtWTTplLk46YxVOysWtWlEghkuGX5QO2B1rNSVtCI1Ycr5VYxphbwOttHlSwIdi/bjj8aLm2ivJvKtZUgGPmJHCj3NRXHz3M1w6KqAAZIwM1LYwpAha7bbli2QM5HYYqzd6K6epPDZ2sVtcwxvLNfiP91Ko+VT69OKh0U6jZarJJdTgWz/AChGQknjrmrF+mpiZZbUvBAE52dW9sVl215exXUT3qzPsbKhznrSWqM0nNPW51N/fKbQCCKJ5s/xrXOX0kN2QtyhglQ5zHyD7e1amr67axpHM9svnHgAMPnrKXXtNn/danZS2wb7kyDP4k0oRdr2M6clT3ix1lDa3peCdcXGDsMg4P41q6PY6Npsjm8miuHOCUjXdt/Gsy3sjJLvspEniIJDowIH+FT2Omho3EbBiDkjPLn2py9TSooyvaWh0cetaXDJ9m0xNxbLu0hwsYHfnrTZ/HViieVp4N9dvwqKuBn39q4vXtEvoLGW7NusqMceUhBdOevFQWNvBb28bW8WyQr825trfSp9lBq+5nHC0ZR5m7/11OibxBYaNO02tSFtSvn2mSFCUhA6LWrBd6bBume4jlckN8hxjHQ1w8tvFLfKI4PtbjortlF46mpb620TT7Jpr0zNIvDRAhQvvx2puCdu5MqEL3bZN4tj0SbWrfUb68nuk27VtYh39c0+413UtatxpumW8dpCBhFfBcAc5yeBWPpd/bX10seh2uZEBZ55Iy2PoKvarCHgntreKZL44ZmYFQ4z2xV2tZPp+BSjShbS78/8iDW9H1C2ktZpo47iRxnejbgCO31rTTR57jTYrsyPCUbayb/vHp0qbQNIuHs4o21Z3lzua3jx8v8AwI1rLAh2WzST7SfkDHdg981Ln0HPENJR6mRD9ptHJt76Z4HbaFCcZ9zVXUrG/j1NEe9MyzfMqRNhV9Qat6jqlzbeIxotpbmS2nXD8fdJ71R1S0vdMuWhcloyMo23jH1oV7+oUpOUt1c1rU6kzzu9pa3gRgQJeGBA6hqq2l9qV/NcC7hMfOTFgHPTinpqV5DbNE2n3CPMM70Bw3vz0Faq38c1h5s8CRzrhAqtk49+Kn5EyvHeKKNvG1153lTW8AIPmQgYYAD9axL7TVS3aO4k8uRm3E5yCDUpLW2pG6ktj5OSSm7GQffvU0914eitWlnmdGYkLERyDVJNbGqbpu/QzJPDEV3GEktZG3dCwwAPX61HqcNvpEtrBZx2qS2p3K5BIPGfm7Gt29j11rK3vY7lZLZMAKuBtXsxFR3MemO/l3QiaSbDsQ3Kn69qpSfXUlv2mr19Dzzxjrt5qTI13tjbGMIMDiubsbye2lV0kZWznINeieKvCn2yNriy2rDEucluG+hNcHHpc/m7HjI54JHGPWrUo20PXwk6bpqMeh6n4c1aWfSULLmdz8iA9R61uG91BbFkOyC4OSCgBJHpXAWyx6ZYL++Z5CowemK2LXVZbSAmGTNuwHmzMvTPpmsnDqebWpRcnym3cO97beTdRI77MuX7e9M0jww0VmNkFkysxYF5BmsTUNZe804XNlIPKjJQlRjPuaw4tf1EplJGUHnHSnyStZaGMaUpL3LI6KXw5c+HtPkSWeN7iVgZEiYsEXPc1f03WL3SrCURoXhlUncei8dapaXqEk9/JaXYV0ly0hY/lz61r6Tp1zLI5iJNsHKYb7pH40Sbt75bfKnGpqWvh7NAYLi5uvKVUDN5jDOM1zsyNNrkt/JKvks22M/xP9BWve6M8JaEAQ2K/OxQ8PVCGzDmS4LbTHh0Xt1604tczkhRUW3O+5q3E0tlEGZPMDNvbHBx6fXFOaZZLCRrS1kix8xid8tgntWddTBrIebIq7yApxnml0uaaSQKxkWXBG/0+gpNaFuHu3LGnzRebGXikMMgwRKP1/OulvLNbvSjaw7YpJQRE5AAJxwK4mM3M4fzYywLY5BAIFauqXAjjt7fTreYyEBgA3Q1Mo3ZnUg3JWK0lteafYw/akeCQr5MsyrkFh0ziqMVw8l6sk8jytACgkUDn8M1qx6ktzY3MfnN5oI3AcdM/wBagsYzalEijF1dfek74qtdbmkXo3Jak1hY293usbxmAlzsOMHJ547Vijw1HZ3tzDHeSCZeVLKCAPqK6S81SOO0ngvbfayoHgVsorODyNw6cVLLJYyGKLT7ZYjtGXWTuRz1pKUlr3MXJt+9f9DCgEWmPGCr3c2370pwKt3Goy3QUQpFbIOixnrWte6fJLFuH2fAGB8xyTWHLaPbuVuo+CMqynjNCaepvSdNrzFttNuLuQ752XPUFiOauJpk2kzLNLF5safMAGyahs1nMCKXCq543Hp71qW2rR6bZzKIvOumfy4geT9aJN9BVJz2jqQJYTLFFe6nsjjlbdmXPA7ACnXvieMj7JawqzKNu4cD6ZFZ9/cm9tJrjWN7So/lQ46Y7qB/M1WuNKSHQi9tdsjz8hF4K/h2oUU/iI5E9amr/A2Lt9R06NJdpQyglgeSv0qONnSzM0jMZn5L7sFRRoSy2lht1y9kvW25y3Ij46e9ZfiSD+1rezggd4LcbmmdThtvamkr2/EiMny6x1G3bRzxJb28hZt+WXPQ+9dn4KsYrOO5lmZZJVwGVuT9Oa4rRdLtrHaYSSw/56c59K3Xubi1uhd+dEcnDKo4/GlNXVkOupVI8iOl8RXJFhLNBbiN+EUk55JwK8+8q5nika3juPtq8Zb5lb8a27/xPcSWvyW0D5OFB6cH0qHSdT1QzeYqQAHgoAeKVNOCOaOHrQV1ovUq6Lo1xqBum1AKs8XEaE43Yxk/TJq/qvhoxWiXEcySR7dzRM3r2FXodFW9aa51PUWjYkgm3f7g9KqWWhz2QlKaqXj5CkNwV98jrQ5a3uawqNP4vwMu20e0tGSW3WWNplOVDH5fWtjTntbi7KXCytHEcZIKr7c96z9Us0jzBLeyNKcYycLg9896rQwNbvN5V7naoHdxx3qm+bVs2ai46M6G+ubpbuNtMkhiVG+cSKGDDPIBqv4ingeOFQbMSF8yLv8AvA+hxVDS31C509p0xeWCsQ0ic4x1qK8t7O6VCJlwgzsI+YnPSp5UnqZxpRk1rt2N3TItKg0a5wWjlK/vNw+6fUVyum6B4euY5Zmu7y/ZZDvRv4WB5yM81o297c27ynZH5aoWMDnO8dD9K5Oa8g0q5lmtEeQOxYp91RnsO5q4RetmT7GSne+h3MFtp0Om3NrZxNYwyxlTdg42+9c7pl1LocUq2eoLqJZsifr+HI4rlri71DWZ/LGbS1JzgEkV1mkxaZpGmqpn+03JO6TzPlA9h603DlVm73KVPkleUXYsRSarfyx3SoYQnO5V2g/X1q1Dr8lpqCpd3cQycEMoz9Ky9Qt7/U7gSWk8psx8uwjCKfaoB4X0m3BN7K95dyHlEbaF/GlaP2gn7ztymzJfJPq3m4ZUJJWSEZOe+c1oS+Io7omCW3dQnR2TcCPemaV4j07TY1j/ALOdEUbQQMnGPWqqeI2illm0+yG2QEM0jAnH0FZ8t+hLpyb+D8TG8R+Jp4dUWA3V2YtgIMSjaPp+VbFrfxvYNcmYqrry7LgL9fesO+WTVlLmKJSxxnaAFq7c2lommm2t5mnhIy4GSQ1aNRskaKnyaFpbuKXT1aBJbhZH2qxGcn1+lc34n0RZpzPFFNK74LDGAMdcVo2WoT6ZbrDYxsRyCWx8tUvEGtzvYfZLa2RFfmSXdlie/OeBVQTUvdFOnJLUt213qF3oItLR7YxxkLsWTDAf1rWn06wezs/skircFdsu5SSGHUk+lcJ4eSO13XMV3HHNnG0gsMe9aw1GW4uAJHjKryNqcH6U5w102HTpNaqR0F9YM5RRJJLa4BJHCsaypv7PtblVMfnE9RnOK0tNv0a3cXkq7Sf9WRyBWz/aOm29uUs4Ldyw+ZXQYH41m21pYpzlDSzfoeWa9o93cXqzxX0SoGzsGcgfStHVF1K90iKzQHgABFAUNjvWhqwgW5aS32opbDhuR68e1T2s1oT587Su8Y4Rej+xPpWkpvR9jTkio3S3K/h+BrLQ005oV86d/qWPb8KsXFn4W0+ZrfUru5nulPzm3X5FP938K5q78UC0a9YRD7X5WIXz/qyTjp9K6Xw94atZtFtJ5USV5kEhYgkkn1rKfuay69jGUlTvKTaXl3JLrUNE1GztbiOaGO/Jy0QOM4PoK6VdTuJrZoLS0kWBoxtKg4J9RXExeEdIGtRy3Uk4Gc/Z0xlj7H0rtZLiSGGWHTvKigEflAzHG3/9VOfLZKP4kSvonrYyP7TuJI0tTO8oDbdjnhPxq1eQJaQsZHdVcDhV/lWfq9pFo8kT2l4sj7N7lgCQ3tUFj4rZ5Yra8PnhmyVdfuiqS5tYm1rpSgtDXitrZ0+0kyxCNd7K44PpisaE3rXbW0BCmVg2SCdg+tdRreqWF1pAMJAkyFKjpx2FUNNk8uUSyMVgB/e56jjOKSbtdoVOclFya+8zYbe+TUI0vZZQqZKrjhhVm1MsN/NeyqYwsYMcQY5Oen+NXbzV2Zkle2NtbkEoSMlhWXFeNdSz3RRVGQFDdKerWpolKau0M0qzluJZGyBGHLNngk+9WmeXTrw3EJ5B++owB9a0vDNpaTNfrcOcKQQe7cdhV/VbOwKC0tyWmlHUnIXiplOzsTOulPkexD/wksVzbGDVLSG9iONzMv3Aawde0K20/UCLS7MEbgPGGOcAjoKiuNPmtV8hkcN/y1K4w3oKGH2940meR7kDaI+wHahJR1iVGlGD5oOyLFpbX6KGjd5UOArPlRmtR9OluLI+ZOWnTliR8pHpVbR4bzSXeW5B8kchM5rS/tCNL2ee3OLeUAMGHGR3/WlJu+hlNy5vdMrULfUbSzW8062inRVPmb2yMdPl/wDrUqP5lm19cZieNfukYYe4q/HdpHHK1qUeJxzHgjb7iuf1nUzYwSzw5kK9Vb5hTV3oTFN3bNaxtPt8Mao/7tY8xmXgSMeSRVRopbed2vYnjMIC7em7/wCtVDRtcu9Qhge7VX8vLDb8uB6cdq7CC6i1GyzKshRx8xwCR75NEuaD1Hzyjq9jNvfIE1rP5am3MZbCngvjofeqLw+VGLuY8yn7hPy47U77M8Ewt5poxGTvjjkbBJx0NLLNDcsIJdwLIWIzjcAP4aEbKyVlqEUUt+zzQxMyL0OcA1CsaSExqrSS54XPStCw8U6fYrDBDZzSsq7XRBwB6n3qCWKa91eP/hHjII93mHC7cfU49aNepCqyTaasiO2s3gtry5aNwbVQwi2bmbnmrWn28mpL9ptpEt4mxyeD9KvyeITOxjv4/st3EdpZRjcff8ax5vskmpQXJlYmN9yxhiA59Wpavcy5q0r33K/jLSW8PiOe7u5FNydqCE4LcdWFGk2WozWEDneYpFBQEnnP866zXUg1qztP7RCSCI7woHT2qut5ZvFDHIWSKHCgIvQUKbcUuoqdWrb3tTi764dWktrgqrx53K/B+lQ6VNMZ3e1lBhkBRwn3SMc4rV8R6Nb6qnmpHLGXJCSu338dqztB0fUbC2FskMTgSDkMfmyB3rVOLj5nT7VNcrW5Y8M3epWa3VlZwuLebJKbTgn1FWora/F0ZHsmVeN7SkBRmpBNqGnThSr27swJZACOPrU1xrNxLcxR3Z8uMsGEm0jn3FS227ozinT+BKzJ7jSJ3uVmuGdYezRfNu9hV+40nRprZ7ZU26lsJAcEndjPTvUWpa/qAtzBarDM+OWVOnuBXKPqWrvq1peGTbJC25uASe2DUKMpLexl+9nZ7DvDt5Y3OoT2VjMy3iZBWeFQOOpFWNShgl1WF9QKTyIoOUwoAz0NTX1pZDWW17ywl5cRgNEg43HvVOOIX907Xk2Qo/1SHgelaXTfMuxpTUpJyqs24NSm1G5Wy04oIAMNt6VlTwrb3zLOJH52hB1NadvOukWzJbnZvHOFyR9KNFe1W6a4vVupZCDsAXPNZbaom/KnyrT8StcwMdghsSmByQ3P5VBHYx4/exzRe2a6G61iZFJ+xKgOSCTlh/hWbf65YiNPP2EsOoGStC5uxMHUa0Q6LRrOeMKt0w46AGom8PyxRk2d3GBjlemaoNdGQstq3y4zvLYqilveLLJIHMoY5YKxxTtLuWqc1vKxdkt5rOJxKqEE4BXk/wD165ySwTzsrFM3+03f610DpeT25nuLiOOCI58s4GagjvpJButreWRBwCBxVxutjSC67mNHZ7XVtqIhPOFrds1gSH55oCOpAGCKq3FrflPPe2aGI4y/arNnpMrRGSa3uBCekoXr780N92aSaa1K5eG4ldYIi5P8TGrUGlXlwhURyAv90bcDHqTU5ktrQRR29sVkIwZWIP6Cp1v1lRvPW6ZAOq8D/wDVQ2+gpVJW91GdLpjzeVZpEXbcRJMDlQK0Hj03STbwXLKYMFM7sc+prMj1+2kFxBbGQTRIxG1ewrzfUbq5vbqYu0z3AfAVTnIPSjlb+IKdOdfRuyNXX9Dtra1vb2K4852YBUUhiOe/NW9A8ZX+jactmYkO0lh5hwRn61kr9t0+VFuEPy9VYYYfT/CuyjtzqMMVy0MT70GDs7Y6dKmUlL4xyoqlG0ndHoGnaCz3sl5dwEcbI1J/M1YktbWFJrNEhKKcqZXBJOOwqtp+tTafa7Q/nLkqd7biT9a53S43Gq3F7cTrIyFnxn8aySbbu9Dz+Wo25SZW1SK5s9SLXFszW7IFR9uVz6mtzT9P0A6dJJPta4b7xHQfjVXUfiBpV3bCyvbWVGTnco6kViWGsQXdybDTxJ5cx4LL0rZRm1ZqxrzOaXN7rRNBZ2KXyCW4kMJYsEjI+Wti8aR7GCIwlbR5PvscMw7Zq7c2tvpmll0lhOyPIDD5ye361zl7LqV1f2c8nnLYooV2XlT64oT5hzrXXP0H6peh5vIdiyqoHAzgU6w0i7uoZJrSBxaqMgv149BW14SW11N7hIrVyigFpZFFa3iTX/smnw2tiiRLuEbcYyB3FJycXypalLEyf7uktTmNKlvbYiKSLyIGXuAHY57n+lWLnVbexuDJsLv5gjDNwAT1xj0rUt76wlBSUBtvz7pOaz9SshGQWRHfJlAxwoPT8aV7vVEQhq1Pdk6aGmoSRytqCwhTuIzgn8zV5ZNGs3IjdHmzgyKtczbwSXWfKt552JxlVJBNaLaG1papNeXEaM2cIvJ96Tt1ZrKMVpKXyNa61G1aByJfKQfeMueRXMRy22qPImnziSCLPzY2rk+metSX0K6jayae0u0FSC46j6VUttKXS0hhtJS7KOoGPm7k1UUkvMUYOEtHZGpaEIvlIhebpwfl/GsS+vRDfG3ETXMjnDMq5A9ua6OSzk02Dz7h8MuOCPv1Dp0kuparsjiiQKNzP2B7ChNbhJppyWxz2lfarTxBcade+XmfmPcQAoPTFdPDPLpU7QXKZUc/WqXiXQmaVb6eVluUI37RkOAeMelRyXxSU3V4jFm+RA44PHvVNqaViKMZSTvqjL8QWpvpFlKqeSyY4YVz1wmqy3UDCFwIwNiK2XGK7C8M01m0mYA3cDqRn2ptuVVElSVYHAABHU565z+ApqVkdkZOMdDD08eILi+E9s0kGW3zSFhgV3/h7Xtbh0u8v7prWXToRhGcbSx9jjmsafW50tRFp7BGnUiUYGUI7iq1p4wn1qzm0OS0RHACgBQu/Bzn26VMk5rZHBOEpS9+Kdy9NqtzdRyXcEVtHcSSAkyxlsDnJxRbCWeHzbnY6Y5mjiwA3p9Pesm70a7uo5bC3vCtwQGaMsAD25NbWg6dP4a0qWHUb9JJ5j8i7iRGPY0e6loOco052iUE1O3jHlI5d8Yyqk7vp9KckYdNzAmNsMI8/Mec9KY1/pFtqQ8m2a5cj7yNjn6GrUnlQl72ZMSygbUB+7Tat0N1VjPSBbvtTSXQ0t44X3I+VDcH6CsqCS8hmLswEX90nOK1NIWe9fy3t1fADlZF2gDPOKvXNjbb2yghR2+Ujkn6Couo6EKcYXhYl0WVktg0k8Qhc58wqRj6Z71m39tc3088sLRPZW/R3PDH2NaWtta29nCygkRERnIx264rLaRo7pXit2IlXayOTtH4VMd7mEH9pIyNUmlsnRrm2VDgHhs8UybV5rmPy7KCNFbg5GOvvVa+vbmTVZ7i4TKOcYIyBjsKWA/aHYjcFXnDfwj+la6W1PQUUoptamhYQSwsUOx5HGWZhuxV2LT1t8SzSbXPPAAJH9KyYNXitInaJsIMhpGGST6CsfUpLrW4Ubz3ijkIUJnLN7nH8qVpNmU4zk+yL9/4m0y1uise+9mBOVQcZ9M1QPjLVLm4WKzs0QH+4Mt9K2dH8DafbAy6jM064yVCbM/XPSte3udF01z/AGfp+6RhgbRnn0zRzQWkVciModI3KFvpOo6mEfVrhrWIjlFbLfie1SPpGhWsMm9JrhgONzAc+5NdFp1lJcGae4kj2s2RCz8Djpmo9Xt9FhgKSG2Ekh+4D5jKT6VHO72/IzeIfNy3+45J5LMwNBZ6fJEM5L7uTirWmaNq+rRrJGlrbWyfKDuHHufepL+WS2keKzaPAXaXkXqPpVSC51WW0ZBNKtqTybdAM1erWhq+Zq8bfM3/AOzDpdqW1W3srgKP3bbuB9apXnjCXyY7aCxtk2/xR8DHpWaxaKMEq8ox8jyuMqfoeKl0fT7+889LqWCbzCCu+RRswewFTZby1M3BW5p6/wBdizPqer6lEqm1t4oIhxkfrioCkssS/br9nyciPfx9MVBbyazDq7R6lZxtaLywjcA47dKnnubV3ZILB1m2kluwx0p7bfgEGn8KLF1qNpZxJbW1tunxuO85GPauc1zXmViz3KRXEXHlDqAe4q3dX8FtpV5eXJijlxtjDLg9O1efeDZ01vxCVvLmOKSR+JJhuX6GrirJy7G9OMY3lLodd4bSw1S+mEWoRW926kBZDt8wn3NczrWm6rol/IhhXcZMl15ye2MdvevYNV8GaC3hTz9TW0gvEiJNxbnaC3bH6V5j4N8WxS3v9i+IkE9vkpb3E/3o/QE+lZqTmnJBRxSbbp6rt/kc9dT6lqF/tUNKzgFnk/hP1ru9Gi1CysI4FuVUL2MldLe+FtNstBmljnGXwRKiZA56VkWsESQIBKmP9o81DlzK/QJ4mNVWitEaFwlymyOSNcMR0bn6Yqjd3VvaXDxkssmRkKenrWzFK/29lzwOnA9KzorK3uNYlM0Sucjr9Kq9nqZwqJ3v0EtLezuNzG1idiu7zHX7vua1LHUdN0+0ZYIFE4GC6xgD86pahBHHDKqIAASAK1tD0+0uXVp4Ecn1FDta7IqONuaWxkQwTau8KYkiV3zvKk59q6/WNQtrCx+y2tolzFAoQof7xFZF/e3MF1e28MpSGNiEVQAF47VyT6jdw3tpFFMVjkly4wPm+tUoOo0jKs+azktOx0+h+JoYbW8i2R2/QAIPvE9qyL5Lu9uYZpGzCSSh7Cup8QWVsILMrBGpMWTgYzxWXfxr9vjjx8iQ7lGehxUqSvdI0o1Ypc8FuZMdxAzPCpBPQuf6VDrmpS+QqqzzXE33Y0HO3oCfQVugCDwxbiEBN4JYqMEnnqetXPC9jbT+DzcTQo87sQ0jDJOOnP4UOaWrWxVWu0rre9jK8KaDqt5IsuqahNYwRkFLeP5SwrYu0muZ0aRD9hhU5lJ3E89TVe7dhbQuGO4EjOfaqWp3c8PhKRYpGUScN70m3N3OVQa95bsikvrJZY5NOsrqa1bh7gLnk9vrWL4iOsTlY9LQRJjiP+MnuTxmucXVL6y0BltLmSEPIQdhxXpfwcZrzRmnumM0wk273OWx6ZreUHTXP2E6zUbT1OO1fxDqsN7ZaZdp5t4dvmd//wBRxW/ZxeTOz28jRJuxubpz6Vr3FlbLq+o3Cwr57S4L9TWHdsUmvNpPy7ce1Z86aVlY1oSbv2NGZ5PtMcjM0tvjjd/EfWm2V5aR6q81/btcQIpCISNoYmqtizf2fK5di23qWJ7U2wjVoAWGTnqfxpHQrOOpM0k13d3ZNikNmQI128YrGkjWbEZDSojbMDgAe9bF58tqGXIYsATnrWbH8rXbLwelUn2Nab0djImurbSNce21G0uEjmC+Vlvun1+ldU1nbi/2zkI6c70GSQe35VieMD9v8KLeXYEl1ENqSEYIHpxXS6DEkfgK0uEGJ9g/eZOenrVSfuqXXY4lJqVpEz6JpmosZ4NUaBoVzIDw59MVAlhpLMwvZdT1KUcqN20D9a5nU55HZZGc793X8auTXdxIIt8rf6vtx6+lTyyS3OiWE2cncfdXEVndf6PZi1gBDETJ8xP1q3pjS6nKJ3jRghwqYxz/AFrU0O0g1DTLNr2MTt5ZOX5NcR4wke11edLdjGqyhVCnGBQnzPl6mtKmpydOOjNHUNV8UzXb21hYmONCRuC43D8av2Wq6vbSW9vqMASRjjcBuOO/PauYi1S+QjbcyDPB561v6ZcS3DkzNuOPQe9XJWVrIVTDygru1juYBp8tlchoxK833t3oPrx3rGMKWd5eIJyGwDC2eNp5NYOs3U4t8CRgMGq7OxRMsfuEfhWKhpe5zQoO177lrVTDIyuZo9ynACtwapyXAtFZYo/Mdh0PQn3qJI0kuoo3XKYBI9auXFnAuqoFjAHHGT6VWi0OqNl7rI9O0y3ubmKa7jF4FHzwxnagNbVtqVrppM9jYWsbLkARAEj8TUOuRrFpjGIbCuMbTjrXLeKuLCHaANzqDgYzwaaXPozKT51d7HVLeNqcN1cTyqPm/wBQOSx98VlRwahcu72kYMS9lqh8PJHgmuxExUNtJ7969F0ONI7wsigHdSm+RtIh1XRukjz/AFAXljNFFcJOJZMNtJOME9TQ9mbXWftsiS4zuEKZIGB6+lbPxXkePU9JkjZldlAYg4zhjXpGmW8PkRt5SFnUFiRnJpSquMU+5zSxnMryR5zbavpI3jVI5mLdAi4/Cpb3xC8tubXT7IW9uozkgZxXLfE92Hj+6RWIRBHtUcAfKK9D8OWsDQbGiQq9vkgjqcUTUYJS7l+1hbna/E4G4vrYvbfa53KytsYlcgMTjoKs6x4WitZf9H1r7NKy7trDA/CqGkIr+IY4nUNH5p+U+1aeugSq0kgBfcRn2zVOTjKyZ1zg41EubQg8HJfveTWN9PFPasMCaJsNn371u6xY3WjyFrc7oDERvVc8e9cPExjuxsJXPpXa6TqF08CwPMzQsCCrAHIpSu3zE1qUqb5k9Dj9ftXvtDltrKYTqx37SMOpHUVzXwyv7DSNbW31qARl3x5zjlK9g1SwtbQH7NAkfTpXK/EfRdOOix3n2SMXJHMgyCfyqHVTXK9mONWNRcnc9XEug3EEbrcwNBH84VnBU14j8WptO1TxVZRaEsXGNzRAAE59q86DNGSqO4XPTca9C+HFjbG5WVoVaQg/M3NVyxox5lqxQwLw0vayle3Q9K0a4n/sJ4ZY49igBh1zjrXNXMcTylsogPYtjFal+xg06cRHYGIBA+tYk0SKwAUYwKinGyMqcLtyWlz/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spherules of Coccidioides spp in a transbronchial biopsy specimen stained with periodic acid-Schiff (PAS).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Houck, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_26_30117=[""].join("\n");
var outline_f29_26_30117=null;
var title_f29_26_30118="Syringohydromyelia";
var content_f29_26_30118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    External appearances of hydromyelic and normal embryos",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 539px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Frontal view of an embryo with a hydromyelic change at the level of lower limb buds (arrowhead).",
"    <br>",
"     (B) A closer view of the caudal part of the same embryo, showing the dilated neural tube.",
"     <br>",
"      (C) The caudal part of a normal embryo at the same stage of development.",
"      <br>",
"       (D, E) Caudal views of embryos with the dilated caudal neural tube at a slightly later stage of development.",
"       <br>",
"        (F) The caudal part of a normal embryo in the same stage of development.",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         Reproduced from: Ikenouchi J, Uwabe C, Nakatsu T, et al. Embryonic hydromyelia: cystic dilation of the lumbosacral neural tube in human embryos. Acta Neuropathol 2002; 103:248, with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2002.",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_26_30118=[""].join("\n");
var outline_f29_26_30118=null;
var title_f29_26_30119="ETOH and HCV Light";
var content_f29_26_30119=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Biopsy showing cirrhosis due to hepatitis C and alcohol",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Needle biopsy of the liver (100x) of a 57-year-old female with cirrhosis from both hepatitis C virus infection and chronic alcohol consumption. Hematoxylin and eosin stain demonstrates prominent steatosis as well as portal and peri-portal inflammation and fibrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeremy Ditelberg, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_26_30119=[""].join("\n");
var outline_f29_26_30119=null;
var title_f29_26_30120="Hypogonadism in HIV-infected males";
var content_f29_26_30120=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypogonadism in HIV-infected males",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/26/30120/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/26/30120/contributors\">",
"     Morris Schambelan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/26/30120/contributors\">",
"     Melissa Weinberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/26/30120/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/26/30120/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/26/30120/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/26/30120/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/26/30120/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H29753725\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypogonadism was recognized as being relatively common early in the HIV epidemic. Low levels of testosterone in HIV-infected men may be associated with a variety of symptoms and signs including weight loss, muscle wasting, low bone mineral density, and decreased libido [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will address hypogonadism in HIV-infected men. Issues related to sex hormones in HIV-infected women, such as menstrual irregularities, fertility, and pregnancy are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=see_link\">",
"     \"HIV and women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The general management and treatment of AIDS-associated tissue wasting is discussed in detail elsewhere. General information about hypogonadism in HIV-uninfected patients, testosterone replacement therapy, and patient monitoring are found in other selected topics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link\">",
"     \"Clinical features and diagnosis of male hypogonadism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"     \"Testosterone treatment of male hypogonadism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42584?source=see_link\">",
"     \"Management of tissue wasting in patients with HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2210457\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone is produced by the Leydig cells of the testes under stimulation of leuteinizing hormone (LH), which is secreted by the pituitary gland. Both LH and follicle-stimulating hormone (FSH) are required for the maturation of spermatozoa. Testosterone, in turn, inhibits gonadotropin secretion. Failure of the testes to produce physiological levels of testosterone results in the syndrome of hypogonadism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1472412\">",
"    <span class=\"h2\">",
"     Primary versus secondary hypogonadism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypogonadism can result from disease of the testes (primary hypogonadism) or disease of the pituitary or hypothalamus (secondary hypogonadism). Differentiation of the two types of hypogonadism has implications for patient evaluation and therapeutic interventions. (See",
"    <a class=\"local\" href=\"#H2211299\">",
"     'How to distinguish between primary and secondary hypogonadism?'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Androgen deficiency is more often a consequence of secondary hypogonadism, rather than primary hypogonadism, in HIV-infected patients who are taking antiretroviral therapy (ART) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Testicular infiltration by opportunistic infections (OIs) rarely occurs in the setting of effective viral suppression by antiretroviral medications [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/4\">",
"     4",
"    </a>",
"    ]. In untreated patients with advanced immunosuppression, opportunistic pathogens to consider include cryptococcus, toxoplasmosis, Pneumocystis, and mycobacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=see_link\">",
"     \"Causes of primary hypogonadism in males\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link\">",
"     \"Causes of secondary hypogonadism in males\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link\">",
"     \"HIV infection and malignancy: Epidemiology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29753739\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low serum testosterone levels were commonly reported in the era prior to the onset of potent ART among men with HIV infection, particularly among those with more advanced immunosuppression (eg, &lt;100 CD4",
"    <span class=\"nowrap\">",
"     cells/mm3).",
"    </span>",
"   </p>",
"   <p>",
"    Studies of overall endocrine dysfunction among HIV-infected patients demonstrated that low testosterone serum concentrations were much more common than thyroid hormone or cortisol abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. In early studies from the 1980s and early 1990s, 30 to 50 percent of symptomatic HIV-infected men had low total testosterone levels, which were strongly correlated with weight loss and CD4 lymphocyte depletion (eg, &lt;100",
"    <span class=\"nowrap\">",
"     cells/mm3)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/2,6,7\">",
"     2,6,7",
"    </a>",
"    ]. One small case-control study of HIV-infected men, with and without weight loss, demonstrated that low testosterone levels often preceded the onset of clinical wasting syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since HIV therapy is now initiated at earlier stages of HIV infection than in the past, the prevalence of hypogonadism is lower. In an early HIV treatment trial including 213 treatment-naive asymptomatic HIV-infected men with a mean CD4 cell count of 263",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    (range 80 to 428",
"    <span class=\"nowrap\">",
"     cells/mm3),",
"    </span>",
"    baseline serum concentrations of testosterone were measured before treatment randomization. Testosterone levels were abnormal in 6 percent of patients at baseline and, in a multivariate analysis, were associated with lower CD4 cell counts. Initiation of ART led to improvements in testosterone levels over a 64-week period [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, a cross-sectional study demonstrated that patients who were taking ART had higher levels of testosterone compared with those who were not taking any antiretroviral medications [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29753767\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A greater understanding of the risk factors for low testosterone among HIV-infected patients has evolved over the past few decades. &nbsp;",
"   </p>",
"   <p>",
"    In early studies of HIV-infected men, mean serum testosterone concentrations were significantly lower among those with symptomatic HIV infection than those who were asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/2\">",
"     2",
"    </a>",
"    ]. In a 1988 study, gonadal function was evaluated in 70 HIV-infected men who were clinically categorized as: a) asymptomatic; b) having mild symptoms and signs of HIV infection (eg, thrush, lymphadenopathy); and c) AIDS. The mean serum testosterone concentrations were significantly higher in the asymptomatic patients compared with the other two groups. Of these hypogonadal men, 18 of 24 (75 percent) had hypogonadotropic hypogonadism (eg, secondary hypogonadism). Although CD4 cell counts were not available in this study, the relationship between advancing immunosuppression and low testosterone levels is inferred by the clinical stage of disease.",
"   </p>",
"   <p>",
"    As HIV-infected patients are living longer, age-related issues are becoming more relevant for the long-term care of HIV-infected patients. This is particularly relevant to hypogonadism, since the prevalence of androgen deficiency in men increases with age in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/11\">",
"     11",
"    </a>",
"    ]. In the CHAMPS observational study (Cohort of HIV At-risk Aging Men&rsquo;s Prospective Study), testosterone levels were assessed in men with and without HIV infection (275 and 227 patients, respectively); all study participants were over 49 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/12\">",
"     12",
"    </a>",
"    ]. CD4 cell counts in the HIV-infected patients were &gt;500",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    in 26 percent; &gt;200 to 499",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    in 49 percent; and were &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    in 25 percent.",
"   </p>",
"   <p>",
"    The study found that low testosterone levels (&lt;300",
"    <span class=\"nowrap\">",
"     ng/dL)",
"    </span>",
"    were common in older men with or without HIV infection (54 percent overall). Although HIV status was not associated with a risk of testosterone deficiency, a detectable HIV RNA level &gt;10,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    was associated with low testosterone levels. No correlation was seen with CD4 cell counts. Among both HIV-infected and uninfected men, low androgen levels were associated with injection drug use, hepatitis C infection, high body mass index, and use of psychotropic medications. Low levels of testosterone appeared to be mainly related to secondary hypogonadism. (See",
"    <a class=\"local\" href=\"#H29753781\">",
"     'Clinical presentation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The association of low testosterone levels with high body mass index in the above study appears to be contradictory to reports from the early AIDS era of testosterone deficiency and HIV-associated wasting. These associations are possibly mediated by different pathogenic mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is well documented that testosterone levels should not be assayed during acute illness since these levels are usually depressed. The association of low testosterone levels in untreated AIDS patients in the era prior to potent ART may have been related to opportunistic infections or uncontrolled HIV viremia, which could not be measured with the assays that were available at that time.",
"     </li>",
"     <li>",
"      In the general population, obesity and insulin resistance are associated with low testosterone levels, particularly among those with visceral adiposity [",
"      <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. In the era of ART, many patients have visceral adiposity and insulin resistance as part of the lipodystrophy syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29753774\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various medications can affect sex hormones and sexual function through different mechanisms. For example, systemic glucocorticoid therapy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    can cause hypogonadism by suppressing the hypothalamic-pituitary-gonadal axis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    , particularly at higher doses (eg, 400 mg) directly inhibits steroidogenesis. Psychotropic medications can lead to hyperprolactinemia and testosterone deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The chronic use of alcohol, opiates, and marijuana can also impair testosterone production [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/16\">",
"     16",
"    </a>",
"    ].The suppression of testosterone is particularly significant in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance therapy;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    suppresses plasma testosterone to a lesser extent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ART, particularly protease inhibitor (PI) therapy, has been associated with sexual dysfunction in men, but the causal nature of this relationship has not been clearly established since many of these patients have normal testosterone levels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/18\">",
"     18",
"    </a>",
"    ]. Furthermore, other small studies have demonstrated that initiation of ART, including protease inhibitors, can restore testosterone levels to normal [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2210812\">",
"    <span class=\"h2\">",
"     Liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the CHAMPS study, hepatitis C was associated with low testosterone levels in HIV-infected men [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/12\">",
"     12",
"    </a>",
"    ]. Testosterone deficiency, impaired release of luteinizing hormone, and low bone mineral density have also been noted in HIV seronegative cirrhotics with liver disease of varying etiologies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29753781\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the general population, symptomatic androgen deficiency that presents initially in adults is characterized by loss of facial and body hair, decreased muscle bulk and strength, low libido, testicular atrophy, and possibly gynecomastia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/21\">",
"     21",
"    </a>",
"    ]. Other nonspecific symptoms include depression, low energy and poor concentration. Low bone mineral density may be seen in association with hypogonadism.",
"   </p>",
"   <p>",
"    Similar clinical observations have been made among HIV-infected patients with low serum testosterone levels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/12,22,23\">",
"     12,22,23",
"    </a>",
"    ]. In one study, low testosterone levels were associated with low bone mineral density as determined by dual x-ray absorptiometry [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29753788\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2211147\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general approach to the diagnosis of testosterone deficiency in the HIV-infected patient is the same as in the uninfected patient; a clinical suspicion of hypogonadism is confirmed with a low serum testosterone level (&lt;300",
"    <span class=\"nowrap\">",
"     ng/mL).",
"    </span>",
"   </p>",
"   <p>",
"    Measurement of the serum total testosterone concentration (free plus protein-bound fractions) is the screening test of choice due to cost and simplicity. Most hospital laboratories are able to perform this routine assay. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link\">",
"     \"Clinical features and diagnosis of male hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2211154\">",
"    <span class=\"h2\">",
"     Free testosterone versus total testosterone levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total testosterone levels may be normal in an HIV-infected male, but free testosterone levels may be low [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/9,24\">",
"     9,24",
"    </a>",
"    ]. The discrepancy between total and free testosterone levels in HIV patients may be explained by higher sex hormone-binding globulin (SHBG) levels in such individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Thus, measurement of total testosterone concentration may be misleading [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/21\">",
"     21",
"    </a>",
"    ]. In one study, total testosterone levels were subnormal in only 5 of the 13 participants who had low free testosterone levels.",
"   </p>",
"   <p>",
"    If the serum total testosterone concentration (measured at 8:00 in the morning) is in the lower half of the normal range (&lt;500",
"    <span class=\"nowrap\">",
"     ng/dL)",
"    </span>",
"    in a patient with suspected testosterone deficiency, assays for free testosterone should be pursued. However, these assays should only be ordered from special endocrine laboratories for accurate assessment since they are technically demanding; these assays are also expensive [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29753795\">",
"    <span class=\"h2\">",
"     Caveats about when to test serum testosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since testosterone concentrations in men demonstrate diurnal variation with peak levels at 8 AM, testosterone testing should be performed in the morning and any abnormal level should be confirmed prior to treatment, as recommended by guideline panels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnostic testing of testosterone levels is not recommended during an acute illness when androgen levels decline transiently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2211299\">",
"    <span class=\"h2\">",
"     How to distinguish between primary and secondary hypogonadism?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a patient has been documented to have a low serum testosterone level with a second confirmatory test, further evaluation (eg, laboratory testing and imaging) are needed to determine if the patient has primary or secondary hypogonadism.",
"   </p>",
"   <p>",
"    Elevated LH and FSH levels in a patient with low serum testosterone suggest primary hypogonadism. Such patients should undergo further imaging of the testicles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=see_link\">",
"     \"Causes of primary hypogonadism in males\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Normal or low levels of gonadotropins (eg, LH and FSH) in the setting of a low testosterone level are consistent with secondary hypogonadism. Such patients should be evaluated for possible reversible etiologies of gonadotropin deficiency, such as hyperprolactinemia and hemochromatosis (by checking serum prolactin and iron studies), though frequently no specific disorder is found. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link\">",
"     \"Causes of secondary hypogonadism in males\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29753809\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A testicular ultrasound is a valuable imaging tool to discern whether an infiltrative or infectious process is present. Concerns regarding opportunistic infections infiltrating the testes are more relevant to patients with untreated HIV infection with advanced immunosuppression (CD4 cell count &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm3).",
"    </span>",
"   </p>",
"   <p>",
"    In patients with confirmed secondary hypogonadism, a dedicated pituitary MRI scan should be obtained to rule out a pituitary or hypothalamic lesion.",
"   </p>",
"   <p>",
"    Symptomatic patients with hypogonadism should also have a DEXA scan to evaluate their bone mineral density, regardless of whether the patient has primary or secondary hypogonadism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29753816\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis depends on the main presenting symptom of hypogonadism. For example, in patients with symptoms of decreased libido, other potential etiologic factors include neurologic disease, diabetes, drug effects, and psychosexual issues [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/28\">",
"     28",
"    </a>",
"    ]. Among those with low muscle bulk, lipoatrophy related to certain HIV medications, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    , should be considered. Among those with hair loss, thyroid dysfunction and iron deficiency should be entertained. For patients with bone loss, several other factors should be considered including smoking, vitamin D deficiency, and certain antiretroviral medications, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38388?source=see_link\">",
"     \"Thyroid gland dysfunction in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32313?source=see_link\">",
"     \"Bone and calcium disorders in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4760228\">",
"    <span class=\"h1\">",
"     CLINICAL TRIAL DATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone treatment appears to have beneficial effects on body composition, bone density, mood, and libido in small clinical studies of HIV-infected patients with hypogonadism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4760235\">",
"    <span class=\"h2\">",
"     Patients with low libido and/or hypogonadal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two small clinical trials have demonstrated that testosterone replacement therapy improves libido among HIV-infected men, as described below.",
"   </p>",
"   <p>",
"    Seventy-four symptomatic HIV-infected patients were enrolled in a double-blind,",
"    <sup>",
"    </sup>",
"    placebo-controlled six-week trial with biweekly testosterone injections (400 mg); testosterone responders and placebo recipients were then offered an additional 12 weeks of open-label testosterone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/29\">",
"     29",
"    </a>",
"    ]. Major",
"    <sup>",
"    </sup>",
"    outcome measures included changes in libido, mood, energy, and erectile dysfunction using well-accepted standardized scoring systems. Body",
"    <sup>",
"    </sup>",
"    composition changes were assessed with bioelectric impedance",
"    <sup>",
"    </sup>",
"    analysis.",
"   </p>",
"   <p>",
"    Among the 70 men who completed the six-week trial, libido improved in a significantly higher proportion of patients taking testosterone compared with placebo (74 versus 19 percent). Testosterone therapy was also associated with overall improvement in fatigue and mood disturbance. In the intervention arm, the average",
"    <sup>",
"    </sup>",
"    increase in muscle mass over 12 weeks was 1.6 kg for the whole",
"    <sup>",
"    </sup>",
"    group, and 2.2 kg for the 14 men with wasting at baseline. Improvement",
"    <sup>",
"    </sup>",
"    of all parameters was maintained during subsequent open-label",
"    <sup>",
"    </sup>",
"    treatment for up to 18 weeks, although no long-term follow-up was reported. Side effects among testosterone recipients included acne and irritability.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     Megestrol acetate",
"    </a>",
"    (MA) stimulates appetite and weight gain. However, much of the weight gain is fat, possibly as a result of MA-induced hypogonadism. A clinical trial was designed to assess whether the coadministration of testosterone could enhance lean body mass gain and sexual functioning compared with megestrol plus placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/30\">",
"     30",
"    </a>",
"    ]. Seventy-nine HIV-infected men with a history of weight loss were randomly assigned to receive MA (800 mg daily) plus testosterone enanthate (200 mg) or placebo biweekly for 12 weeks. In the patients who received megestrol acetate and placebo, self-reported sexual functioning worsened, while those who received testosterone supplementation reported improved libido and sexual satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/30\">",
"     30",
"    </a>",
"    ]. However, no enhancement of lean body mass was seen with coadministration of testosterone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4760242\">",
"    <span class=\"h2\">",
"     Patients with low bone mineral density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone stimulates bone formation and inhibits bone resorption through multiple mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/31\">",
"     31",
"    </a>",
"    ]. Few data are available on the use of testosterone for HIV-infected patients with low bone mineral density.",
"   </p>",
"   <p>",
"    A 12-week intervention study was performed in 54 eugonadal men with AIDS wasting (weight &lt;90 percent ideal body weight or weight loss &gt;10 percent from HIV diagnosis) to evaluate the effect of testosterone replacement and resistance training on bone mineral density (BMD) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/32\">",
"     32",
"    </a>",
"    ]. Patients were randomly assigned to testosterone replacement (200",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    intramuscularly) or placebo with or without resistance training in a 2 x 2 factorial design.",
"   </p>",
"   <p>",
"    At baseline, lumbar spine BMD (as assessed by dual energy x-ray absorptiometry; DEXA), was significantly lower in the AIDS patients compared with HIV-seronegative controls at baseline. Testosterone administration led to significant increases in lumbar spine BMD on DEXA scan at the end of treatment, while resistance training had no effect.",
"   </p>",
"   <p>",
"    However, it is unknown whether testosterone replacement therapy may lead to a lower incidence of clinical fractures in this patient population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4760249\">",
"    <span class=\"h2\">",
"     Patients with weight loss and low lean body mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of eight randomized, placebo-controlled trials in HIV-infected patients with weight loss (n = 417 patients) concluded that testosterone therapy leads to greater gains in body weight and lean body mass than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/33\">",
"     33",
"    </a>",
"    ]. The short-term use of testosterone replacement therapy for tissue wasting secondary to hypogonadism is discussed elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42584?source=see_link\">",
"     \"Management of tissue wasting in patients with HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4760064\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TESTOSTERONE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients with low serum concentrations of testosterone and any of the following symptoms or signs may be candidates for testosterone replacement therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with symptoms of low libido",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypogonadal symptoms",
"     </li>",
"     <li>",
"      Low bone mineral density",
"     </li>",
"     <li>",
"      Low body mass or weight loss, despite viral suppression on ART",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Testosterone replacement therapy should not be given to patients with normal serum levels. Before initiating exogenous testosterone therapy, we would recommend obtaining the following baseline laboratory studies: a complete blood count, a metabolic panel, lipid panel, and a prostate specific antigen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4760091\">",
"    <span class=\"h2\">",
"     Patients with low libido",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hypogonadism and low libido may improve on testosterone replacement therapy. Prior to initiation of testosterone replacement therapy, patients should be evaluated for depression and psychosocial stressors, which often co-exists with low libido. However, if there is no effect on libido after three months of adequate testosterone replacement therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adverse effects occur, treatment should be discontinued.",
"   </p>",
"   <p>",
"    If erectile dysfunction is also present, other adjuvant therapies can be considered, such as phosphodiesterase inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    ). Prior to starting a phosphodiesterase inhibitor, potential drug interactions with antiretroviral medications should be considered. For example, it is important to be aware that several protease inhibitors (PIs), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/34\">",
"     34",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    , impair the metabolism of sildenafil through effects on hepatic cytochrome P450 3A4. This may result in elevated levels of sildenafil and greater risk of sildenafil-related adverse events. Caution should be exercised in administering sildenafil to patients who are taking PIs; only low doses of sildenafil (25 mg in a 48-hour period) should be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4760098\">",
"    <span class=\"h2\">",
"     Patients with low bone mineral density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone replacement therapy should be offered to patients with hypogonadism and low bone mineral density, although there are no data to show that supplementation decreases fracture risk.",
"   </p>",
"   <p>",
"    Other correctable causes of low BMD should also be addressed, including vitamin D deficiency, hyperthyroidism, and hyperparathyroidism. Patients who smoke cigarettes should be encouraged to stop. Although there are some observational epidemiologic data linking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    to a modest loss of BMD, there are no prospective data evaluating this relationship. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32313?source=see_link\">",
"     \"Bone and calcium disorders in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to testosterone therapy, HIV-infected patients with osteoporosis should also be treated with approved therapies specifically directed at osteoporosis (eg, bisphosphonates or teriparatide). Bone mineral density should be re-evaluated one to two years after initiating therapy. The treatment of HIV-infected patients with osteoporosis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32313?source=see_link\">",
"     \"Bone and calcium disorders in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4760105\">",
"    <span class=\"h2\">",
"     Patients with wasting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of testosterone replacement therapy for patients with AIDS-associated wasting is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42584?source=see_link\">",
"     \"Management of tissue wasting in patients with HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22157302\">",
"    <span class=\"h1\">",
"     DRUG FORMULATION AND DOSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the older studies noted above used intramuscular testosterone injections. Guidelines for the use of testosterone replacement therapy suggest choosing a particular route of drug administration (eg, injection, patches, gel) according to the patient&rsquo;s preference, since pharmacokinetic parameters appear comparable in terms of drug delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/21\">",
"     21",
"    </a>",
"    ]. We generally use one of the transdermal approaches (ie, a gel or patch) as first-line treatment because of their ease of use and more consistent drug delivery pattern. The testosterone patch is applied nightly over the skin of the back, thigh, or upper arm. There are now several different testosterone gel formulations, which are applied daily over a covered area of nongenital skin.",
"   </p>",
"   <p>",
"    The patch or gel methods can be associated with skin irritation, but are otherwise well tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7069530\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For each of the indications described above, we generally continue testosterone therapy as long as there is some symptomatic benefit and no adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2211589\">",
"    <span class=\"h1\">",
"     ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone replacement therapy is generally well tolerated. Drug-related side effects include acne and oiliness of skin. With chronic administration, patients can develop erythrocytosis. Pre-existing sleep apnea can also worsen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12617787\">",
"    <span class=\"h1\">",
"     CAUTIONS REGARDING TESTOSTERONE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although testosterone treatment has been associated with some clinical benefits, many questions remain unanswered including the long-term effects of suppression of the hypothalamic-pituitary-gonadal axis, as well as the possibility of promoting or unmasking malignancy of the prostate [21]. Therefore, we do not recommend using supraphysiological doses of testosterone or treating eugonadal men with additional testosterone. Testosterone should also not be initiated in a patient with any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of prostate cancer",
"     </li>",
"     <li>",
"      A palpable prostate nodule",
"     </li>",
"     <li>",
"      An elevated prostate specific antigen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Older patients who take testosterone replacement therapy may be at increased risk of cardiovascular disease. A placebo-controlled clinical trial of testosterone replacement therapy was performed among HIV-seronegative hypogonadal men older than 60 years of age with limitations in mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/35\">",
"     35",
"    </a>",
"    ]. The trial was terminated after 209 patients had been enrolled due to an excess number of cardiovascular events in the testosterone intervention arm compared with placebo within the first six months of the study (23 versus 5 events). Many of these patients had other comorbidities, including hypertension, diabetes, obesity, and hyperlipidemia; none were HIV-infected.",
"   </p>",
"   <p>",
"    Further discussion of these issues is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"     \"Testosterone treatment of male hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75334498\">",
"    <span class=\"h2\">",
"     Caution regarding unintentional drug transfer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who use topical testosterone gel should be made aware of the risk of unintentional transfer of drug, particularly to female partners or children, who may become virilized as a result. Secondary exposure can be avoided by washing hands after application, covering the application site, and allowing the gel to completely dry before any direct skin-to-skin contact. The relative advantages and disadvantages of the different formulations are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"     \"Testosterone treatment of male hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75334505\">",
"    <span class=\"h2\">",
"     Male infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous testosterone therapy causes oligospermia and is NOT a treatment for male infertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2211520\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone levels (aiming for the mid-normal range), clinical efficacy, and adverse effects should be monitored every three to six months. The target goal should be attainment of normal serum testosterone levels within the mid-normal range.",
"   </p>",
"   <p>",
"    Hematocrit should be checked at baseline, after three months, and annually thereafter, since testosterone therapy can be associated with erythrocytosis.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    PSA should be measured at baseline, after three months, and then according to evidence-based guidelines for prostate cancer screening, based on the patient's age and race [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30120/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=see_link\">",
"     \"Screening for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    BMD should be assessed every one to two years with a dual energy X-ray absorptiometry (DEXA) scan among patients with established osteoporosis or history of low trauma fracture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29753935\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypogonadism in HIV-infected patients is associated with clinical AIDS, wasting, and low CD4 cell counts. (See",
"      <a class=\"local\" href=\"#H29753725\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypogonadism can result from disease of the testes (primary hypogonadism) or disease of the pituitary or hypothalamus (secondary hypogonadism). Differentiation of the two types of hypogonadism has implications for patient evaluation and therapeutic interventions. (See",
"      <a class=\"local\" href=\"#H2210457\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians should evaluate whether any medications (eg, glucocorticoid therapy) or substance abuse (eg, alcohol, opiates) could be contributing to abnormalities in sex hormone levels. (See",
"      <a class=\"local\" href=\"#H29753774\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the general population, symptomatic androgen deficiency that presents initially in adults is characterized by loss of facial and body hair, decreased muscle bulk and strength, low libido, testicular atrophy, and possibly gynecomastia. Other nonspecific symptoms include depression, low energy and poor concentration. Low bone mineral density may be seen in association with hypogonadism. (See",
"      <a class=\"local\" href=\"#H29753781\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Male patients who attain viral suppression on antiretroviral therapy (ART), but who do not achieve normal body weight, should undergo testing for hypogonadism as part of a weight loss evaluation. Androgen deficiency is usually a consequence of hypogonadotropic (secondary) hypogonadism. (See",
"      <a class=\"local\" href=\"#H29753788\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When total testosterone levels are only modestly reduced, measurement of free testosterone measurements may be required. However, these assays should only be ordered from special endocrine laboratories for accurate assessment. If hypogonadism is evident, patients should also have measurements of luteinizing hormone (LH) and follicular stimulating hormone (FSH) to help distinguish between primary and secondary hypogonadism. (See",
"      <a class=\"local\" href=\"#H2211299\">",
"       'How to distinguish between primary and secondary hypogonadism?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Testosterone treatment appears to have beneficial effects on body composition, bone density, mood, and libido in small clinical studies of HIV-infected patients with hypogonadism. (See",
"      <a class=\"local\" href=\"#H4760228\">",
"       'Clinical trial data'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest testosterone replacement therapy in HIV-infected men with low testosterone levels and hypogonadal symptoms, low bone mineral density, or low body mass or weight loss. Patients should be offered counseling on the risks and benefits of therapy, recognizing the lack of long-term safety data. (See",
"      <a class=\"local\" href=\"#H4760064\">",
"       'Indications for testosterone treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We generally use one of the transdermal approaches (ie, a gel or patch) as first-line testosterone treatment because of their ease of use and more consistent drug delivery pattern. (See",
"      <a class=\"local\" href=\"#H22157302\">",
"       'Drug formulation and dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Testosterone replacement therapy should not be offered to any patient with a history of prostate cancer or a prostate nodule, or who has an elevated prostate specific antigen. (See",
"      <a class=\"local\" href=\"#H12617787\">",
"       'Cautions regarding testosterone therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not recommend testosterone treatment to supraphysiologic levels in hypogonadal men or any use in eugonadal men. (See",
"      <a class=\"local\" href=\"#H4760064\">",
"       'Indications for testosterone treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Testosterone levels (aiming for the mid-normal range), clinical efficacy, and adverse effects should be monitored every three to six months. (See",
"      <a class=\"local\" href=\"#H2211520\">",
"       'Patient monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/1\">",
"      Wanke CA, Silva M, Knox TA, et al. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 31:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/2\">",
"      Dobs AS, Dempsey MA, Ladenson PW, Polk BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1988; 84:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/3\">",
"      Arver S, Sinha-Hikim I, Beall G, et al. Serum dihydrotestosterone and testosterone concentrations in human immunodeficiency virus-infected men with and without weight loss. J Androl 1999; 20:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/4\">",
"      Cooley TP. Non-AIDS-defining cancer in HIV-infected people. Hematol Oncol Clin North Am 2003; 17:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/5\">",
"      Etzel JV, Brocavich JM, Torre M. Endocrine complications associated with human immunodeficiency virus infection. Clin Pharm 1992; 11:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/6\">",
"      Raffi F, Brisseau JM, Planchon B, et al. Endocrine function in 98 HIV-infected patients: a prospective study. AIDS 1991; 5:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/7\">",
"      Christeff N, Gharakhanian S, Thobie N, et al. Evidence for changes in adrenal and testicular steroids during HIV infection. J Acquir Immune Defic Syndr 1992; 5:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/8\">",
"      Dobs AS, Few WL 3rd, Blackman MR, et al. Serum hormones in men with human immunodeficiency virus-associated wasting. J Clin Endocrinol Metab 1996; 81:4108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/9\">",
"      Dub&eacute; MP, Parker RA, Mulligan K, et al. Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384. Clin Infect Dis 2007; 45:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/10\">",
"      Collazos J, Martinez E, Mayo J, Ibarra S. Sexual hormones in HIV-infected patients: the influence of antiretroviral therapy. AIDS 2002; 16:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/11\">",
"      Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89:5920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/12\">",
"      Klein RS, Lo Y, Santoro N, Dobs AS. Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis 2005; 41:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/13\">",
"      Grossmann M, Gianatti EJ, Zajac JD. Testosterone and type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010; 17:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/14\">",
"      Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol 2009; 5:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/15\">",
"      Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004; 65:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/16\">",
"      Cooper OB, Brown TT, Dobs AS. Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clin Infect Dis 2003; 37 Suppl 2:S132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/17\">",
"      Bliesener N, Albrecht S, Schwager A, et al. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab 2005; 90:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/18\">",
"      Collazos J. Sexual dysfunction in the highly active antiretroviral therapy era. AIDS Rev 2007; 9:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/19\">",
"      George J, Ganesh HK, Acharya S, et al. Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol 2009; 15:3516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/20\">",
"      Bannister P, Handley T, Chapman C, Losowsky MS. Hypogonadism in chronic liver disease: impaired release of luteinising hormone. Br Med J (Clin Res Ed) 1986; 293:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/21\">",
"      Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95:2536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/22\">",
"      Dobs A. Role of testosterone in maintaining lean body mass and bone density in HIV-infected patients. Int J Impot Res 2003; 15 Suppl 4:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/23\">",
"      Tindall B, Forde S, Goldstein D, et al. Sexual dysfunction in advanced HIV disease. AIDS Care 1994; 6:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/24\">",
"      Rietschel P, Corcoran C, Stanley T, et al. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis 2000; 31:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/25\">",
"      Martin ME, Benassayag C, Amiel C, et al. Alterations in the concentrations and binding properties of sex steroid binding protein and corticosteroid-binding globulin in HIV+patients. J Endocrinol Invest 1992; 15:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/26\">",
"      de Ronde W, van der Schouw YT, Pols HA, et al. Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms. Clin Chem 2006; 52:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/27\">",
"      Rosner W, Auchus RJ, Azziz R, et al. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007; 92:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/28\">",
"      Lo JC, Schambelan M. Reproductive function in human immunodeficiency virus infection. J Clin Endocrinol Metab 2001; 86:2338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/29\">",
"      Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 2000; 57:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/30\">",
"      Mulligan K, Zackin R, Von Roenn JH, et al. Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Endocrinol Metab 2007; 92:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/31\">",
"      Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med 2008; 358:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/32\">",
"      Fairfield WP, Finkelstein JS, Klibanski A, Grinspoon SK. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. J Clin Endocrinol Metab 2001; 86:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/33\">",
"      Kong A, Edmonds P. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis 2002; 2:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/34\">",
"      Sekar V, Lefebvre E, De Marez T, et al. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study. Clin Drug Investig 2008; 28:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30120/abstract/35\">",
"      Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363:109.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13969 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-042A3B073A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_26_30120=[""].join("\n");
var outline_f29_26_30120=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29753935\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29753725\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2210457\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1472412\">",
"      Primary versus secondary hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29753739\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29753767\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29753774\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2210812\">",
"      Liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29753781\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29753788\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2211147\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2211154\">",
"      Free testosterone versus total testosterone levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29753795\">",
"      Caveats about when to test serum testosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2211299\">",
"      How to distinguish between primary and secondary hypogonadism?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29753809\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29753816\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4760228\">",
"      CLINICAL TRIAL DATA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4760235\">",
"      Patients with low libido and/or hypogonadal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4760242\">",
"      Patients with low bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4760249\">",
"      Patients with weight loss and low lean body mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4760064\">",
"      INDICATIONS FOR TESTOSTERONE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4760091\">",
"      Patients with low libido",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4760098\">",
"      Patients with low bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4760105\">",
"      Patients with wasting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22157302\">",
"      DRUG FORMULATION AND DOSING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7069530\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2211589\">",
"      ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12617787\">",
"      CAUTIONS REGARDING TESTOSTERONE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H75334498\">",
"      Caution regarding unintentional drug transfer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H75334505\">",
"      Male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2211520\">",
"      PATIENT MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29753935\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32313?source=related_link\">",
"      Bone and calcium disorders in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=related_link\">",
"      Causes of primary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=related_link\">",
"      Causes of secondary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=related_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=related_link\">",
"      HIV and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=related_link\">",
"      HIV infection and malignancy: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42584?source=related_link\">",
"      Management of tissue wasting in patients with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=related_link\">",
"      Screening for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38388?source=related_link\">",
"      Thyroid gland dysfunction in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_26_30121="Overview of fetal assessment";
var content_f29_26_30121=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of fetal assessment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/26/30121/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/26/30121/contributors\">",
"     Caroline Signore, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/26/30121/contributors\">",
"     Catherine Spong, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/26/30121/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/26/30121/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/26/30121/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/26/30121/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/26/30121/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of antenatal testing is to identify fetuses at risk of intrauterine neurologic injury or death so that these adverse outcomes can be prevented. Many techniques for assessment of fetal well-being have been introduced into clinical practice, beginning in the 1970s (",
"    <a class=\"graphic graphic_table graphicRef50223 \" href=\"UTD.htm?42/24/43405\">",
"     table 1",
"    </a>",
"    ). Despite widespread use of these techniques, there is limited evidence to guide their optimal use or to demonstrate their effectiveness at improving perinatal outcomes.",
"   </p>",
"   <p>",
"    This topic will provide an overview of fetal assessment. Detailed discussions of the various techniques used and conditions where antenatal assessment is indicated are available separately. (See individual topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal hypoxia and acidosis represent the final common pathway to fetal injury and death in many high risk pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/1\">",
"     1",
"    </a>",
"    ]. The basis for antepartum testing is the premise that the fetus whose oxygenation in utero is challenged will respond with a series of detectable physiologic adaptive or decompensatory signs as hypoxemia or frank metabolic acidemia develop. For example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood flow is directed to the brain, heart, and adrenals and away from the kidney. The reduction in renal perfusion leads to decreased fetal urine production, which results in decreased amniotic fluid volume.",
"     </li>",
"     <li>",
"      Fetal movements decrease as the fetus attempts to conserve energy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/2\">",
"       2",
"      </a>",
"      ]. The loss of fetal movement can be a sign of ongoing central nervous system hypoxia and injury.",
"     </li>",
"     <li>",
"      A chemoreceptor response to hypoxemia leads to vagally-mediated reflex slowing of the fetal heart rate (FHR), which may appear clinically as late decelerations associated with uterine contractions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of investigators have described sequences of measurable changes in fetal blood flow and biophysical parameters that occur as placental insufficiency worsens and fetal hypoxemia and acidemia develop [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Although the precise sequences of observed characteristics differ slightly in these reports, a general pattern of fetal response to intrauterine challenge emerges: loss of FHR reactivity (nonreactive nonstress test) and abnormal blood flow in the umbilical artery (absent or reversed end-diastolic flow) are often the earliest signs of fetal compromise. Sequential changes in other fetal vessels (middle cerebral artery, venous circulation) are detectable next, followed by abnormalities in biophysical parameters such as fetal breathing movements, fetal body movements, and fetal tone. However, not all fetuses who exhibit the full range of these findings will exhibit significant metabolic acidosis at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTENATAL TESTING METHODS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fetal movement counting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal movements are usually first perceptible to the mother at 17 to 20 weeks (termed quickening) and become more prominent as gestation advances. When correlated sonographically, about 50 percent of isolated limb movements are perceived by the mother, whereas 80 percent of trunk and limb movements are perceived [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetal movement decreases in response to hypoxemia, making formalized maternal assessment of fetal movements a potentially simple method of monitoring fetal oxygenation and well-being. However, existing evidence does not support any specific fetal movement threshold or \"alarm limit\" below which fetal risk is increased.",
"   </p>",
"   <p>",
"    Results of trials of routine fetal movement assessment for reduction of stillbirth have been mixed. In a randomized trial conducted in Denmark, fetal movement counting was associated with a 73 percent reduction in avoidable stillbirths (RR 0.27, 95% CI 0.08-0.93) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/7\">",
"     7",
"    </a>",
"    ]. In contrast, a subsequent large (N = 68,654) international trial found no significant difference in potentially avoidable late fetal deaths between women who were instructed to count routinely and controls [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/8\">",
"     8",
"    </a>",
"    ]. A systematic review concluded that there was insufficient evidence to recommend routine fetal movement counting to prevent stillbirth [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An approach to counseling women about monitoring fetal activity and evaluation of women with decreased fetal activity can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15959?source=see_link\">",
"     \"Evaluation of decreased fetal movements\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Contraction stress test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contraction stress test (CST) is based on the premise that uterine contractions transiently restrict oxygen delivery to the fetus and that a hypoxic fetus will demonstrate recurrent late decelerations (",
"    <a class=\"graphic graphic_waveform graphicRef67464 \" href=\"UTD.htm?23/19/23861\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef50223 \" href=\"UTD.htm?42/24/43405\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=see_link&amp;anchor=H6#H6\">",
"     \"Antepartum fetal heart rate assessment\", section on 'Cardiovascular response to hypoxia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rate of antepartum stillbirth within one week of a negative CST (ie, the false negative rate) is 0.04 percent, thus providing reassurance of fetal well-being [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/10\">",
"     10",
"    </a>",
"    ]. After a positive CST, however, up to 30 percent of patients have been reported to tolerate labor without FHR changes necessitating intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Assessment of FHR reactivity can help differentiate false-positive from true-positive CSTs. In one study, 50 percent of reactive positive CSTs were false positives, but 100 percent of non-reactive positive CSTs were true positives, ie, intrapartum FHR was non-reassuring [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/12\">",
"     12",
"    </a>",
"    ]. Overall, the high false positive rate, as well as the need to stimulate contractions and the fact that inducing contractions is contraindicated in a number of conditions (eg, placenta previa), are major drawbacks to use of the CST (",
"    <a class=\"graphic graphic_table graphicRef50223 \" href=\"UTD.htm?42/24/43405\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=see_link&amp;anchor=H13#H13\">",
"     \"Antepartum fetal heart rate assessment\", section on 'Contraction stress test'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nonstress test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nonstress test (NST) was developed as a result of observations that (1) the presence of two or more fetal heart rate accelerations during a CST often predicted a negative CST, and (2) the absence of accelerations on a baseline FHR tracing was associated with adverse perinatal outcomes (",
"    <a class=\"graphic graphic_table graphicRef50223 \" href=\"UTD.htm?42/24/43405\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main advantage of the NST over the CST is that it does not require an intravenous line,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    , or contractions. Disadvantages are that the false negative and false positive rates are higher than for the CST: the false negative rate of a reactive NST is about 0.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/14\">",
"     14",
"    </a>",
"    ] and the false positive rate (ie, a back-up test is normal) of a nonreactive NST is about 55 percent (",
"    <a class=\"graphic graphic_table graphicRef50223 \" href=\"UTD.htm?42/24/43405\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=see_link&amp;anchor=H10#H10\">",
"     \"Antepartum fetal heart rate assessment\", section on 'Nonstress test'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Amniotic fluid volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amniotic fluid volume (AFV) may be too low (oligohydramnios) or too high (polyhydramnios). Abnormalities of AFV are associated with a variety of pregnancy complications, including adverse perinatal outcome, premature rupture of the fetal membranes, and some congenital anomalies. These associations are the rationale for AFV evaluation.",
"   </p>",
"   <p>",
"    The amniotic fluid index (AFI) measurement is a common method of AFV assessment. The maximum vertical amniotic fluid pocket diameter in each quadrant not containing cord or fetal extremities is measured in centimeters; the sum of these measurements is the AFI.",
"   </p>",
"   <p>",
"    There are a variety of other methods for estimating AFV; these methods and the AFI are discussed in detail separately. Dye-dilution studies have shown that the AFI and other methods have poor sensitivity (5 to 30 percent) for detecting true abnormalities in AFV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31558?source=see_link\">",
"     \"Assessment of amniotic fluid volume\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Biophysical profile",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biophysical profile (BPP) combines the NST with ultrasonographic estimation of AFV and assessments of fetal breathing, body, and",
"    <span class=\"nowrap\">",
"     reflex/tone/flexion-extension",
"    </span>",
"    movements, assigning points to each parameter (",
"    <a class=\"graphic graphic_table graphicRef50223 \" href=\"UTD.htm?42/24/43405\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/17\">",
"     17",
"    </a>",
"    ]. Thus, this test assesses indicators of both acute hypoxia (NST, breathing, body movement) and chronic hypoxia (AFV). The BPP score is linearly correlated with fetal pH [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/18\">",
"     18",
"    </a>",
"    ]. The risk of fetal death within one week of a normal biophysical assessment is estimated to be 1 in 1300 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The modified biophysical profile (mBPP) consists of the NST as a measure of acute oxygenation and the AFI as a measure of longer term oxygenation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/20\">",
"     20",
"    </a>",
"    ]. The false negative rate of the mBPP was reported to be",
"    <span class=\"nowrap\">",
"     0.8/1000,",
"    </span>",
"    but 60 percent of abnormal modified BPPs were false positives (",
"    <a class=\"graphic graphic_table graphicRef50223 \" href=\"UTD.htm?42/24/43405\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The BPP is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11928?source=see_link\">",
"     \"The fetal biophysical profile\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Doppler velocimetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of blood flow velocities in the maternal and fetal vessels gives information about uteroplacental blood flow and fetal responses to physiologic challenges. Inadequate normal vascular development of the placenta, such as in preeclampsia, results in progressive hemodynamic changes in the fetoplacental circulation. Doppler indices from the umbilical artery increase when 60 to 70 percent of the placental vascular tree is compromised [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/22\">",
"     22",
"    </a>",
"    ]; eventually, middle cerebral artery impedance falls and aortic resistance rises to preferentially direct blood to the fetal brain and heart [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Ultimately, end diastolic flow in the umbilical artery ceases or reverses and resistance increases in the venous system (ductus venosus, inferior vena cava) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/4,5,23,24\">",
"     4,5,23,24",
"    </a>",
"    ]. These changes occur over variable periods of time and correlate with fetal acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to most other methods of fetal assessment, Doppler-based tests have been rigorously evaluated in randomized trials. The information derived from velocity waveforms varies according to the specific vessel assessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Uterine artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impedance to flow in the uterine arteries normally decreases as pregnancy progresses. Failure of adequate trophoblast invasion and remodeling of maternal spiral arteries are characterized by a persistent high-pressure uterine circulation and increased impedance to uterine artery blood flow. Elevated resistance indices",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    persistent uterine artery notching at 22 to 24 weeks of gestation indicate reduced blood flow in the maternal compartment of the placenta and have been associated with development of preeclampsia, fetal growth restriction, and perinatal death [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=see_link\">",
"     \"Diagnosis of fetal growth restriction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11480?source=see_link&amp;anchor=H7#H7\">",
"     \"Prediction of preeclampsia\", section on 'Uterine artery Doppler velocimetry'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of investigators have explored the use of uterine artery Doppler for third trimester fetal assessment among women with complicated pregnancies, but its role in these settings has not been clearly defined [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Umbilical artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The umbilical artery waveform pattern is compatible with a low-resistance system: there is forward blood flow throughout the cardiac cycle. Umbilical artery flow velocity waveforms of normally growing fetuses are characterized by high-velocity diastolic flow, whereas in growth restricted fetuses, umbilical artery diastolic flow is diminished, absent, or even reversed in severe cases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/30\">",
"     30",
"    </a>",
"    ]. This progressive reduction of umbilical artery diastolic flow is associated with worsening destruction of placental villous vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/31\">",
"     31",
"    </a>",
"    ]. In the growth restricted fetus, absent or reversed end diastolic flow is associated with fetal hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/24\">",
"     24",
"    </a>",
"    ] and increased perinatal morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Umbilical artery Doppler assessments are most useful for monitoring fetuses with early-onset growth restriction due to uteroplacental insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/33\">",
"     33",
"    </a>",
"    ]. American College of Obstetricians and Gynecologists (ACOG) practice guidelines support the use of umbilical artery Doppler assessments only in the management of suspected intrauterine growth restriction, stipulating that decisions regarding the timing of delivery should be based on umbilical artery Doppler results in combination with other tests of fetal well-being [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=see_link\">",
"     \"Fetal growth restriction: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no strong evidence to support umbilical artery Doppler surveillance in other settings. A systematic review of 16 randomized trials including approximately 10,000 high-risk patients found the use of Doppler ultrasound was associated with decreased perinatal mortality (OR 0.71, 95% CI 0.52-0.98) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/34\">",
"     34",
"    </a>",
"    ]. The definition of 'high risk' varied among studies. By comparison, several randomized trials have demonstrated that routine umbilical artery Doppler screening of low risk obstetrical populations does not improve perinatal outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=see_link\">",
"     \"Doppler ultrasound of the umbilical artery for fetal surveillance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Middle cerebral artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the compromised fetus, systemic blood flow is redistributed from the periphery to the brain. Doppler measurement of flow velocity in the fetal middle cerebral artery can detect this \"brain-sparing effect\" and is under investigation as an assessment tool [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/3\">",
"     3",
"    </a>",
"    ]. The limited data available are mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Doppler assessment of the fetal middle cerebral artery peak systolic velocity has emerged as the best tool for predicting fetal anemia in at-risk pregnancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5464?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of pregnancy complicated by Rhesus (Rh) alloimmunization\", section on 'Middle cerebral artery-peak systolic velocity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Fetal veins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although flow velocity waveforms have been reported for many venous vessels, the precordial veins (ductus venosus and inferior vena cava) and the umbilical vein are the vessels most evaluated in clinical practice. Blood flow in the umbilical vein is continuous in normal pregnancies after 15 weeks of gestation. In pathological states, such as fetal growth restriction, flow in the umbilical vein may be pulsatile, which reflects cardiac dysfunction related to increased afterload. The ductus venosus regulates oxygenated blood in the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/39\">",
"     39",
"    </a>",
"    ] and is resistant to alterations in flow except in the most severely growth restricted fetuses. Doppler evaluation of fetal veins combined with arterial assessment may be useful for predicting outcomes in growth restricted fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14217?source=see_link\">",
"     \"Venous Doppler for fetal assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Emerging methods",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Fetal physiology assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the fetal central nervous system matures, there are distinctive alterations in fetal physiological and behavioral parameters, such as heart rate patterns, motor activity, and sleep-wake cycles. One important developmental feature is increased coupling between fetal movement and FHR that normally occurs with advancing gestational age and reflects maturation of the parasympathetic and sympathetic components of the fetal autonomic nervous system.",
"   </p>",
"   <p>",
"    The use of a fetal actocardiograph, which electronically records FHR and fetal movement, and novel analytic techniques allow computation of time-dependent cross-correlation coefficients between FHR and fetal movement [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/42\">",
"     42",
"    </a>",
"    ]. Studies have suggested that high levels of maternal stress, preterm birth, and other pregnancy complications are associated with alterations in",
"    <span class=\"nowrap\">",
"     FHR/fetal",
"    </span>",
"    movement coupling, as well as FHR reactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Potential impairment or maturational delay of the fetal autonomic nervous system from a variety of insults or exposures may be detected by monitoring movement-related patterns of FHR in combination with",
"    <span class=\"nowrap\">",
"     FHR/fetal",
"    </span>",
"    movement coupling measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Fetal magnetoencephalography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal magnetoencephalography aims for direct assessment of fetal cortical and brainstem function. A specialized apparatus incorporating an array of ultrasensitive magnetic field detectors allows noninvasive, direct continuous recording of fetal electrocortical signals, and can record fetal brain activity in response to auditory and visual stimuli applied to the maternal abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. This technology may contribute to future clinically important assessments of fetal CNS status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ANTENATAL TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some indications for antepartum fetal testing are listed in the table and discussed below (",
"    <a class=\"graphic graphic_table graphicRef61128 \" href=\"UTD.htm?33/51/34619\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, insulin-dependent diabetes has been a major contributor to perinatal mortality; however, due to both improved treatment and antepartum monitoring, the stillbirth rate in pregnancies complicated by diabetes now is equivalent to or lower than uncomplicated pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/47\">",
"     47",
"    </a>",
"    ]. Poorly controlled maternal diabetes is still associated with increased perinatal mortality, largely related to congenital anomalies and indicated preterm deliveries, but also to sudden unexplained fetal death.",
"   </p>",
"   <p>",
"    Although observational studies have described the use of the NST [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/48\">",
"     48",
"    </a>",
"    ], CST [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/49\">",
"     49",
"    </a>",
"    ], and BPP [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/50\">",
"     50",
"    </a>",
"    ] in management of pregnancies complicated by diabetes, no method(s) have been assessed in well-designed clinical trials and it is not clear which method, if any, is superior. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35818?source=see_link\">",
"     \"Obstetrical management of pregnancy complicated by pregestational diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no evidence supporting routine antepartum fetal assessment in gestational diabetes well-controlled with nutritional therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4313?source=see_link\">",
"     \"Obstetrical management of pregnancies complicated by gestational diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hypertensive disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal hypertension in pregnancy, whether chronic, pregnancy-induced (preeclampsia, gestational hypertension), or a combination, is a risk factor for perinatal death and is a common indication for antenatal testing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/14\">",
"     14",
"    </a>",
"    ]. There are insufficient data to recommend one testing modality over another, or to make conclusions about when testing should begin and how frequently it should be repeated.",
"   </p>",
"   <p>",
"    Some authorities opine that mild to moderate chronic hypertension in the absence of growth restriction or superimposed preeclampsia is not an indication for routine fetal surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/52\">",
"     52",
"    </a>",
"    ]. A systematic review concluded that benefits and harms of routine antenatal assessment in women with chronic hypertension could not be determined with currently available evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No randomized trials have assessed the best method for antenatal testing in the preeclamptic patient for whom delayed delivery is desired. The National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy has recommended daily fetal movement assessment, and weekly NSTs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    BPP for patients with mild preeclampsia before term; if fetal growth restriction or decreased AFV are present, testing is recommended twice weekly [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/52\">",
"     52",
"    </a>",
"    ]. Daily fetal cardiotocographic or ultrasound surveillance may be useful in conservative management of severe preterm preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link\">",
"     \"Preeclampsia: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Fetal growth restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal growth restriction is a well-recognized risk factor for fetal death. Abnormalities in Doppler velocimetry indices may help distinguish between fetal growth restriction due to placental insufficiency, in which impedance indices tend to be increased, and growth restriction from other causes (eg, congenital infection) or constitutional smallness, which are less frequently associated with increased impedance to blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. There are no data from randomized trials indicating the optimal mode and frequency of antenatal testing of the fetus with growth restriction. Given the limitations in predictive value, timing delivery based on results of antenatal testing in preterm fetal growth restriction presents a particular problem, as the risks of fetal loss must be balanced against the risks of iatrogenic prematurity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=see_link\">",
"     \"Fetal growth restriction: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Multiple gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple gestations are associated with higher perinatal mortality rates than singleton gestations due to the greater prevalence of maternal risk factors (eg, advanced maternal age, preterm labor, preeclampsia) and fetal risk factors (eg, abnormal growth, abnormal placentation, congenital anomalies).",
"   </p>",
"   <p>",
"    Chorionicity is an important consideration in the assessment of risk, with higher rates of adverse outcomes among monochorionic twins. Limited data specific to twin pregnancy suggest that testing both twins with weekly NSTs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/57\">",
"     57",
"    </a>",
"    ], BPPs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/58\">",
"     58",
"    </a>",
"    ], or mBPPs, with umbilical artery Doppler, alone or in combination [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/59\">",
"     59",
"    </a>",
"    ], may be of benefit in predicting outcomes in twin pregnancies. There are scant data to indicate the gestational age at which testing should start; some suggest that fetal surveillance among diamniotic-dichorionic twins with concordant growth may not be needed before 38 weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=see_link&amp;anchor=H23#H23\">",
"     \"Twin pregnancy: Prenatal issues\", section on 'Assessment of fetal well-being'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is insufficient evidence to support specific recommendations for any antenatal testing strategy in triplets and higher-order multiples. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/34/12842?source=see_link&amp;anchor=H14#H14\">",
"     \"Triplet pregnancy: Mid and late pregnancy complications and management\", section on 'Antepartum monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Amniotic fluid abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities of AFV have long been viewed as risk factors for poor perinatal outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/60,61\">",
"     60,61",
"    </a>",
"    ], although this concept has been challenged [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/62\">",
"     62",
"    </a>",
"    ]. There are few data on which to base recommendations for antenatal testing in pregnancies with abnormalities of AFV.",
"   </p>",
"   <p>",
"    Polyhydramnios and oligohydramnios each frequently coexist with other maternal or fetal problems, such as congenital anomalies, diabetes, hypertension, postterm pregnancy, and fetal growth restriction. There is controversy over whether isolated oligohydramnios [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/63\">",
"     63",
"    </a>",
"    ] or polyhydramnios [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/64\">",
"     64",
"    </a>",
"    ] near term is associated with adverse pregnancy outcomes. Approximately 40 percent of pregnancies with isolated oligohydramnios or polyhydramnios have normal AFI on subsequent assessment and good outcomes, suggesting misdiagnosis or a nonpathological state in many cases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14233?source=see_link\">",
"     \"Oligohydramnios\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/44/4808?source=see_link\">",
"     \"Polyhydramnios\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Persistent polyhydramnios is associated with poorer pregnancy outcomes, including fetal anomalies, maternal diabetes, and perinatal death [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/66\">",
"     66",
"    </a>",
"    ]; these pregnancies may benefit from antenatal surveillance, but there are little data to support specific methodologies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preterm premature rupture of membranes (PPROM) is associated with oligohydramnios and subclinical intrauterine infection. The goal of antenatal testing in this setting is early recognition of chorioamnionitis necessitating delivery. Most experts recommend daily antenatal testing in patients with PPROM, either with the NST [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/67\">",
"     67",
"    </a>",
"    ] or the BPP [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Postterm pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postterm pregnancy is associated with increased fetal mortality and neonatal seizures, especially if growth restriction is present [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/69\">",
"     69",
"    </a>",
"    ]. If testing is performed, the optimal gestational age at which to initiate testing has not been established. Because adverse pregnancy outcomes increase after 40 weeks, ACOG guidelines support initiating antenatal assessment at that time, although there are no randomized trial data to show that testing improves perinatal outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16535?source=see_link\">",
"     \"Postterm pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oligohydramnios in postterm pregnancy is associated with poorer outcomes, although some studies have questioned the utility of AFV estimation as an independent predictor of adverse outcomes in postterm pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Twice-weekly assessment of AFV is commonly recommended for patients at &ge;41 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/70\">",
"     70",
"    </a>",
"    ]; the mBPP appears to be a reasonable alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/21,73\">",
"     21,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Doppler assessments of placental circulation would not be expected to be helpful since elevated fetal risk in postterm pregnancy is related to impaired placental gas exchange rather than impaired blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/33\">",
"     33",
"    </a>",
"    ]. Correlation of umbilical artery Doppler results with neonatal outcome has been shown to be poor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/74\">",
"     74",
"    </a>",
"    ]. There is no clear role for Doppler velocimetry in monitoring postterm pregnancies given the existing evidence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     History of prior stillbirth",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of previous stillbirth is associated with a 2- to 10-fold increased risk of fetal death in subsequent pregnancy, depending in part on the etiology of the previous loss [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/75\">",
"     75",
"    </a>",
"    ]. Given this concern, previous stillbirth has long been considered an indication for antepartum testing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/76\">",
"     76",
"    </a>",
"    ], but there are no randomized trial data and scant other data on when to initiate testing or whether antepartum surveillance by any method is effective at reducing the risk of recurrent stillbirth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31306?source=see_link&amp;anchor=H34#H34\">",
"     \"Incidence, etiology, and prevention of stillbirth\", section on 'Antepartum fetal monitoring and timed delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some authors recommend initiating testing at 34 weeks, or one week prior to the previous loss [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/21\">",
"     21",
"    </a>",
"    ]. One group [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/77\">",
"     77",
"    </a>",
"    ] followed 300 otherwise healthy patients for whom history of prior stillbirth was the only indication for antenatal testing with weekly CSTs or semiweekly mBPPs. In this cohort, there was one perinatal death (recurrent stillbirth three days after a negative CST and &lt;24 hours after a reactive NST), and 13.6 percent of patients were delivered for positive or equivocal fetal testing results. All three of the patients whose first abnormal test result occurred at &lt;32 weeks were delivered at term without complications. Additionally, there was no association between gestational age at previous stillbirth and the incidence of an abnormal test or cesarean delivery for nonreassuring fetal FHR. The authors concluded that it is reasonable to initiate antenatal testing for history of stillbirth at 32 weeks of gestation. Comparing the recurrent fetal death rate in this study",
"    <span class=\"nowrap\">",
"     (1/300",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     3.3/1000)",
"    </span>",
"    to that in another relatively low-risk population",
"    <span class=\"nowrap\">",
"     (19.0/1000)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/78\">",
"     78",
"    </a>",
"    ] suggests that serial CSTs or mBPPs may reduce the risk of recurrent stillbirth, but this has not been rigorously tested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Decreased fetal movement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased fetal movement has been associated with adverse pregnancy outcomes such as congenital malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/79\">",
"     79",
"    </a>",
"    ], fetal growth restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/80\">",
"     80",
"    </a>",
"    ], preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/81\">",
"     81",
"    </a>",
"    ], and perinatal death [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/82\">",
"     82",
"    </a>",
"    ]. However, not all [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/83\">",
"     83",
"    </a>",
"    ] studies link decreased fetal movement to adverse outcome. Although women with decreased fetal movement require evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/11\">",
"     11",
"    </a>",
"    ], there are no randomized trials and little other data to support a specific protocol for such evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15959?source=see_link\">",
"     \"Evaluation of decreased fetal movements\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A NST is the minimum evaluation of decreased fetal movement. Patients in whom fetal assessment by NST, BPP, or modified BPP is normal and have no further complaint of decreased fetal movement do not need repetitive testing for this indication [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/84\">",
"     84",
"    </a>",
"    ]. There is no clear evidence that adding Doppler assessments to the evaluation of decreased fetal movement in otherwise low-risk women improves perinatal outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other indications for antenatal testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACOG practice bulletin on antepartum fetal surveillance suggests that antepartum testing may be appropriate for any \"pregnancies in which the risk of antepartum fetal demise is increased,\" including the conditions described above [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/11\">",
"     11",
"    </a>",
"    ]. Research has highlighted a small increased stillbirth risk for a number of additional conditions, including: advanced maternal age [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/86\">",
"     86",
"    </a>",
"    ], nulliparity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/87\">",
"     87",
"    </a>",
"    ], grand multiparity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/88\">",
"     88",
"    </a>",
"    ], obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/89\">",
"     89",
"    </a>",
"    ], conception with assisted reproductive technologies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/90\">",
"     90",
"    </a>",
"    ], black race [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/91\">",
"     91",
"    </a>",
"    ], some hereditary and acquired thrombophilias [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/92\">",
"     92",
"    </a>",
"    ], and abnormalities in first and second trimester serum screening results [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. Whether a program of antenatal testing in women with these risk factors can reduce the incidence of stillbirth is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     COSTS AND BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gaps in the evidence regarding the efficacy of antepartum testing in preventing fetal neurologic injury or death preclude a definite conclusion about the benefits of antepartum testing. One concern is that cerebral palsy and stillbirth may share a common etiologic pathway since they have many common risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30121/abstract/95\">",
"     95",
"    </a>",
"    ]. If true, identification of fetuses with nonreassuring antenatal testing may allow those with neurological injury who would have died in utero to survive with permanent neurological impairment.",
"   </p>",
"   <p>",
"    Limitations of the existing evidence also prevent a comprehensive understanding of the costs of fetal surveillance. Potential costs include the actual dollars spent on tests and their interpretation; opportunity costs of patients' and practitioners' time spent in testing; and maternal and infant morbidity (or even mortality) from delivery for abnormal results, especially given the frequency of false positive tests. Little is known about the effects of antenatal testing on maternal mental states: antenatal testing both provokes anxiety and offers reassurance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary goal of antenatal testing is to identify fetuses at risk of intrauterine neurologic injury or death so that these adverse outcomes can be prevented. Techniques for assessment of fetal well-being are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef50223 \" href=\"UTD.htm?42/24/43405\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The basis for antepartum testing is the premise that the fetus whose oxygenation in utero is challenged will respond with a series of detectable physiologic adaptive or decompensatory signs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal choice and application of technique(s) for fetal assessment have not been determined. The best evidence is for umbilical artery Doppler assessment for monitoring fetuses with early-onset growth restriction due to uteroplacental insufficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=see_link\">",
"       \"Fetal growth restriction: Evaluation and management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/1\">",
"      Vintzileos AM, Campbell WA, Rodis JF, et al. The relationship between fetal biophysical assessment, umbilical artery velocimetry, and fetal acidosis. Obstet Gynecol 1991; 77:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/2\">",
"      Olesen AG, Svare JA. Decreased fetal movements: background, assessment, and clinical management. Acta Obstet Gynecol Scand 2004; 83:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/3\">",
"      Hecher K, Bilardo CM, Stigter RH, et al. Monitoring of fetuses with intrauterine growth restriction: a longitudinal study. Ultrasound Obstet Gynecol 2001; 18:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/4\">",
"      Ferrazzi E, Bozzo M, Rigano S, et al. Temporal sequence of abnormal Doppler changes in the peripheral and central circulatory systems of the severely growth-restricted fetus. Ultrasound Obstet Gynecol 2002; 19:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/5\">",
"      Baschat AA, Gembruch U, Harman CR. The sequence of changes in Doppler and biophysical parameters as severe fetal growth restriction worsens. Ultrasound Obstet Gynecol 2001; 18:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/6\">",
"      de Vries JI, Fong BF. Normal fetal motility: an overview. Ultrasound Obstet Gynecol 2006; 27:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/7\">",
"      Neldam S. Fetal movements as an indicator of fetal well-being. Dan Med Bull 1983; 30:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/8\">",
"      Grant A, Elbourne D, Valentin L, Alexander S. Routine formal fetal movement counting and risk of antepartum late death in normally formed singletons. Lancet 1989; 2:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/9\">",
"      Mangesi L, Hofmeyr GJ. Fetal movement counting for assessment of fetal wellbeing. Cochrane Database Syst Rev 2007; :CD004909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/10\">",
"      Freeman RK, Anderson G, Dorchester W. A prospective multi-institutional study of antepartum fetal heart rate monitoring. II. Contraction stress test versus nonstress test for primary surveillance. Am J Obstet Gynecol 1982; 143:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/11\">",
"      ACOG practice bulletin. Antepartum fetal surveillance. Number 9, October 1999 (replaces Technical Bulletin Number 188, January 1994). Clinical management guidelines for obstetrician-gynecologists. Int J Gynaecol Obstet 2000; 68:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/12\">",
"      Braly P, Freeman RK. The significance of fetal heart rate reactivity with a positive oxytocin challenge test. Obstet Gynecol 1977; 50:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/13\">",
"      Evertson LR, Gauthier RJ, Schifrin BS, Paul RH. Antepartum fetal heart rate testing. I. Evolution of the nonstress test. Am J Obstet Gynecol 1979; 133:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/14\">",
"      Freeman RK, Anderson G, Dorchester W. A prospective multi-institutional study of antepartum fetal heart rate monitoring. I. Risk of perinatal mortality and morbidity according to antepartum fetal heart rate test results. Am J Obstet Gynecol 1982; 143:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/15\">",
"      Rochard F, Schifrin BS, Goupil F, et al. Nonstressed fetal heart rate monitoring in the antepartum period. Am J Obstet Gynecol 1976; 126:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/16\">",
"      Magann EF, Chauhan SP, Barrilleaux PS, et al. Amniotic fluid index and single deepest pocket: weak indicators of abnormal amniotic volumes. Obstet Gynecol 2000; 96:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/17\">",
"      Manning FA, Platt LD, Sipos L. Antepartum fetal evaluation: development of a fetal biophysical profile. Am J Obstet Gynecol 1980; 136:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/18\">",
"      Manning FA, Snijders R, Harman CR, et al. Fetal biophysical profile score. VI. Correlation with antepartum umbilical venous fetal pH. Am J Obstet Gynecol 1993; 169:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/19\">",
"      Manning FA, Morrison I, Harman CR, et al. Fetal assessment based on fetal biophysical profile scoring: experience in 19,221 referred high-risk pregnancies. II. An analysis of false-negative fetal deaths. Am J Obstet Gynecol 1987; 157:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/20\">",
"      Nageotte MP, Towers CV, Asrat T, Freeman RK. Perinatal outcome with the modified biophysical profile. Am J Obstet Gynecol 1994; 170:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/21\">",
"      Miller DA, Rabello YA, Paul RH. The modified biophysical profile: antepartum testing in the 1990s. Am J Obstet Gynecol 1996; 174:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/22\">",
"      Thompson RS, Trudinger BJ. Doppler waveform pulsatility index and resistance, pressure and flow in the umbilical placental circulation: an investigation using a mathematical model. Ultrasound Med Biol 1990; 16:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/23\">",
"      al-Ghazali W, Chita SK, Chapman MG, Allan LD. Evidence of redistribution of cardiac output in asymmetrical growth retardation. Br J Obstet Gynaecol 1989; 96:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/24\">",
"      Nicolaides KH, Bilardo CM, Soothill PW, Campbell S. Absence of end diastolic frequencies in umbilical artery: a sign of fetal hypoxia and acidosis. BMJ 1988; 297:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/25\">",
"      Weiner CP. The relationship between the umbilical artery systolic/diastolic ratio and umbilical blood gas measurements in specimens obtained by cordocentesis. Am J Obstet Gynecol 1990; 162:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/26\">",
"      Papageorghiou AT, Yu CK, Cicero S, et al. Second-trimester uterine artery Doppler screening in unselected populations: a review. J Matern Fetal Neonatal Med 2002; 12:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/27\">",
"      Gudmundsson S, Korszun P, Olofsson P, Dubiel M. New score indicating placental vascular resistance. Acta Obstet Gynecol Scand 2003; 82:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/28\">",
"      Hernandez-Andrade E, Brodszki J, Lingman G, et al. Uterine artery score and perinatal outcome. Ultrasound Obstet Gynecol 2002; 19:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/29\">",
"      Soregaroli M, Valcamonico A, Scalvi L, et al. Late normalisation of uterine artery velocimetry in high risk pregnancy. Eur J Obstet Gynecol Reprod Biol 2001; 95:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/30\">",
"      Gudmundsson S, Marsal K. Umbilical and uteroplacental blood flow velocity waveforms in pregnancies with fetal growth retardation. Eur J Obstet Gynecol Reprod Biol 1988; 27:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/31\">",
"      Giles WB, Trudinger BJ, Baird PJ. Fetal umbilical artery flow velocity waveforms and placental resistance: pathological correlation. Br J Obstet Gynaecol 1985; 92:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/32\">",
"      Karsdorp VH, van Vugt JM, van Geijn HP, et al. Clinical significance of absent or reversed end diastolic velocity waveforms in umbilical artery. Lancet 1994; 344:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/33\">",
"      Kontopoulos EV, Vintzileos AM. Condition-specific antepartum fetal testing. Am J Obstet Gynecol 2004; 191:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/34\">",
"      Alfirevic Z, Stampalija T, Gyte GM. Fetal and umbilical Doppler ultrasound in high-risk pregnancies. Cochrane Database Syst Rev 2010; :CD007529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/35\">",
"      Alfirevic Z, Stampalija T, Gyte GM. Fetal and umbilical Doppler ultrasound in normal pregnancy. Cochrane Database Syst Rev 2010; :CD001450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/36\">",
"      Picklesimer AH, Oepkes D, Moise KJ Jr, et al. Determinants of the middle cerebral artery peak systolic velocity in the human fetus. Am J Obstet Gynecol 2007; 197:526.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/37\">",
"      Mari G, Hanif F, Kruger M, et al. Middle cerebral artery peak systolic velocity: a new Doppler parameter in the assessment of growth-restricted fetuses. Ultrasound Obstet Gynecol 2007; 29:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/38\">",
"      Johnson P, Stojilkovic T, Sarkar P. Middle cerebral artery Doppler in severe intrauterine growth restriction. Ultrasound Obstet Gynecol 2001; 17:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/39\">",
"      Kiserud T, Eik-Nes SH, Blaas HG, et al. Ductus venosus blood velocity and the umbilical circulation in the seriously growth-retarded fetus. Ultrasound Obstet Gynecol 1994; 4:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/40\">",
"      Baschat AA, Gembruch U, Reiss I, et al. Relationship between arterial and venous Doppler and perinatal outcome in fetal growth restriction. Ultrasound Obstet Gynecol 2000; 16:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/41\">",
"      Kiserud T, Kessler J, Ebbing C, Rasmussen S. Ductus venosus shunting in growth-restricted fetuses and the effect of umbilical circulatory compromise. Ultrasound Obstet Gynecol 2006; 28:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/42\">",
"      Dipietro JA, Irizarry RA, Hawkins M, et al. Cross-correlation of fetal cardiac and somatic activity as an indicator of antenatal neural development. Am J Obstet Gynecol 2001; 185:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/43\">",
"      DiPietro JA, Hodgson DM, Costigan KA, et al. Development of fetal movement--fetal heart rate coupling from 20 weeks through term. Early Hum Dev 1996; 44:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/44\">",
"      Monk C, Sloan RP, Myers MM, et al. Fetal heart rate reactivity differs by women's psychiatric status: an early marker for developmental risk? J Am Acad Child Adolesc Psychiatry 2004; 43:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/45\">",
"      Eswaran H, Preissl H, Wilson JD, et al. Short-term serial magnetoencephalography recordings offetal auditory evoked responses. Neurosci Lett 2002; 331:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/46\">",
"      Holst M, Eswaran H, Lowery C, et al. Development of auditory evoked fields in human fetuses and newborns: a longitudinal MEG study. Clin Neurophysiol 2005; 116:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/47\">",
"      Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol 1996; 174:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/48\">",
"      Kjos SL, Leung A, Henry OA, et al. Antepartum surveillance in diabetic pregnancies: predictors of fetal distress in labor. Am J Obstet Gynecol 1995; 173:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/49\">",
"      Lagrew DC, Pircon RA, Towers CV, et al. Antepartum fetal surveillance in patients with diabetes: when to start? Am J Obstet Gynecol 1993; 168:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/50\">",
"      Dicker D, Feldberg D, Yeshaya A, et al. Fetal surveillance in insulin-dependent diabetic pregnancy: predictive value of the biophysical profile. Am J Obstet Gynecol 1988; 159:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/51\">",
"      Landon MB, Vickers S. Fetal surveillance in pregnancy complicated by diabetes mellitus: is it necessary? J Matern Fetal Neonatal Med 2002; 12:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/52\">",
"      Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183:S1.",
"     </a>",
"    </li>",
"    <li>",
"     Mulrow CD, Chiquette E, Ferrer RL, Sibai BM, Stevens KR, Harris M, et al. Management of chronic hypertension during pregnancy. Evid Rep Technol Assess (Summ) 2000; 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/54\">",
"      Sibai BM, Barton JR. Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. Am J Obstet Gynecol 2007; 196:514.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/55\">",
"      Baschat AA, Weiner CP. Umbilical artery doppler screening for detection of the small fetus in need of antepartum surveillance. Am J Obstet Gynecol 2000; 182:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/56\">",
"      Soothill PW, Ajayi RA, Campbell S, Nicolaides KH. Prediction of morbidity in small and normally grown fetuses by fetal heart rate variability, biophysical profile score and umbilical artery Doppler studies. Br J Obstet Gynaecol 1993; 100:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/57\">",
"      Devoe LD, Azor H. Simultaneous nonstress fetal heart rate testing in twin pregnancy. Obstet Gynecol 1981; 58:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/58\">",
"      Lodeiro JG, Vintzileos AM, Feinstein SJ, et al. Fetal biophysical profile in twin gestations. Obstet Gynecol 1986; 67:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/59\">",
"      Devoe LD, Ware DJ. Antenatal assessment of twin gestation. Semin Perinatol 1995; 19:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/60\">",
"      Chamberlain PF, Manning FA, Morrison I, et al. Ultrasound evaluation of amniotic fluid volume. I. The relationship of marginal and decreased amniotic fluid volumes to perinatal outcome. Am J Obstet Gynecol 1984; 150:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/61\">",
"      Chamberlain PF, Manning FA, Morrison I, et al. Ultrasound evaluation of amniotic fluid volume. II. The relationship of increased amniotic fluid volume to perinatal outcome. Am J Obstet Gynecol 1984; 150:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/62\">",
"      Ott WJ. Reevaluation of the relationship between amniotic fluid volume and perinatal outcome. Am J Obstet Gynecol 2005; 192:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/63\">",
"      Zhang J, Troendle J, Meikle S, et al. Isolated oligohydramnios is not associated with adverse perinatal outcomes. BJOG 2004; 111:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/64\">",
"      Magann EF, Chauhan SP, Doherty DA, et al. A review of idiopathic hydramnios and pregnancy outcomes. Obstet Gynecol Surv 2007; 62:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/65\">",
"      Lagrew DC, Pircon RA, Nageotte M, et al. How frequently should the amniotic fluid index be repeated? Am J Obstet Gynecol 1992; 167:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/66\">",
"      Golan A, Wolman I, Sagi J, et al. Persistence of polyhydramnios during pregnancy--its significance and correlation with maternal and fetal complications. Gynecol Obstet Invest 1994; 37:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/67\">",
"      Harding JA, Jackson DM, Lewis DF, et al. Correlation of amniotic fluid index and nonstress test in patients with preterm premature rupture of membranes. Am J Obstet Gynecol 1991; 165:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/68\">",
"      Vintzileos AM, Bors-Koefoed R, Pelegano JF, et al. The use of fetal biophysical profile improves pregnancy outcome in premature rupture of the membranes. Am J Obstet Gynecol 1987; 157:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/69\">",
"      Divon MY, Haglund B, Nisell H, et al. Fetal and neonatal mortality in the postterm pregnancy: the impact of gestational age and fetal growth restriction. Am J Obstet Gynecol 1998; 178:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/70\">",
"      ACOG Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin. Clinical management guidelines for obstetricians-gynecologists. Number 55, September 2004 (replaces practice pattern number 6, October 1997). Management of Postterm Pregnancy. Obstet Gynecol 2004; 104:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/71\">",
"      Lam H, Leung WC, Lee CP, Lao TT. Amniotic fluid volume at 41 weeks and infant outcome. J Reprod Med 2006; 51:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/72\">",
"      Morris JM, Thompson K, Smithey J, et al. The usefulness of ultrasound assessment of amniotic fluid in predicting adverse outcome in prolonged pregnancy: a prospective blinded observational study. BJOG 2003; 110:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/73\">",
"      Clark SL, Sabey P, Jolley K. Nonstress testing with acoustic stimulation and amniotic fluid volume assessment: 5973 tests without unexpected fetal death. Am J Obstet Gynecol 1989; 160:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/74\">",
"      Guidetti DA, Divon MY, Cavalieri RL, et al. Fetal umbilical artery flow velocimetry in postdate pregnancies. Am J Obstet Gynecol 1987; 157:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/75\">",
"      Reddy UM. Prediction and prevention of recurrent stillbirth. Obstet Gynecol 2007; 110:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/76\">",
"      Freeman RK, Dorchester W, Anderson G, Garite TJ. The significance of a previous stillbirth. Am J Obstet Gynecol 1985; 151:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/77\">",
"      Weeks JW, Asrat T, Morgan MA, et al. Antepartum surveillance for a history of stillbirth: when to begin? Am J Obstet Gynecol 1995; 172:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/78\">",
"      Sharma PP, Salihu HM, Kirby RS. Stillbirth recurrence in a population of relatively low-risk mothers. Paediatr Perinat Epidemiol 2007; 21 Suppl 1:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/79\">",
"      Valentin L, Mars&aacute;l K. Pregnancy outcome in women perceiving decreased fetal movement. Eur J Obstet Gynecol Reprod Biol 1987; 24:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/80\">",
"      Mor-Yosef S, Sadovsky E, Brzezinski A, et al. Fetal movements and intrauterine growth retardation. Int J Gynaecol Obstet 1983; 21:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/81\">",
"      Valentin L, Mars&aacute;l K, Wahlgren L. Subjective recording of fetal movements. III. Screening of a pregnant population; the clinical significance of decreased fetal movement counts. Acta Obstet Gynecol Scand 1986; 65:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/82\">",
"      Navot D, Yaffe H, Sadovsky E. Diagnosis of fetal jeopardy by assessment of fetal movement and heart rate accelerations. J Perinat Med 1983; 11:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/83\">",
"      Harrington K, Thompson O, Jordan L, et al. Obstetric outcome in women who present with a reduction in fetal movements in the third trimester of pregnancy. J Perinat Med 1998; 26:77.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics and the American College of Obstetricians and Gynecologists. Guidelines for perinatal care, 7th ed, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/85\">",
"      Korszun P, Dubiel M, Kudla M, Gudmundsson S. Doppler velocimetry for predicting outcome of pregnancies with decreased fetal movements. Acta Obstet Gynecol Scand 2002; 81:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/86\">",
"      Reddy UM, Ko CW, Willinger M. Maternal age and the risk of stillbirth throughout pregnancy in the United States. Am J Obstet Gynecol 2006; 195:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/87\">",
"      Bai J, Wong FW, Bauman A, Mohsin M. Parity and pregnancy outcomes. Am J Obstet Gynecol 2002; 186:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/88\">",
"      Aliyu MH, Salihu HM, Keith LG, et al. Extreme parity and the risk of stillbirth. Obstet Gynecol 2005; 106:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/89\">",
"      Salihu HM, Dunlop AL, Hedayatzadeh M, et al. Extreme obesity and risk of stillbirth among black and white gravidas. Obstet Gynecol 2007; 110:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/90\">",
"      Jackson RA, Gibson KA, Wu YW, Croughan MS. Perinatal outcomes in singletons following in vitro fertilization: a meta-analysis. Obstet Gynecol 2004; 103:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/91\">",
"      Reddy UM, Laughon SK, Sun L, et al. Prepregnancy risk factors for antepartum stillbirth in the United States. Obstet Gynecol 2010; 116:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/92\">",
"      Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 2002; 101:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/93\">",
"      Dugoff L, Hobbins JC, Malone FD, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol 2004; 191:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/94\">",
"      Dugoff L, Hobbins JC, Malone FD, et al. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 2005; 106:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30121/abstract/95\">",
"      Mathews TJ, MacDorman MF. Infant mortality statistics from the 2004 period linked birth/infant death data set. Natl Vital Stat Rep 2007; 55:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 457 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-AB557005D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_26_30121=[""].join("\n");
var outline_f29_26_30121=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTENATAL TESTING METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fetal movement counting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Contraction stress test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nonstress test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Amniotic fluid volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Biophysical profile",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Doppler velocimetry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Uterine artery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Umbilical artery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Middle cerebral artery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Fetal veins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Emerging methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Fetal physiology assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Fetal magnetoencephalography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      INDICATIONS FOR ANTENATAL TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hypertensive disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Multiple gestation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Amniotic fluid abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Postterm pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      History of prior stillbirth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Decreased fetal movement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other indications for antenatal testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      COSTS AND BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/457\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/457|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/24/43405\" title=\"table 1\">",
"      Methods fetal assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/51/34619\" title=\"table 2\">",
"      Indications for antepartum fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/457|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?23/19/23861\" title=\"waveform 1\">",
"      Late decelerations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=related_link\">",
"      Antepartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31558?source=related_link\">",
"      Assessment of amniotic fluid volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=related_link\">",
"      Diagnosis of fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=related_link\">",
"      Doppler ultrasound of the umbilical artery for fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15959?source=related_link\">",
"      Evaluation of decreased fetal movements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=related_link\">",
"      Fetal growth restriction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31306?source=related_link\">",
"      Incidence, etiology, and prevention of stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5464?source=related_link\">",
"      Management of pregnancy complicated by Rhesus (Rh) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4313?source=related_link\">",
"      Obstetrical management of pregnancies complicated by gestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35818?source=related_link\">",
"      Obstetrical management of pregnancy complicated by pregestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14233?source=related_link\">",
"      Oligohydramnios",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/44/4808?source=related_link\">",
"      Polyhydramnios",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16535?source=related_link\">",
"      Postterm pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11480?source=related_link\">",
"      Prediction of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11928?source=related_link\">",
"      The fetal biophysical profile",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/34/12842?source=related_link\">",
"      Triplet pregnancy: Mid and late pregnancy complications and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=related_link\">",
"      Twin pregnancy: Prenatal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14217?source=related_link\">",
"      Venous Doppler for fetal assessment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_26_30122="Clinical manifestations and natural history of hepatitis B virus infection";
var content_f29_26_30122=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and natural history of hepatitis B virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/26/30122/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/26/30122/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/26/30122/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/26/30122/contributors\">",
"     Rafael Esteban, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/26/30122/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/26/30122/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/26/30122/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of clinical manifestations of hepatitis B virus (HBV) infection varies in both acute and chronic disease. During the acute phase, manifestations range from subclinical or anicteric hepatitis to icteric hepatitis and, in some cases, fulminant hepatitis; during the chronic phase, manifestations range from an asymptomatic carrier state to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Extrahepatic manifestations can also occur with both acute and chronic infection.",
"   </p>",
"   <p>",
"    The clinical manifestations and natural history of HBV infection will be reviewed here. Issues related to epidemiology, transmission, and treatment are discussed separately. (See appropriate topic reviews). Terms used to define different clinical states are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef81182 \" href=\"UTD.htm?0/3/52\">",
"     table 1",
"    </a>",
"    ). These terms will be used throughout the discussion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE HEPATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 70 percent of patients with acute hepatitis B have subclinical or anicteric hepatitis, while 30 percent develop icteric hepatitis. The disease may be more severe in patients coinfected with other hepatitis viruses or with underlying liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fulminant hepatic failure is unusual, occurring in approximately 0.1 to 0.5 percent of patients. Fulminant hepatitis B is believed to be due to massive immune-mediated lysis of infected hepatocytes. This explains why many patients with fulminant hepatitis B have no evidence of HBV replication at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reasons that HBV has a fulminant course in some patients are not well-understood. A case-control study evaluated risk factors for a fulminant course in an outbreak among injection drug users [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/3\">",
"     3",
"    </a>",
"    ]. Compared with control patients, case patients were more likely to have used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    during their illness (p = 0.08), used more alcohol and methamphetamine, and lost more weight in the six months before illness. Furthermore, all nine isolates were genotype D. Whether viral or environmental factors led to the fulminant course in this outbreak is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=see_link\">",
"     \"Clinical significance of hepatitis B virus genotypes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The method of acquiring HBV infection varies geographically. Perinatal transmission and occasionally horizontal transmission early in life are most common in high prevalence areas such as southeast Asia and China, while sexual contact and percutaneous transmission (eg, intravenous drug use) are most common in the United States, Canada, and western Europe (",
"    <a class=\"graphic graphic_table graphicRef81182 \" href=\"UTD.htm?0/3/52\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incubation period lasts one to four months. A serum sickness-like syndrome may develop during the prodromal period, followed by constitutional symptoms, anorexia, nausea, jaundice, and right upper quadrant discomfort. The symptoms and jaundice generally disappear after one to three months, but some patients have prolonged fatigue even after normalization of serum aminotransferase concentrations.",
"   </p>",
"   <p>",
"    Laboratory testing during the acute phase reveals elevations in the concentration of alanine and aspartate aminotransferase levels (ALT and AST); values up to 1000 to 2000 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    are typically seen during the acute phase with ALT being higher than AST. The serum bilirubin concentration may be normal in patients with anicteric hepatitis. The prothrombin time is the best indicator of prognosis. In patients who recover, the normalization of serum aminotransferases usually occurs within one to four months. A persistent elevation of serum ALT for more than six months indicates a progression to chronic hepatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who recover from acute hepatitis B, it has been thought that the virus is completely cleared by antiviral antibodies and specific cytotoxic T lymphocytes. However, traces of HBV are often detectable in the blood by PCR for many years after a clinical recovery from acute hepatitis, despite the presence of serum antibodies and HBV-specific cytotoxic T cells, which can be present at high levels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. HBV-specific cytotoxic T cells may express activation markers, indicating recent contact with antigen, in patients studied up to 23 years after clinical and serologic recovery. One study found that HBV DNA was detected in the liver tissues in 13 of 14 healthy liver transplant donors who were positive for anti-HBc and anti-hepatitis B surface antibodies (anti-HBs) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/7\">",
"     7",
"    </a>",
"    ]. Persistent histologic abnormalities (including fibrosis and mild inflammation) were present as long as 10 years in another series focusing on nine patients who demonstrated a complete serologic recovery after acute infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations suggest that the complete eradication of HBV rarely occurs after recovery from acute HBV infection and that latent infection can maintain the T cell response for decades following clinical recovery, thereby keeping the virus under control [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/5\">",
"     5",
"    </a>",
"    ]. Although some studies suggest that liver damage may be present in patients with latent infection, it is not clear how common this is since these studies were based on very few patients. However, immunosuppression in such patients can lead to reactivation of the virus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rate of progression from acute to chronic hepatitis B is determined primarily by the age at infection. The rate is approximately 90 percent for a perinatally acquired infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/9\">",
"     9",
"    </a>",
"    ], 20 to 50 percent for infections between the age of one and five years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], and less than 5 percent for an adult-acquired infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/12\">",
"     12",
"    </a>",
"    ]. The factors responsible for the high rate of progression in neonates and children are discussed below. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Phases of chronic HBV infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for acute HBV is mainly supportive. In addition, appropriate measures should be taken to prevent infection in exposed contacts.",
"   </p>",
"   <p>",
"    The decision to hospitalize patients should be individualized. Patients who have a coagulopathy, are deeply jaundiced, or are encephalopathic should generally be hospitalized. Hospitalization might also be considered in patients who are older, have significant comorbidities, cannot tolerate oral intake, or have poor social support systems.",
"   </p>",
"   <p>",
"    Whether patients should be treated with",
"    <span class=\"nowrap\">",
"     nucleoside/tide",
"    </span>",
"    therapy is unsettled since few studies have addressed the benefits of antiviral therapy during acute infection. We do not believe that all patients with acute HBV require antiviral treatment since the likelihood of fulminant hepatitis B is less than 1 percent, and in immunocompetent adults, the likelihood of progression to chronic HBV infection is less than 5 percent.",
"   </p>",
"   <p>",
"    This recommendation was supported by a placebo-controlled study that included 71 patients with acute hepatitis B (31 randomized to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    for three months and 40 to placebo), which showed no biochemical or clinical benefit to lamivudine, including the subset of 47 patients with severe acute hepatitis B [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/13\">",
"     13",
"    </a>",
"    ]. There was also no difference in HBsAg loss after 12 months (94 versus 97 percent in the groups that received lamivudine and placebo, respectively). These data support that antiviral therapy is not indicated in the vast majority of patients with acute hepatitis B, but the role of antiviral therapy in patients with severe or protracted acute hepatitis B was not adequately addressed as the duration of illness was not mentioned, and only 3 of the 47 patients with severe acute hepatitis had encephalopathy.",
"   </p>",
"   <p>",
"    As a general rule, we treat patients with a severe (such as those who develop a coagulopathy [INR &gt;1.5]) or a protracted course (such as persistent symptoms or marked jaundice [bilirubin &gt;10",
"    <span class=\"nowrap\">",
"     mg/dL]",
"    </span>",
"    for more than four weeks after presentation). We also suggest treating patients with fulminant hepatitis B to reduce the likelihood of reinfection post-liver transplant, those who are immunocompromised, have a concomitant infection with hepatitis C or D virus, have a preexisting liver disease, or are elderly.",
"   </p>",
"   <p>",
"    Interferon should be avoided because of the increased risk of hepatic necroinflammation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     Telbivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    are acceptable options given as monotherapy as the duration of treatment should be short. Treatment can be stopped after confirmation (two consecutive tests four weeks apart) that the patient has cleared HBsAg.",
"   </p>",
"   <p>",
"    Issues related to preventing HBV infection in individuals exposed to the patient are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CHRONIC HEPATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of acute hepatitis is elicited in only a small percentage of patients with chronic HBV infection. In low or intermediate prevalence areas, approximately 30 to 50 percent of patients with chronic HBV infection have a past history of acute hepatitis; such a history is lacking in the remaining patients in these areas and in the majority of patients in high prevalence areas (predominantly perinatal infection).",
"   </p>",
"   <p>",
"    Many patients with chronic hepatitis B are asymptomatic (unless they progress to decompensated cirrhosis or have extrahepatic manifestations), while others have nonspecific symptoms such as fatigue. Some patients experience exacerbations of the infection which may be asymptomatic, mimic acute hepatitis, or manifest as hepatic failure.",
"   </p>",
"   <p>",
"    Physical examination may be normal, or there may be stigmata of chronic liver disease. Jaundice, splenomegaly, ascites, peripheral edema, and encephalopathy may be present in patients with decompensated cirrhosis. Laboratory tests may be normal, but most patients have a mild to moderate elevation in serum AST and ALT. During exacerbations, the serum ALT concentration may be as high as 50 times the upper limit of normal, and alfa-fetoprotein (AFP) concentrations as high as 1000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/14\">",
"     14",
"    </a>",
"    ]. A progression to cirrhosis is suspected when there is evidence of hypersplenism (decreased white blood cell and platelet counts) or impaired hepatic synthetic function (hypoalbuminemia, prolonged prothrombin time, hyperbilirubinemia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Extrahepatic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extrahepatic manifestations, which are thought to be mediated by circulating immune complexes, occur in 10 to 20 percent of patients with chronic HBV infection. As mentioned above, acute hepatitis may be heralded by a serum sickness-like syndrome manifested as fever, skin rashes, arthralgia, and arthritis, which usually subsides with the onset of jaundice. The two major extrahepatic complications of chronic HBV are polyarteritis nodosa and glomerular disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A variable proportion of patients with polyarteritis nodosa are HBsAg positive. The clinical manifestations are similar to those in patients with polyarteritis who are HBV-negative [",
"      <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/15\">",
"       15",
"      </a>",
"      ]. Patients with HBV-related polyarteritis may benefit from antiviral therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link\">",
"       \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=see_link\">",
"       \"Renal disease associated with hepatitis B virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HBV can induce both membranous nephropathy and, less often, membranoproliferative glomerulonephritis. Most cases of HBV-related glomerulonephropathy occur in children [",
"      <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/16-18\">",
"       16-18",
"      </a>",
"      ]. The typical presentation is with nephrotic range proteinuria. Approximately 30 to 60 percent of children with HBV-related membranous nephropathy undergo spontaneous remission, usually in association with HBeAg to anti-HBe seroconversion. A progression to renal failure can occur, particularly in adults. The efficacy of antiviral therapy is uncertain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=see_link\">",
"       \"Renal disease associated with hepatitis B virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aplastic anemia has been described in association with HBV infection, although most cases of post-hepatitis aplastic anemia are not due to HBV. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=see_link&amp;anchor=H7#H7\">",
"       \"Acquired aplastic anemia in children and young adults\", section on 'Hepatitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PHASES OF CHRONIC HBV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural course of chronic hepatitis B virus (HBV) infection is determined by the interplay between virus replication and the host immune response. Other factors that may play a role in the progression of HBV-related liver disease include gender, alcohol consumption, and concomitant infection with other hepatitis virus(es). The outcome of chronic HBV infection depends upon the severity of liver disease at the time HBV replication is arrested.",
"   </p>",
"   <p>",
"    Chronic HBV infection generally consists of two phases: an early replicative phase with active liver disease, and a later phase with low replication and remission of liver disease (",
"    <a class=\"graphic graphic_figure graphicRef67609 \" href=\"UTD.htm?3/23/3455\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In patients with a perinatally acquired HBV infection, there is an additional immune tolerance phase in which virus replication is not accompanied by active liver disease (",
"    <a class=\"graphic graphic_figure graphicRef76907 \" href=\"UTD.htm?9/24/9614\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/21\">",
"     21",
"    </a>",
"    ]. In some patients, reactivation of HBV replication occurs after a varying period of quiescence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Replicative phase: Immune tolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a perinatally acquired HBV infection, the initial phase is characterized by high levels of HBV replication&mdash;the presence of HBeAg (hepatitis B e antigen) and high levels of HBV DNA in serum&mdash;but no evidence of active liver disease as manifested by lack of symptoms, normal serum ALT concentrations, and minimal changes on liver biopsy (",
"    <a class=\"graphic graphic_figure graphicRef76907 \" href=\"UTD.htm?9/24/9614\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Two studies found that 30 to 50 percent of patients in this phase had stage 0 while the others had stage I fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. One of these studies showed that fibrosis scores on repeat biopsies were unchanged after five years among patients who remained in the immune tolerance phase [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of liver disease despite high levels of HBV replication is believed to be due to immune tolerance to HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/26\">",
"     26",
"    </a>",
"    ]. The exact mechanisms by which this occurs are unknown. Experiments in mice suggest that the transplacental transfer of maternal HBeAg may induce specific unresponsiveness of T cells to HBeAg and to HBcAg, resulting in an ineffective cytotoxic T cell lysis of infected hepatocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/27\">",
"     27",
"    </a>",
"    ]. Immune tolerance is believed to be the major reason for the poor response to interferon therapy in HBeAg-positive Asian patients who have normal serum ALT concentrations.",
"   </p>",
"   <p>",
"    The immune tolerance phase usually lasts 10 to 30 years, during which there is a very low rate of spontaneous HBeAg clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Studies in Chinese children, for example, have found HBeAg in as many as 90 percent below the age of five, and up to 80 percent below the age of 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/23,28\">",
"     23,28",
"    </a>",
"    ]. The cumulative rate of spontaneous HBeAg clearance is estimated to be approximately 2 percent during the first three years and only 15 percent after 20 years of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The low rate of viral clearance in adolescence and early adulthood accounts for the high frequency of maternal-infant transmission in Asian countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Replicative phase: Immune clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transition from the immune tolerance to the immune clearance phase occurs during the second and third decades in patients with perinatally acquired HBV infection. During the immune clearance phase, spontaneous HBeAg clearance increases to an annual rate of 10 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. A seroconversion rate of 70 percent during 10 years of follow-up was described in a population-based study of 1536 Alaskan natives who acquired HBV as adults [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/31\">",
"     31",
"    </a>",
"    ]. Several studies from Asia found that patients with genotype B infection undergo HBeAg seroconversion at an earlier age than those with genotype C infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=see_link\">",
"     \"Clinical significance of hepatitis B virus genotypes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HBeAg seroconversion is frequently, but not always, accompanied by biochemical exacerbations (abrupt increases in serum ALT) (",
"    <a class=\"graphic graphic_figure graphicRef76907 \" href=\"UTD.htm?9/24/9614\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/14,32,33\">",
"     14,32,33",
"    </a>",
"    ]. Exacerbations are believed to be due to a sudden increase in immune-mediated lysis of infected hepatocytes. They are often preceded by an increase in serum HBV DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/34\">",
"     34",
"    </a>",
"    ] and a shift of HBcAg (hepatitis B core antigen) from nuclear to cytoplasmic sites within hepatocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/35\">",
"     35",
"    </a>",
"    ], suggesting that immune clearance may be triggered by an increase in viral load or a change in the presentation of viral antigens. How these changes occur is not known.",
"   </p>",
"   <p>",
"    Most exacerbations are asymptomatic and are discovered during routine follow-up. However, some are accompanied by symptoms of acute hepatitis and may lead to the incorrect diagnosis of acute hepatitis B in patients who are not previously known to have chronic HBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/36\">",
"     36",
"    </a>",
"    ]. Exacerbations may be associated with an elevation in the IgM anti-HBc titer, which may lead to misdiagnosis of acute HBV infection and an increase in the serum alpha-fetoprotein concentration, which may raise concerns about the diagnosis of HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/14,37\">",
"     14,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, exacerbations are more commonly observed in men than in women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The reason for the gender difference is not clear, but a higher frequency of exacerbations in men may at least in part account for a higher incidence of HBV-related cirrhosis and HCC among men.",
"   </p>",
"   <p>",
"    In a small percentage of patients, exacerbations result in hepatic decompensation and rarely death from hepatic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/40\">",
"     40",
"    </a>",
"    ]. One report found that a serum HBV DNA level of 1.55 x 10(9)",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    or greater at the onset of a flare predicted decompensation in HBeAg positive patients without cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with severe exacerbations should be referred to specialized centers for liver transplantation or treatment with",
"    <span class=\"nowrap\">",
"     nucleos/tide",
"    </span>",
"    analogues. Interferon is not indicated in this setting since it can cause further exacerbation of the disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=see_link\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=see_link\">",
"     \"Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11752?source=see_link\">",
"     \"Entecavir in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25750?source=see_link\">",
"     \"Telbivudine in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=see_link\">",
"     \"Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Not all exacerbations lead to HBeAg seroconversion and clearance of HBV DNA from the serum, a phenomenon termed",
"    <strong>",
"     abortive",
"    </strong>",
"    immune clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/14,33\">",
"     14,33",
"    </a>",
"    ]. These patients may develop recurrent exacerbations with an intermittent disappearance of serum HBV DNA with or without a transient loss of HBeAg (",
"    <a class=\"graphic graphic_figure graphicRef76907 \" href=\"UTD.htm?9/24/9614\">",
"     figure 2",
"    </a>",
"    ). Such repeated episodes of hepatitis may increase the risk of developing cirrhosis and hepatocellular carcinoma (HCC). One study of 151 patients with chronic HBeAg positive hepatitis B (all with genotype C infection) found that early HBeAg seroconversion was more likely in patients who acquired HBV infection after the perinatal period and those with HBV DNA levels &le;7 log",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, the initial phase in patients with childhood or adult-acquired chronic HBV infection consists of virus replication (presence of HBeAg and high serum HBV DNA) and active liver disease (elevated serum ALT and chronic hepatitis on liver biopsy) (",
"    <a class=\"graphic graphic_figure graphicRef67609 \" href=\"UTD.htm?3/23/3455\">",
"     figure 1",
"    </a>",
"    ). The prevalence of HBeAg among non-Asian adults with chronic HBV infection is usually in the range of 10 to 20 percent, lower than the 30 to 50 percent seen among Chinese adults with chronic HBV infection. The rate of spontaneous HBeAg clearance during the immune tolerance appears to be similar&mdash;10 percent to 20 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/19,20,29,43\">",
"     19,20,29,43",
"    </a>",
"    ]. Exacerbations accompanying HBeAg seroconversion are less completely described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Low or nonreplication phase/inactive carrier state",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in the low or nonreplicating",
"    <span class=\"nowrap\">",
"     phase/inactive",
"    </span>",
"    carrier state are HBeAg negative and anti-HBe positive. In some patients, HBV DNA is undetectable in serum, even when tested by polymerase chain reaction assays, and liver disease is in remission as evidenced by normal serum ALT concentrations and the resolution of necroinflammation in liver biopsies. One study found that about 40 percent of inactive carriers had HBV DNA levels of 10(4)",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    or greater [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HBeAg-negative patients with a persistently normal serum ALT can still have significant histologic inflammation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/45,46\">",
"     45,46",
"    </a>",
"    ], although a meta-analysis found that significant liver disease was rare in those with a persistently normal ALT who had an HBV DNA level &le;20,000 int.",
"    <span class=\"nowrap\">",
"     unit/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/47\">",
"     47",
"    </a>",
"    ] In another report, only patients with high serum HBV DNA &gt;4 log",
"    <sub>",
"     10",
"    </sub>",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    were biopsied; in such patients, age was a predictor of significant histologic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/45\">",
"     45",
"    </a>",
"    ]. In a third study, the authors reported that 21 percent of HBeAg-negative patients with a persistently normal ALT and HBV DNA level of &lt;5 log",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    had histologically active liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/46\">",
"     46",
"    </a>",
"    ]. However, only 29 of 75 (39 percent) HBeAg-negative patients who had persistently normal ALT and HBV DNA &lt;5 log",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    were biopsied, and only six had active liver disease. It was unclear if patients who were biopsied were representative of the entire population. These data indicate that significant liver disease can be found in patients with HBeAg-negative chronic HBV, but this is rare in those with truly persistent normal ALT defined by at least three normal ALT over a 12-month period and HBV DNA &lt;4 log",
"    <sub>",
"     10",
"    </sub>",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (&lt;2000 int.",
"    <span class=\"nowrap\">",
"     unit/mL).",
"    </span>",
"   </p>",
"   <p>",
"    Because of the fluctuating nature of chronic HBV infection, patients should not be categorized as inactive carriers unless there are at least three ALT levels and two to three HBV DNA levels over a 12-month period of observation. Studies suggest that combined quantification of HBsAg level and HBV DNA at a single time point may help in differentiating inactive carrier phase versus HBeAg-negative chronic hepatitis. HBsAg &lt;1000 int.",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    in an HBeAg-negative patient with serum HBV DNA &lt;2000 int.",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    identifies the inactive carrier phase with a high diagnostic accuracy (94 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     HBeAg-negative chronic hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients continue to have moderate levels of HBV replication and active liver disease (elevated serum ALT and chronic inflammation on liver biopsies), but remain HBeAg negative [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Such patients are said to have HBeAg-negative chronic hepatitis. They have a residual wild-type virus or HBV variants that cannot produce HBeAg due to precore or core promoter genetic variations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/51-54\">",
"     51-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with HBeAg-negative chronic hepatitis are older and have more advanced liver disease. They also tend to have fluctuations in HBV DNA and ALT levels.",
"   </p>",
"   <p>",
"    The frequency of flares was estimated in a study of 217 asymptomatic patients with chronic HBV who were HBeAg negative, anti-HBe positive, and had a normal ALT level at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/38\">",
"     38",
"    </a>",
"    ]. During a median follow-up of almost six years, spontaneous ALT flares occurred in 43 patients (4.3 percent per year) with a cumulative probability of a flare of 11 and 47 percent after 5 and 10 years, respectively. On multivariable analysis, flares were significantly associated with age &ge;30, male sex, and the presence of a precore mutation. The authors noted that follow-up every three months captured up to 90 percent of flares [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, 283 patients who underwent spontaneous HBeAg seroconversion were followed for a median of 8.6 (range 1 to 18) years; 67 percent had sustained biochemical remission [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/55\">",
"     55",
"    </a>",
"    ]. The risk of cirrhosis and HCC were negligible in those with sustained remission and significantly higher in those with ALT elevation after HBeAg seroconversion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Resolution of chronic HBV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with chronic HBV infection become HBsAg negative. The annual rate of delayed clearance of HBsAg has been estimated to be 0.5 to 2 percent in Western patients and much lower (0.1 to 0.8 percent) in Asian countries [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/43,56,57\">",
"     43,56,57",
"    </a>",
"    ]. A study from Taiwan estimated that the cumulative probability of HBsAg seroclearance was only 8 percent after 10 years, but increased to 25 and 45 percent, respectively, after 20 and 25 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/58\">",
"     58",
"    </a>",
"    ]. Another report followed 3087 patients with chronic HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/57\">",
"     57",
"    </a>",
"    ]. The patients median age was 45, 65 percent were men, and the majority (84 percent) were HBeAg seronegative. HBsAg clearance occurred in 562 participants (an annual clearance rate of 2.26 percent).Clearance was preceded by a decrease in HBV DNA. The cumulative incidence of HBsAg clearance after 5 and 8 years were approximately 26 and 51 percent, respectively, in patients whose serum HBV DNA became undetectable. HBsAg clearance may be preceded by decreasing levels of HBsAg [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most reports, patients without cirrhosis who cleared HBsAg appeared to have a good prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. One of the largest series to address this issue focused on 218 such patients who were followed for a median of 62 months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/61\">",
"     61",
"    </a>",
"    ]. Of 189 patients who did not have cirrhosis at the time of HBsAg clearance, three developed cirrhosis, two developed hepatocellular carcinoma, and one died of hepatocellular carcinoma. However, these complications developed only in patients who had concurrent HCV or HDV infection.",
"   </p>",
"   <p>",
"    Despite a generally favorable prognosis, clearance of HBsAg does not preclude the development of cirrhosis or hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. In one report, the likelihood of developing HCC was greater in those who cleared HBsAg when older than age 50 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/64\">",
"     64",
"    </a>",
"    ]. In another series of 55 patients who spontaneously cleared HBsAg, complications developed in 33 percent (11 hepatocellular carcinoma, six cirrhosis, and one subfulminant liver failure) during a mean follow-up of 23 months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/63\">",
"     63",
"    </a>",
"    ]. The latter study probably overestimated the frequency with which complications occur, as it included 20 patients (36 percent) who had coinfection with either hepatitis C or hepatitis D. Furthermore, some of the patients may have had undocumented cirrhosis or irreversible liver damage prior to seroconversion.",
"   </p>",
"   <p>",
"    Many patients who cleared HBsAg remained HBV DNA positive when tested by PCR assays, particularly during the first 10 years of HBsAg clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .) A small proportion of these patients may be infected with a mixture of the wild-type virus and HBV variants with a deletion in the pre-S1 region, which are associated with a reduction in HBsAg synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/65\">",
"     65",
"    </a>",
"    ]. A reactivation of HBV replication with reappearance of HBeAg and HBV DNA (by hybridization assays) in serum and recrudescence of liver disease may occur when these patients are immunosuppressed. The reactivation can vary in severity from mild and asymptomatic to severe with possible fulminant hepatic failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SEQUELAE AND PROGNOSIS OF CHRONIC HBV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sequelae of chronic HBV infection vary from an inactive carrier state to the development of cirrhosis, hepatic decompensation, hepatocellular carcinoma (HCC), extrahepatic manifestations, and death. The prognosis appears to vary with the clinical setting. Long-term follow-up studies of HBsAg positive blood donors have shown that the majority remain asymptomatic with a very low risk of cirrhosis or HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. In a 16-year follow-up study of 317 HBsAg positive blood donors from Montreal, for example, only three died from HBV-related cirrhosis and none developed HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/66\">",
"     66",
"    </a>",
"    ]. Another report included 296 potential blood donors who were excluded from donation after they were found to be HBsAg positive and were followed for 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/68\">",
"     68",
"    </a>",
"    ]. The incidence of clinically significant liver disease, HCC, or other liver-related morbidity or mortality was not significantly greater than a control population of HBV negative blood donors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis is worse in HBV-infected patients from endemic areas and in patients with chronic hepatitis B [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. The estimated five-year rates of progression are [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/73\">",
"     73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic hepatitis to cirrhosis &ndash; 12 to 20 percent",
"     </li>",
"     <li>",
"      Compensated cirrhosis to hepatic decompensation &ndash; 20 to 23 percent (",
"      <a class=\"graphic graphic_figure graphicRef53694 \" href=\"UTD.htm?1/59/1981\">",
"       figure 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Compensated cirrhosis to HCC &ndash; 6 to 15 percent (",
"      <a class=\"graphic graphic_figure graphicRef67001 \" href=\"UTD.htm?34/63/35836\">",
"       figure 4",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"local\" href=\"#H17\">",
"       'Surveillance for hepatocellular carcinoma'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cumulative survival rate at each of these stages of progressive disease is [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/70,72-75\">",
"     70,72-75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Compensated cirrhosis &ndash; 85 percent at five years (",
"      <a class=\"graphic graphic_figure graphicRef72204 \" href=\"UTD.htm?11/56/12173\">",
"       figure 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Decompensated cirrhosis &ndash; 55 to 70 percent at one year and 14 to 35 percent at five years (",
"      <a class=\"graphic graphic_figure graphicRef58396 \" href=\"UTD.htm?39/20/40268\">",
"       figure 6",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among Chinese patients with chronic HBV infection, the life-time risk of a liver-related death has been estimated at 40 to 50 percent for men and 15 percent for women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/76\">",
"     76",
"    </a>",
"    ]. The risk of progression appears to be greatest in patients who stayed in the immune clearance phase [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/25\">",
"     25",
"    </a>",
"    ], in patients who have delayed HBeAg seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/77\">",
"     77",
"    </a>",
"    ], and in patients who had reactivation of HBV replication after HBeAg seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/31,55,78\">",
"     31,55,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be noted that the rates of progression and rates of survival cited above were based on data in the",
"    <span class=\"nowrap\">",
"     pre-nucleos/tide",
"    </span>",
"    analogue era and prognosis of patients with chronic hepatitis B have improved markedly in the last 10 years.",
"   </p>",
"   <p>",
"    A follow-up report of a placebo controlled trial evaluating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    in patients with bridging fibrosis or compensated cirrhosis described the natural history in 215 patients randomized to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/79\">",
"     79",
"    </a>",
"    ]. The primary endpoint of the study was defined as time to first occurrence of disease progression (an increase of &ge;2 points in the Child-Pugh score, the development of hepatocellular carcinoma, or bleeding varices). One of these endpoints was reached in 18 percent of patients after a median follow-up of 32 months (9 percent with an increase in the Child-Pugh score, 7 percent with the development of HCC, and 1 percent with bleeding varices). Disease progression was more likely in patients with higher baseline fibrosis scores. There was a possible association between HBV genotype C and disease progression, but there were insufficient data for detailed analysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=see_link\">",
"     \"Clinical significance of hepatitis B virus genotypes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Factors predictive of disease progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have evaluated factors influencing disease progression and survival in patients with chronic HBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/74,75,79,80\">",
"     74,75,79,80",
"    </a>",
"    ]. HBeAg positivity, high serum HBV DNA levels (HBV DNA &gt;2000 int.",
"    <span class=\"nowrap\">",
"     units/mL),",
"    </span>",
"    and HBsAg &gt;1000 int.",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    in patients with HBeAg negative chronic HBV and low HBV DNA levels have been associated with disease progression.",
"   </p>",
"   <p>",
"    Patients with a prolonged replication phase have a worse prognosis, mostly due to the development of cirrhosis and hepatocellular carcinoma. This was illustrated in a study of 98 patients with HBsAg positive compensated cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/74\">",
"     74",
"    </a>",
"    ]. The five-year survival rate was significantly lower in patients who were HBeAg positive (72 versus 97 percent in those who were HBeAg negative). Clearance of HBeAg was associated with a 2.2-fold decrease in death rate.",
"   </p>",
"   <p>",
"    Similar findings were noted in another series of 366 European patients with HBsAg positive compensated cirrhosis; the five-year survival rates in HBeAg positive and HBeAg negative patients were 77 and 88 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/75\">",
"     75",
"    </a>",
"    ]. Other independent factors associated with poor survival were older age, hypoalbuminemia, thrombocytopenia, splenomegaly, and hyperbilirubinemia. Biochemical remission and clearance of HBeAg or HBV DNA from the serum were significantly associated with a higher rate of survival.",
"   </p>",
"   <p>",
"    The worse prognosis in patients with a prolonged replicative phase may be related to a longer duration of necroinflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/14,81\">",
"     14,81",
"    </a>",
"    ]. Recurrent episodes of hepatitis may, either directly or indirectly through immune-mediated injury, increase the risk of fibrosis, cirrhosis, and perhaps carcinogenesis. Even among patients with decompensated cirrhosis, the suppression of HBV replication and delayed HBsAg clearance can result in an improvement in liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/60,82\">",
"     60,82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\", section on 'Hepatitis B'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HBV DNA levels also correlate with a progression to cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/83\">",
"     83",
"    </a>",
"    ]. In a population-based prospective cohort study (REVEAL HBV) in Taiwan, the cumulative incidence of cirrhosis during a mean follow-up of 11 years ranged from 4.5 percent for those with an HBV DNA level of less than 300",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    to 36 percent for those with an HBV DNA level of 10(6)",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    or more at study entry. The HBV DNA level remained an independent predictor of cirrhosis after adjusting for HBeAg status, age, sex, ALT level, cigarette smoking, and alcohol consumption. High serum HBV DNA (&gt;10",
"    <sup>",
"     6",
"    </sup>",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    was also an independent predictor of HCC after adjusting for HBe antigen status, serum alanine aminotransferase, and the presence of cirrhosis (hazard ratio [HR] 5.3, 95% CI 2.9-9.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with HBeAg negative chronic HBV with a low viral load, HBsAg levels &gt;1000 int.",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    have been associated with an increased risk of disease progression and hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. In a prospective cohort study in Taiwan, 1068 patients with chronic HBV genotype B or C infection and a low viral load (HBV DNA &lt;2000 int.",
"    <span class=\"nowrap\">",
"     units/mL),",
"    </span>",
"    HBsAg levels &gt;1000 int.",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    were associated with an increased risk of HBeAg negative hepatitis, hepatitis flares, and cirrhosis after adjusting for age, HBV DNA, and ALT levels (HR 1.5, 2.3, and 4.1, respectively). These data indicate that among patients with low viral load, the narrow range of HBV DNA from undetectable to &lt;2000 int.",
"    <span class=\"nowrap\">",
"     units/mL,",
"    </span>",
"    makes it difficult to stratify patients for risk of cirrhosis or hepatocellular carcinoma and other markers such as HBsAg level need to be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Reactivation following seroconversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of patients who achieve HBeAg seroconversion experience reactivation. Reactivation can occur in patients who receive immunosuppressive therapy, but can also occur spontaneously. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Only a few studies have described risk factors for spontaneous reactivation. One of the most detailed reports described 133 asymptomatic blood donors who had documented HBeAg seroconversion and were followed regularly for an average of six years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/78\">",
"     78",
"    </a>",
"    ]. Reactivation occurred in 26 patients at a rate of 3.3 percent per year. On multivariate analysis, reactivation was associated with HBV genotype C, male sex, serum ALT levels &gt;5 times the upper limit of normal during the HBeAg-positive phase, and age at HBeAg seroconversion &ge;40.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Reactivation associated with immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B virus reactivation associated with immunosuppression is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Surveillance for hepatocellular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance for HCC is recommended for chronic HBV carriers. Recommendations for surveillance for HCC have been issued by the American Association for the Study of Liver Diseases (AASLD) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/87,88\">",
"     87,88",
"    </a>",
"    ], which can be accessed through the AASLD web site at",
"    <a class=\"external\" href=\"file://aasld.org/practiceguidelines/pages/practiceguidelinelisting.aspx\">",
"     aasld.org/practiceguidelines/Pages/practiceGuidelineListing.aspx",
"    </a>",
"    . Surveillance can lead to early detection of HCC, but available testing is far from satisfactory. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=see_link\">",
"     \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     HBV AND CHRONIC ALCOHOL ABUSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of serum HBV markers among alcoholics has been estimated to be two- to fourfold higher than a corresponding control population, suggesting an increased rate of HBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. There is no clear evidence that alcoholics have an enhanced risk of chronic HBV infection. However, HBV DNA has been detected in the sera and liver tissues in some HBsAg negative alcoholics who present with liver disease, implying that occult HBV infection may have contributed to liver disease in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alcoholics with HBV infection have also been reported to have accelerated liver injury, an elevated risk of developing cirrhosis and HCC, and reduced survival compared with alcoholics who are not HBV-infected [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/93-96\">",
"     93-96",
"    </a>",
"    ]. In a case-control study, for example, the relative risk of HBsAg positivity in patients with hepatocellular carcinoma was 11.4 compared to controls, while the relative risk of concurrent HBsAg and alcohol intake was 64.7 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     COINFECTION WITH HCV OR HDV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B infected patients may also be infected with hepatitis C virus (HCV) or hepatitis D virus (HDV).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hepatitis C virus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute coinfection with HBV and HCV may shorten the duration of HBs antigenemia and lower the peak serum aminotransferase concentration compared with acute HBV infection alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/97\">",
"     97",
"    </a>",
"    ]. These findings suggest that HCV coinfection may interfere with the replication of HBV, leading to attenuation of liver damage. However, acute coinfection of HCV and HBV, or acute HCV on preexisting chronic HBV have also been reported to increase the risk of severe hepatitis and fulminant hepatic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/98-100\">",
"     98-100",
"    </a>",
"    ]. Similarly, acute HBV in patients with chronic HCV can lead to severe hepatitis, but may also lead to clearance of HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coexistent HCV infection has been estimated to be present in 10 to 15 percent of patients with HBV-associated chronic hepatitis, cirrhosis, or HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/102\">",
"     102",
"    </a>",
"    ]. Similarly, in a study of 1257 patients with chronic HCV infection, 62 percent had evidence of exposure to HBV, while 6 percent had coexisting chronic HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HCV superinfection in HBsAg carriers appears to reduce HBV DNA levels in serum and liver tissues and to increase the rate of HBsAg seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/104-108\">",
"     104-108",
"    </a>",
"    ]. Most patients who have dual HCV and HBV infections have detectable serum HCV RNA but undetectable or low HBV DNA levels, indicating that HCV is the predominant cause of liver disease in these patients. On the other hand, levels of HBV DNA and HCV RNA fluctuate over time in about one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/109\">",
"     109",
"    </a>",
"    ]. Liver disease is usually more severe than in patients infected by HBV alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/110\">",
"     110",
"    </a>",
"    ]. Patients with dual HBV and HCV infection may also have a higher rate of HCC compared with patients infected by either virus alone, particularly those who are anti-HCV and HBeAg positive [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/108,111,112\">",
"     108,111,112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of HCV infection with peginterferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    in patients with concomitant HBV infection can lead to a sustained virologic response. The rate of sustained virologic response is similar to that observed in patients with HCV alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/87\">",
"     87",
"    </a>",
"    ]. However, HBV replication may increase after clearance of HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/87,113\">",
"     87,113",
"    </a>",
"    ]. Thus, close monitoring of both viruses is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hepatitis D virus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although HDV can replicate autonomously, the simultaneous presence of HBV is required for complete virion assembly and secretion. As a result, individuals with hepatitis D are",
"    <strong>",
"     always",
"    </strong>",
"    dually infected with HDV and HBV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15543?source=see_link\">",
"     \"Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute HBV and HDV coinfection tends to be more severe than acute HBV infection alone and is more likely to result in fulminant hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/114\">",
"     114",
"    </a>",
"    ]. HDV superinfection in patients with chronic HBV infection is usually accompanied by a suppression of HBV replication due to interference mechanisms that are not well understood [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/115\">",
"     115",
"    </a>",
"    ]. HDV superinfection in such patients has been associated with more severe liver disease and accelerated progression to cirrhosis in most studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/116-118\">",
"     116-118",
"    </a>",
"    ], although discordant data have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Hepatitis C and D virus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interaction of viral replication in patients coinfected with HBV, HCV, and HDV remains unclear. Triple infection was associated with inhibition of HCV and HBV replication, suggesting that HDV had the dominant role [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/107\">",
"     107",
"    </a>",
"    ]. Similar results had been described by others [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/120\">",
"     120",
"    </a>",
"    ]. In contrast, another study found that triple infection was usually dominated by HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15543?source=see_link\">",
"     \"Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     HEPATITIS A VIRUS VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Advisory Committee on Immunization Practices (ACIP) recommends the immunization of all patients with chronic liver disease against hepatitis A virus (HAV). This recommendation is based upon theoretical grounds (that patients with chronic liver disease might have a worse prognosis if they developed superimposed acute hepatitis) rather than firm data, particularly with respect to HBV. In one study, in which 163 patients with chronic hepatitis B were prospectively followed for seven years, hepatitis A superinfection occurred in 10 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/26/30122/abstract/121\">",
"     121",
"    </a>",
"    ]. An uncomplicated course occurred in nine of these patients; one patient who also had preexisting cirrhosis developed marked cholestasis. The outcome was much worse in patients with chronic HCV. Fulminant hepatic failure developed in 7 of the 17 patients who acquired hepatitis A. Six of these patients died.",
"   </p>",
"   <p>",
"    Despite the sparse data, we follow the ACIP guidelines and recommend immunization with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     Hepatitis A vaccine",
"    </a>",
"    in patients with chronic hepatitis B. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=see_link\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8569?source=see_link\">",
"     \"Immunizations for patients with chronic liver disease\"",
"    </a>",
"    .) However, countries with a high prevalence of HBV also have a high prevalence of HAV. Thus, testing for the HAV antibody should be performed, with the vaccine being given only to patients who are HAV antibody-negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=see_link\">",
"       \"Patient information: Hepatitis B (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"       \"Patient information: Hepatitis B (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The spectrum of clinical manifestations of hepatitis B virus (HBV) infection varies in both acute and chronic disease. During the acute phase, manifestations range from subclinical or anicteric hepatitis to icteric hepatitis and, in some cases, fulminant hepatitis; during the chronic phase, manifestations range from an asymptomatic carrier state to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Extrahepatic manifestations also can occur with both acute and chronic infection.",
"     </li>",
"     <li>",
"      Approximately 70 percent of patients with acute hepatitis B have subclinical or anicteric hepatitis, while 30 percent develop icteric hepatitis. The disease may be more severe in patients coinfected with other hepatitis viruses or with underlying liver disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Acute hepatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with acute hepatitis B, we suggest treatment with a",
"      <span class=\"nowrap\">",
"       nucleoside/tide",
"      </span>",
"      analogue in those who have severe hepatitis (such as those who develop a coagulopathy [INR &gt;1.5]) or a protracted course (such as persistent symptoms or marked jaundice [bilirubin &gt;10",
"      <span class=\"nowrap\">",
"       mg/dL]",
"      </span>",
"      for more than four weeks after presentation) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We also suggest treating patients with fulminant hepatitis B to reduce the likelihood of reinfection post-liver transplant, those who are immunocompromised, have concomitant infection with hepatitis C or D virus, have preexisting liver disease, or are elderly. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Acute hepatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The natural course of chronic hepatitis B virus infection is determined by the interplay between virus replication and the host immune response. Chronic HBV infection generally consists of two phases: an early replicative phase with active liver disease, and a late or low replicative phase with remission of liver disease (",
"      <a class=\"graphic graphic_figure graphicRef67609 \" href=\"UTD.htm?3/23/3455\">",
"       figure 1",
"      </a>",
"      ). In patients with perinatally acquired HBV infection, there is an additional immune tolerance phase in which virus replication is not accompanied by active liver disease (",
"      <a class=\"graphic graphic_figure graphicRef76907 \" href=\"UTD.htm?9/24/9614\">",
"       figure 2",
"      </a>",
"      ). In some patients, reactivation of HBV replication occurs after a varying period of quiescence. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Phases of chronic HBV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The sequelae of chronic HBV infection vary from an inactive carrier state to the development of cirrhosis, hepatic decompensation, hepatocellular carcinoma (HCC), extrahepatic manifestations, and death. The prognosis appears to vary with the clinical setting. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Sequelae and prognosis of chronic HBV infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/1\">",
"      Liaw YF, Tsai SL, Sheen IS, et al. Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers. Am J Gastroenterol 1998; 93:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/2\">",
"      Wright TL, Mamish D, Combs C, et al. Hepatitis B virus and apparent fulminant non-A, non-B hepatitis. Lancet 1992; 339:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/3\">",
"      Garfein RS, Bower WA, Loney CM, et al. Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. Hepatology 2004; 40:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/4\">",
"      Sato S, Suzuki K, Akahane Y, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995; 122:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/5\">",
"      Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/6\">",
"      Yotsuyanagi H, Yasuda K, Iino S, et al. Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology 1998; 27:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/7\">",
"      Marusawa H, Uemoto S, Hijikata M, et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000; 31:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/8\">",
"      Yuki N, Nagaoka T, Yamashiro M, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 2003; 37:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/9\">",
"      Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975; 292:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/10\">",
"      Beasley RP, Hwang LY, Lin CC, et al. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 1982; 146:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/11\">",
"      Coursaget P, Yvonnet B, Chotard J, et al. Age- and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J Med Virol 1987; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/12\">",
"      Tassopoulos NC, Papaevangelou GJ, Sjogren MH, et al. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987; 92:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/13\">",
"      Kumar M, Satapathy S, Monga R, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007; 45:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/14\">",
"      Lok AS, Lai CL. alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989; 9:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/15\">",
"      Guillevin L, Lhote F, Cohen P, et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 1995; 74:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/16\">",
"      Johnson RJ, Couser WG. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990; 37:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/17\">",
"      Lai KN, Lai FM, Chan KW, et al. The clinico-pathologic features of hepatitis B virus-associated glomerulonephritis. Q J Med 1987; 63:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/18\">",
"      Lin CY. Clinical features and natural course of HBV-related glomerulopathy in children. Kidney Int Suppl 1991; 35:S46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/19\">",
"      Hoofnagle JH, Dusheiko GM, Seeff LB, et al. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981; 94:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/20\">",
"      Realdi G, Alberti A, Rugge M, et al. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology 1980; 79:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/21\">",
"      Lok AS. Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis 1992; 10:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/22\">",
"      Chang MH, Hwang LY, Hsu HC, et al. Prospective study of asymptomatic HBsAg carrier children infected in the perinatal period: clinical and liver histologic studies. Hepatology 1988; 8:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/23\">",
"      Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988; 8:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/24\">",
"      Andreani T, Serfaty L, Mohand D, et al. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol 2007; 5:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/25\">",
"      Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007; 46:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/26\">",
"      Hsu HY, Chang MH, Hsieh KH, et al. Cellular immune response to HBcAg in mother-to-infant transmission of hepatitis B virus. Hepatology 1992; 15:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/27\">",
"      Milich DR, Jones JE, Hughes JL, et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci U S A 1990; 87:6599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/28\">",
"      Liaw YF, Chu CM, Lin DY, et al. Age-specific prevalence and significance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in Taiwan: a comparison among asymptomatic carriers, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Med Virol 1984; 13:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/29\">",
"      Lok AS, Lai CL, Wu PC, et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/30\">",
"      Chang MH, Hsu HY, Hsu HC, et al. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology 1995; 22:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/31\">",
"      McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/32\">",
"      Liaw YF, Chu CM, Su IJ, et al. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983; 84:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/33\">",
"      Liaw YF, Pao CC, Chu CM, et al. Changes of serum hepatitis B virus DNA in two types of clinical events preceding spontaneous hepatitis B e antigen seroconversion in chronic type B hepatitis. Hepatology 1987; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/34\">",
"      Maruyama T, Iino S, Koike K, et al. Serology of acute exacerbation in chronic hepatitis B virus infection. Gastroenterology 1993; 105:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/35\">",
"      Hsu HC, Su IJ, Lai MY, et al. Biologic and prognostic significance of hepatocyte hepatitis B core antigen expressions in the natural course of chronic hepatitis B virus infection. J Hepatol 1987; 5:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/36\">",
"      Chu CM, Liaw YF, Pao CC, Huang MJ. The etiology of acute hepatitis superimposed upon previously unrecognized asymptomatic HBsAg carriers. Hepatology 1989; 9:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/37\">",
"      Liaw YF, Chu CM, Huang MJ, et al. Determinants for hepatitis B e antigen clearance in chronic type B hepatitis. Liver 1984; 4:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/38\">",
"      Kumar M, Chauhan R, Gupta N, et al. Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients. Gastroenterology 2009; 136:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/39\">",
"      Lok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol 1990; 10:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/40\">",
"      Sheen IS, Liaw YF, Tai DI, Chu CM. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology 1985; 89:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/41\">",
"      Jeng WJ, Sheen IS, Liaw YF. Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. Clin Gastroenterol Hepatol 2010; 8:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/42\">",
"      Kim HS, Kim HJ, Shin WG, et al. Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2009; 136:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/43\">",
"      Alward WL, McMahon BJ, Hall DB, et al. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1985; 151:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/44\">",
"      Chu CM, Chen YC, Tai DI, Liaw YF. Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase. Clin Gastroenterol Hepatol 2010; 8:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/45\">",
"      Lai M, Hyatt BJ, Nasser I, et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007; 47:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/46\">",
"      Kumar M, Sarin SK, Hissar S, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008; 134:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/47\">",
"      Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol 2012; 57:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/48\">",
"      Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/49\">",
"      Bonino F, Rosina F, Rizzetto M, et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986; 90:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/50\">",
"      Lok AS, Hadziyannis SJ, Weller IV, et al. Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection. Gut 1984; 25:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/51\">",
"      Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/52\">",
"      Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A 1994; 91:4077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/53\">",
"      Okamoto H, Tsuda F, Akahane Y, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68:8102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/54\">",
"      Brunetto MR, Giarin MM, Oliveri F, et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A 1991; 88:4186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/55\">",
"      Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/56\">",
"      Liaw YF, Sheen IS, Chen TJ, et al. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991; 13:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/57\">",
"      Liu J, Yang HI, Lee MH, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010; 139:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/58\">",
"      Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/59\">",
"      Chen YC, Jeng WJ, Chu CM, Liaw YF. Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection. Clin Gastroenterol Hepatol 2012; 10:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/60\">",
"      Chung HT, Lai CL, Lok AS. Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. Hepatology 1995; 22:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/61\">",
"      Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/62\">",
"      Yuen MF, Wong DK, Sablon E, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004; 39:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/63\">",
"      Huo TI, Wu JC, Lee PC, et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998; 28:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/64\">",
"      Yuen MF, Wong DK, Fung J, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/65\">",
"      Cabrerizo M, Bartolom&eacute; J, Caramelo C, et al. Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. Hepatology 2000; 32:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/66\">",
"      Villeneuve JP, Desrochers M, Infante-Rivard C, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994; 106:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/67\">",
"      Dragosics B, Ferenci P, Hitchman E, Denk H. Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases. Hepatology 1987; 7:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/68\">",
"      Manno M, Camm&agrave; C, Schepis F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004; 127:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/69\">",
"      Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/70\">",
"      Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995; 21:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/71\">",
"      Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/72\">",
"      Liaw YF, Lin DY, Chen TJ, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989; 9:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/73\">",
"      Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/74\">",
"      de Jongh FE, Janssen HL, de Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/75\">",
"      Realdi G, Fattovich G, Hadziyannis S, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994; 21:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/76\">",
"      Beasley RP, Lin CC, Chien CS, et al. Geographic distribution of HBsAg carriers in China. Hepatology 1982; 2:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/77\">",
"      Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat 2007; 14:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/78\">",
"      Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007; 133:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/79\">",
"      Liaw YF, Farrell G, Sung JJY, et al. Disease progression in chronic hepatitis B with advanced fibrosis or cirrhosis (abstract). J Hepatol 2005; (Suppl).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/80\">",
"      Di Marco V, Lo Iacono O, Camm&agrave; C, et al. The long-term course of chronic hepatitis B. Hepatology 1999; 30:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/81\">",
"      Liaw YF, Tai DI, Chu CM, et al. Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients. Hepatology 1987; 7:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/82\">",
"      Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/83\">",
"      Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/84\">",
"      Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/85\">",
"      Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/86\">",
"      Tseng TC, Liu CJ, Yang HC, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 2013; 57:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/87\">",
"      Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/88\">",
"      Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/89\">",
"      Laskus T, Radkowski M, Lupa E, et al. Prevalence of markers of hepatitis viruses in out-patient alcoholics. J Hepatol 1992; 15:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/90\">",
"      Mills PR, Pennington TH, Kay P, et al. Hepatitis Bs antibody in alcoholic cirrhosis. J Clin Pathol 1979; 32:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/91\">",
"      Br&eacute;chot C, Nalpas B, Courouc&eacute; AM, et al. Evidence that hepatitis B virus has a role in liver-cell carcinoma in alcoholic liver disease. N Engl J Med 1982; 306:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/92\">",
"      Nalpas B, Berthelot P, Thiers V, et al. Hepatitis B virus multiplication in the absence of usual serological markers. A study of 146 chronic alcoholics. J Hepatol 1985; 1:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/93\">",
"      Nakanuma Y, Ohta G. Morphology of cirrhosis and occurrence of hepatocellular carcinoma in alcoholics with and without HBsAg and in non-alcoholic HBsAg-positive patients. A comparative autopsy study. Liver 1983; 3:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/94\">",
"      Ohnishi K, Iida S, Iwama S, et al. The effect of chronic habitual alcohol intake on the development of liver cirrhosis and hepatocellular carcinoma: relation to hepatitis B surface antigen carriage. Cancer 1982; 49:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/95\">",
"      Donato F, Tagger A, Chiesa R, et al. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study. Hepatology 1997; 26:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/96\">",
"      Bedogni G, Miglioli L, Masutti F, et al. Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study. Am J Gastroenterol 2008; 103:2248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/97\">",
"      Mimms LT, Mosley JW, Hollinger FB, et al. Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. BMJ 1993; 307:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/98\">",
"      Sagnelli E, Coppola N, Messina V, et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 2002; 36:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/99\">",
"      F&eacute;ray C, Gigou M, Samuel D, et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology 1993; 104:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/100\">",
"      Liaw YF, Chen YC, Sheen IS, et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004; 126:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/101\">",
"      Sagnelli E, Coppola N, Pisaturo M, et al. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology 2009; 49:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/102\">",
"      Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995; 22:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/103\">",
"      Bini EJ, Perumalswami PV. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions. Hepatology 2010; 51:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/104\">",
"      Liaw YF, Tsai SL, Chang JJ, et al. Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis. Gastroenterology 1994; 106:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/105\">",
"      Pontisso P, Ruvoletto MG, Fattovich G, et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993; 105:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/106\">",
"      Sheen IS, Liaw YF, Lin DY, Chu CM. Role of hepatitis C and delta viruses in the termination of chronic hepatitis B surface antigen carrier state: a multivariate analysis in a longitudinal follow-up study. J Infect Dis 1994; 170:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/107\">",
"      Jardi R, Rodriguez F, Buti M, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001; 34:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/108\">",
"      Huang YT, Yang HI, Jen CL, et al. Suppression of hepatitis B virus replication by hepatitis C virus: combined effects on risk of hepatocellular carcinoma (abstract). Hepatology 2005; 42 (Suppl 1):230A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/109\">",
"      Raimondo G, Brunetto MR, Pontisso P, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 2006; 43:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/110\">",
"      Fong TL, Di Bisceglie AM, Waggoner JG, et al. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology 1991; 14:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/111\">",
"      Benvegn&ugrave; L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994; 74:2442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/112\">",
"      Yu MW, You SL, Chang AS, et al. Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan. Cancer Res 1991; 51:5621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/113\">",
"      Potthoff A, Wedemeyer H, Boecher WO, et al. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol 2008; 49:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/114\">",
"      Smedile A, Farci P, Verme G, et al. Influence of delta infection on severity of hepatitis B. Lancet 1982; 2:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/115\">",
"      Pastore G, Monno L, Santantonio T, et al. Hepatitis B virus clearance from serum and liver after acute hepatitis delta virus superinfection in chronic HBsAg carriers. J Med Virol 1990; 31:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/116\">",
"      Fattovich G, Boscaro S, Noventa F, et al. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis 1987; 155:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/117\">",
"      Sagnelli E, Piccinino F, Pasquale G, et al. Delta agent infection: an unfavourable event in HBsAg positive chronic hepatitis. Liver 1984; 4:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/118\">",
"      Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000; 46:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/119\">",
"      Jacobson IM, Dienstag JL, Werner BG, et al. Epidemiology and clinical impact of hepatitis D virus (delta) infection. Hepatology 1985; 5:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/120\">",
"      Mathurin P, Thibault V, Kadidja K, et al. Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. J Viral Hepat 2000; 7:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/26/30122/abstract/121\">",
"      Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338:286.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3627 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-655E7897C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_26_30122=[""].join("\n");
var outline_f29_26_30122=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE HEPATITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CHRONIC HEPATITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Extrahepatic manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PHASES OF CHRONIC HBV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Replicative phase: Immune tolerance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Replicative phase: Immune clearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Low or nonreplication phase/inactive carrier state",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HBeAg-negative chronic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Resolution of chronic HBV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SEQUELAE AND PROGNOSIS OF CHRONIC HBV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Factors predictive of disease progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Reactivation following seroconversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Surveillance for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      HBV AND CHRONIC ALCOHOL ABUSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      COINFECTION WITH HCV OR HDV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hepatitis D virus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Hepatitis C and D virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      HEPATITIS A VIRUS VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3627\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3627|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/23/3455\" title=\"figure 1\">",
"      Course of chronic HBV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/24/9614\" title=\"figure 2\">",
"      Course perinatal chronic HBV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/59/1981\" title=\"figure 3\">",
"      Decompensation in HBV cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/63/35836\" title=\"figure 4\">",
"      HBV cirrhosis and HCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/56/12173\" title=\"figure 5\">",
"      Survival in HBV cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/20/40268\" title=\"figure 6\">",
"      Survival decompensated HBV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3627|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/3/52\" title=\"table 1\">",
"      HBV consensus definitions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=related_link\">",
"      Acquired aplastic anemia in children and young adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=related_link\">",
"      Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=related_link\">",
"      Clinical significance of hepatitis B virus genotypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11752?source=related_link\">",
"      Entecavir in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=related_link\">",
"      Hepatitis A virus vaccination and postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8569?source=related_link\">",
"      Immunizations for patients with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=related_link\">",
"      Lamivudine monotherapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15543?source=related_link\">",
"      Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=related_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=related_link\">",
"      Patient information: Hepatitis B (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=related_link\">",
"      Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=related_link\">",
"      Renal disease associated with hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25750?source=related_link\">",
"      Telbivudine in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=related_link\">",
"      Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_26_30123="Medicare qualifying conditions for intensive rehab facility";
var content_f29_26_30123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F86417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F86417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medicare qualifying medical conditions for intensive rehabilitation facility",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spinal cord injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital deformity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amputation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Major multiple trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Femur fracture (hip fracture)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurological disorders (including multiple sclerosis, muscular dystrophy, Parkinson disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burns",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active polyarticular rheumatoid/psoriatic arthritis and seronegative arthritides, with qualifiers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic vasculitides with joint inflammation, with qualifiers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe or advanced osteoarthritis involving&nbsp;two or more major weight-bearing joints, with qualifiers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hip or knee joint replacement, or both, with qualifiers",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Source: CMS Manual System. Pub. 100-04, Medicare Claims Processing, Transmittal 347. Department of Health and Human Services, Centers for Medicare and Medicaid Services 2005. Available at:&nbsp;",
"     <a href=\"https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/R347CP.pdf\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/R347CP.pdf",
"     </a>",
"     (Accessed September 11, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_26_30123=[""].join("\n");
var outline_f29_26_30123=null;
var title_f29_26_30124="Birth trauma by delivery type";
var content_f29_26_30124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of birth trauma related to mode of delivery cases per 10,000 births",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Trauma",
"       </td>",
"       <td class=\"subtitle1\">",
"        Spontaneous birth",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vacuum assisted",
"       </td>",
"       <td class=\"subtitle1\">",
"        Forceps assisted",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cesarean no labor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cesarean with labor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subdural or cerebral hemorrhage",
"       </td>",
"       <td>",
"        2.9",
"       </td>",
"       <td>",
"        8.0",
"       </td>",
"       <td>",
"        9.8",
"       </td>",
"       <td>",
"        4.1",
"       </td>",
"       <td>",
"        7.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraventricular hemorrhage",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subarachnoid hemorrhage",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"       <td>",
"        3.3",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Facial nerve injury",
"       </td>",
"       <td>",
"        3.3",
"       </td>",
"       <td>",
"        4.6",
"       </td>",
"       <td>",
"        45.4",
"       </td>",
"       <td>",
"        4.9",
"       </td>",
"       <td>",
"        3.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brachial plexus injury",
"       </td>",
"       <td>",
"        7.7",
"       </td>",
"       <td>",
"        17.6",
"       </td>",
"       <td>",
"        25.0",
"       </td>",
"       <td>",
"        4.1",
"       </td>",
"       <td>",
"        1.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Convulsions",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"       <td>",
"        11.7",
"       </td>",
"       <td>",
"        9.8",
"       </td>",
"       <td>",
"        8.6",
"       </td>",
"       <td>",
"        21.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CNS depression",
"       </td>",
"       <td>",
"        3.1",
"       </td>",
"       <td>",
"        9.2",
"       </td>",
"       <td>",
"        5.2",
"       </td>",
"       <td>",
"        6.7",
"       </td>",
"       <td>",
"        9.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Feeding difficulty",
"       </td>",
"       <td>",
"        68.5",
"       </td>",
"       <td>",
"        72.1",
"       </td>",
"       <td>",
"        74.6",
"       </td>",
"       <td>",
"        106.3",
"       </td>",
"       <td>",
"        117.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mechanical ventilation",
"       </td>",
"       <td>",
"        25.8",
"       </td>",
"       <td>",
"        39.1",
"       </td>",
"       <td>",
"        45.4",
"       </td>",
"       <td>",
"        71.3",
"       </td>",
"       <td>",
"        103.2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:&nbsp;Towner D, Castro MA, Eby-Wilkens E, et al. Effect of mode of delivery in nulliparous women on neonatal intracranial injury.&nbsp;N Engl J Med 1999; 341:1709.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_26_30124=[""].join("\n");
var outline_f29_26_30124=null;
var title_f29_26_30125="BP response to TZ diuretics";
var content_f29_26_30125=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F76363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F76363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Determinants of hypotensive response to thiazide diuretic",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 228px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sequential changes in vascular resistance in nonresponders (blue squares) and responders (red circles) to the hypotensive effect of a thiazide diuretic in patients with essential hypertension. Although both groups had an initial diuresis and reduction in plasma volume, there was no significant fall in blood pressure in the nonresponders due to a rise in vascular resistance mediated in part by increased production of angiotensin II. In comparison, vascular resistance fell over time in the responders via an unknown mechanism.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Van Brummelen, P, Man in't Veld, AJ, Schalekamp, MA, Clin Pharmacol Ther 1980; 27:328.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_26_30125=[""].join("\n");
var outline_f29_26_30125=null;
var title_f29_26_30126="Irritant diaper dermatitis";
var content_f29_26_30126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pattern for irritant diaper dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_26_30126=[""].join("\n");
var outline_f29_26_30126=null;
var title_f29_26_30127="Normal Ab IgG Patterns";
var content_f29_26_30127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Different patterns in the evolution of specific antibody and total immunoglobulin G (IgG) levels",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 673px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Time course of serum tetanus toxoid antibodies (blue) and IgG levels (red) in four patients (A and B in this figure; C and D in accompanying figure) demonstrating various patterns in the evolution of specific antibody and IgG levels. Black arrowheads represent immunization with tetanus and diphtheria toxoid, poliovirus and Bordetella pertussis. The area above the dashed line indicates normal levels of tetanus toxoid antibodies (&ge;0.05 IU/mL). A normal pattern is shown in which the ability to mount sustained specific antibody response precedes the normalization of total IgG levels (A) and parallels the normalization of serum IgG levels (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Dalal, I, Roifman, C. Humoral immunodeficiency. In: Immunology and Allergy Clin North Am 2001; 21:129.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_26_30127=[""].join("\n");
var outline_f29_26_30127=null;
